Compounds for the treatment of neurodegenerative diseases

Pharmaceutical compounds targeting amyloid-beta aggregation and neuroinflammation effectively cross the blood-brain barrier, addressing multiple aspects of Alzheimer's disease pathology, reducing plaques and inflammation, and enhancing synaptic health.

WO2026192853A9PCT designated stage Publication Date: 2026-11-19COGNITIVE SYNERGY CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/018058
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-03-11
Filing Date
2026-03-06
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current therapeutic approaches for Alzheimer's disease, such as cholinesterase inhibitors and monoclonal antibody therapies, fail to effectively address the multifactorial nature of the disease, including amyloid-beta aggregation, tau pathology, and neuroinflammation, while also facing challenges with blood-brain barrier penetration and efficacy.

Method used

Development of pharmaceutical compounds with specific structures (Formula (I)) that inhibit amyloid-beta aggregation, reduce neuroinflammation, and cross the blood-brain barrier, formulated as oral, parenteral, or nasal dosage forms, potentially combined with cholinesterase inhibitors and anti-inflammatory agents.

Benefits of technology

The compounds demonstrate therapeutic effects by reducing amyloid plaque density, neuroinflammation, and microglial activation, increasing synaptic markers, and improving neuronal health, thereby potentially slowing the progression of Alzheimer's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000003_0002
    Figure IMGF000003_0002
  • Figure IMGF000004_0001
    Figure IMGF000004_0001
Patent Text Reader

Abstract

The present disclosure provides pharmaceutical compositions and methods for the treatment, delaying progression and prevention of degenerative cognitive disorders such as Alzheimer's disease (AD) and its variations. There are also provided methods of treating AD in human subject by reducing amyloid pathology and improving synaptic integrity.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Attorney Docket# COGN-01-PCT

[0002] Compounds for the Treatment of Neurodegenerative Diseases

[0003] RELATED APPLICATIONS

[0004] This application claims the benefit of U. S. Provisional Application No. 63 / 770,271, filed March 11, 2025, entitled “Compounds for the Treatment of Neurodegenerative Diseases”, which is hereby incorporated by reference in its entirety.

[0005] FIELD OF THE INVENTION

[0006] The disclosed subject matter relates to a pharmaceutical composition and method for the treatment and prevention of degenerative cognitive disorders such as Alzheimer’s disease and its variations.

[0007] BACKGROUND

[0008] Degenerative cognitive disorders represent a group of progressive neurological conditions characterized by the gradual decline in cognitive functions, including memory, attention, language, reasoning, and executive function. These disorders are typically caused by the deterioration of neurons and their connections, leading to irreversible damage and impairments in daily functioning. Common types of degenerative cognitive disorders include Alzheimer's Disease, Parkinson's Disease, and Lewy Body Dementia.

[0009] Alzheimer's Disease is characterized by the accumulation of beta-amyloid plaques and neurofibrillary tangles of tau protein, leading to neuronal loss and brain atrophy. The disease is marked by the presence of amyloid-beta (AP) amyloid fibrils, which are extracellular deposits of Ap protein plaques in the brain's gray matter. Additionally, the disease is characterized by neurofibrillary tangles, which are abnormal accumulations of tau protein within neurons. Inflammation is also increasingly recognized as a contributing factor in the progression of Alzheimer's disease. Despite the widespread impact of Alzheimer's disease, there is no cure, and current therapies offer marginal relief while the financial, emotional, and social costs of the disease continue to rise as life expectancy increases.

[0010] Several therapeutic approaches have been developed to address Alzheimer's disease and related cognitive disorders. Cholinesterase inhibitors, such as donepezil, rivastigmine, andAttorney Docket# COGN-01-PCT

[0011] galantamine, can improve memory, attention, and other cognitive functions by increasing the levels of acetylcholine in the brain. However, these drugs do not reduce toxic Ap or reduce inflammation, and they do not cure Alzheimer's disease or stop its progression. They provide symptomatic relief that is often temporary and modest.

[0012] Monoclonal antibody therapies targeting amyloid-beta, such as aducanumab, have been developed to reduce amyloid plaque burden. However, these therapies face challenges related to blood-brain barrier penetration. Monoclonal antibodies have a relatively low rate and extent of crossing the blood-brain barrier compared to small molecule drugs, which limits their therapeutic efficacy. Additionally, such therapies have faced controversy regarding their effectiveness in slowing cognitive decline despite regulatory approval.

[0013] Small molecule approaches have also been explored. Tamiprosate, for example, binds to multiple sites on Ap and inhibits the aggregation of Ap monomers into oligomers and fibrils. While tamiprosate showed promise in preclinical studies and early-phase clinical trials, larger Phase III clinical trials did not demonstrate efficacy in slowing cognitive decline in patients with Alzheimer's disease. The efficiency and consistency of blood-brain barrier crossing varied among patients, and targeting amyloid-beta aggregation alone may be insufficient to halt or reverse disease progression given the complex, multifactorial nature of Alzheimer's disease.

[0014] Alzheimer's disease involves multiple pathological processes, including amyloid-beta aggregation, tau pathology, neuroinflammation, and neurodegeneration. Existing therapeutic approaches that target a single pathway may be insufficient to address the full spectrum of disease pathology. There remains a need for therapeutic agents that can address multiple aspects of Alzheimer's disease pathology, including both amyloid-beta aggregation and neuroinflammation, while also demonstrating the ability to cross the blood-brain barrier effectively.

[0015] BRIEF SUMMARY

[0016] The present disclosure provides pharmaceutical compositions and methods for the treatment and prevention of degenerative cognitive disorders such as Alzheimer’s disease and its variations.

[0017] Attorney Docket# COGN-01-PCT

[0018] In a first aspect, there is provided a compound having the structure of Formula (I), or pharmaceutically accepted salt or solvate thereof

[0019]

[0020] wherein Ri is substituted or unsubstituted phenyl group, heterocyclic group, or pyridone group. In one embodiment,

[0021]

[0022] R-2 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl; and

[0023] R3 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkylcarbonyl, arylcarbonyl, aryloxy, heteroaryloxy, carbocyclyl, halo, haloalkyl, or hydroxyalkyl.

[0024] Attorney Docket# COGN-01-PCT

[0025] In another aspect, the compound of Formula (I) has the structures of Formula (la)-(Id) as set forth below, or a pharmaceutically acceptable salt or solvate thereof.

[0026] Formula 1(a) is with the following structure.

[0027]

[0028] wherein:

[0029] R2 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl;

[0030] R3 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkylcarbonyl, arylcarbonyl, aryloxy, heteroaryloxy, carbocyclyl, halo, haloalkyl, or hydroxyalkyl;

[0031] R4 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl; and

[0032] A-E are independently selected from CH or N.

[0033] Formula 1(b) is with the following structure.

[0034] Attorney Docket# COGN-01-PCT

[0035]

[0036] wherein:

[0037] R2 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl;

[0038] R3 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkylcarbonyl, arylcarbonyl, aryloxy, heteroaryloxy, carbocyclyl, halo, haloalkyl, or hydroxy alkyl;

[0039] Rs is alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, acyl, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, carbocyclyl, or haloalkyl; and

[0040] Re is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl,

[0041] Attorney Docket# COGN-01-PCT arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl.

[0042] Formula 1(c) is with the following structure.

[0043]

[0044] wherein:

[0045] R2 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl;

[0046] R3 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkylcarbonyl, arylcarbonyl, aryloxy, heteroaryloxy, carbocyclyl, halo, haloalkyl, or hydroxyalkyl;

[0047] R7 is alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, acyl, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, carbocyclyl, or haloalkyl; and

[0048] Rs is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl,

[0049] Attorney Docket# COGN-01-PCT heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl.

[0050] Formula 1(d) is with the following structure.

[0051]

[0052] wherein:

[0053] R2 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl;

[0054] R3 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkylcarbonyl, arylcarbonyl, aryloxy, heteroaryloxy, carbocyclyl, halo, haloalkyl, or hydroxyalkyl; and

[0055] A-D are independently selected from CH, O, N, or NR$>, wherein:

[0056] R9 is alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkylene, acyl, aminoalkyl, carbonyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, carbocyclyl, haloalkyl, or hydroxy alkyl.

[0057] Attorney Docket# COGN-01-PCT

[0058] In one aspect, the compound having the structure of:

[0059]

[0060] In another aspect, the compound having the structure of:

[0061]

[0062] In another aspect, the compound exists as a single enantiomer or a single diastereomer.

[0063] In another aspect, the compound is optionally substituted with deuterium at one or more positions.

[0064] In further aspects, the present disclosure also provides pharmaceutical compositions comprising a compound of the disclosure and a pharmaceutically acceptable excipient. The pharmaceutically acceptable excipient is selected from the group consisting of carriers, diluents, binders, disintegrants, lubricants, glidants, fillers, coating agents, solubilizers, stabilizers, preservatives, flavoring agents, and coloring agents.

[0065] In further aspects, the pharmaceutical composition is formulated as a dosage form for oral, parenteral or nasal delivery. The oral dosage form is selected from tablets, capsules, powders, granules, solutions, suspensions, emulsions, and syrups.

[0066] The present disclosure also provides methods of treating, delaying progression or preventing degenerative cognitive disorders, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention. The degenerativeAttorney Docket# COGN-01-PCT cognitive disorders include, such as Alzheimer’s Disease (AD), Parkinson’s Disease, and Lewy Body Dementia.

[0067] Also provided herein are methods of treating, delaying progression or preventing Alzheimer’s Disease (AD), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the disclosure.

[0068] The disclosure further provides methods of inhibiting Ap production in a cell, by contacting the cell with an effective amount of a compound of the disclosure. The cell is a neuronal cell or a glial cell.

[0069] In one aspect, the method of inhibiting Ap production comprises reducing C-terminal fragments of amyloid precursor protein.

[0070] The disclosure provides methods of treating, delaying progression of, or preventing degenerative cognitive disorders comprising administering a therapeutically effective amount of a compound of the invention, which results in at least one of the effects:

[0071] reduction of C-terminal fragments of amyloid precursor protein;

[0072] reduction of Api-42 levels;

[0073] increased phosphorylation of GSK3P at Ser9;

[0074] increased levels of synapsin;

[0075] increased levels of synaptophysin;

[0076] increased levels of PSD95;

[0077] increased levels of Homer;

[0078] reduction of IB Al; and

[0079] attenuation of microgliosis / microglial activation.

[0080] The disclosure also provides methods of treating, delaying progression of, or preventing degenerative cognitive disorders comprising administering a therapeutically effective amount of a compound of the invention, which results in at least one of the effects:

[0081] reduction of IB Al; and

[0082] attenuation of microgliosis / microglial activation.

[0083] The disclosure further provides methods of treating, delaying progression of, or preventing degenerative cognitive disorders comprising administering a therapeutically effective amount of a compound of the invention, which results in at least one of the effects:

[0084] reduced amyloid plaque density;

[0085] reduced neuroinflammation, and

[0086] Attorney Docket# COGN-01-PCT increased synaptic markers.

[0087] The pharmaceutical composition provided herein further comprising one or more additional pharmaceutically active agents. The composition includes a second therapeutically active agent, consisting of cholinesterase inhibitor, an NMD A receptor antagonist, and an antiinflammatory agent. The cholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine, and galantamine.

[0088] BRIEF DESCRIPTION OF THE DRAWINGS

[0089] Those of skill in the art will understand that the drawings, described below, are for illustrative purposes only. The drawings are not intended to limit the scope of the present teachings in any way.

[0090] FIG. 1 depicts the relative levels of C-terminal fragments (CTFs) in untreated 5xFAD mice and 5xFAD mice treated with selected compounds of the disclosure.

[0091] FIG. 2 shows APP full-length levels across treatment groups.

[0092] FIG. 3 illustrates the relative levels of phosphorylated GSK3P (pGSK3P) at Ser9 across the control, untreated 5xFAD, and various treatment groups.

[0093] FIG. 4 displays the relative levels of synapsin across various groups in the 5xFAD AD model and treatment conditions.

[0094] FIG. 5 displays the relative levels of synaptophysin across various groups in the 5xFAD AD model and treatment conditions.

[0095] FIG. 6 displays Api(Abetal)-42 levels in the hippocampus by ELISA.

[0096] FIG. 7 displays the percentage of fibril disaggregation in different samples using Thioflavin T (ThT) fluorescence.

[0097] FIG. 8 shows a Thioflavin T (ThT) defibrillation assay where pre-formed Api-42 fibrils (10 pM) were incubated with Example 24-D1 or Example 23-D1.

[0098] FIG. 9 shows an MTT cell viability assay where cells were challenged with Api-42 (10 pM) to induce cytotoxicity and then co-treated with Example 24-D1 or Example 23-D1.

[0099] FIG. 10 shows Western blot analysis of brain lysates after 2 months of once-daily oral dosing (30 mg / kg) in non-transgenic control mice for presynaptic proteins (synaptophysin and synapsin), with actin as the loading control.

[0100] Left: Western blot assay

[0101] Upper right: analysis on synaptophysin

[0102] Lower right: analysis on synapsin

[0103] Attorney Docket# COGN-01-PCT

[0104] FIG. 11 shows Western blot analysis of brain lysates after 2 months of once-daily oral dosing (30 mg / kg) in non-transgenic control mice for post synaptic proteins (PSD95 and Homer), with actin as the loading control.

[0105] Left: Western blot assay

[0106] Upper right: analysis on PSD95

[0107] Lower right: analysis on Homer

[0108] FIG. 12 shows brain lysates analyzed for APP C-terminal fragments (APP-CTFs) by Western blot at Day 15 in 5xFAD mice treated once daily by oral gavage.

[0109] Left: Western blot assay

[0110] Right: analysis on APP-CTF

[0111] FIG. 13 shows brain lysates analyzed for AKT pathway activation by Western blot at Day 15, with pAKT quantified relative to total AKT (pAKT / AKT).

[0112] Left: Western blot assay

[0113] Right: analysis on pAKT

[0114] FIG. 14 shows brain lysates analyzed for AKT pathway activation by Western blot at Day 30, with pAKT quantified relative to total AKT (pAKT / AKT).

[0115] Left: Western blot assay

[0116] Right: analysis on pAKT

[0117] FIG. 15 shows brain lysates analyzed for inhibitory phosphorylation of GSK3P at Ser9 (pGSK3p Ser9) by Western blot at Day 15.

[0118] Left: Western blot assay

[0119] Right: analysis on pGSK3p

[0120] FIG. 16 shows brain lysates analyzed for inhibitory phosphorylation of GSK3P at Ser9 (pGSK3p Ser9) by Western blot at Day 30.

[0121] Left: Western blot assay

[0122] Right: analysis on pGSK3p

[0123] FIG. 17 shows synaptic integrity assessed in brain lysates at Day 15 by quantifying key presynaptic markers (synaptophysin and synapsin).

[0124] Left: presynaptic marker synaptophysin

[0125] Right: presynaptic marker synapsin

[0126] FIG. 18 shows synaptic integrity assessed in brain lysates at Day 15 by quantifying key postsynaptic markers (PSD95 and Homer)

[0127] Left: postsynaptic markerPSD95

[0128] Right: postsynaptic marker Homer

[0129] Attorney Docket# COGN-01-PCT

[0130] FIG. 19 shows presynaptic marker levels quantified in brain lysates at Day 30, focusing on synaptophysin and synapsin (presynaptic proteins).

[0131] Left: presynaptic marker synaptophysin

[0132] Right: presynaptic marker synapsin

[0133] FIG. 20 shows postsynaptic marker levels quantified in brain lysates at Day 30, focusing on PSD95 and Homer (postsynaptic scaffolding proteins).

[0134] Left: postsynaptic markerPSD95

[0135] Right: postsynaptic marker Homer

[0136] FIG. 21 shows brain lysates analyzed by Western blot to quantify tau phosphorylation at Thrl81 (pTaul81) normalized to total tau.

[0137] Left: Western blot assay

[0138] Right: analysis on pTaul81

[0139] FIG. 22 shows brain lysates analyzed by Western blot to quantify tau phosphorylation at Thr217 (pTau217) normalized to total tau.

[0140] Left: Western blot assay

[0141] Right: analysis on pTau217

[0142] FIG. 23 shows brain lysates analyzed by Western blot for IB Al, a marker of microglial activation.

[0143] Left: Western blot assay

[0144] Right: analysis on IBA1

[0145] FIG. 24 represents images depicting histopathology and plaque quantification after 2 months of once-daily dosing with Example 24-D1 (30 mg / kg, QD) in 5xFAD mice.

[0146] Left: control sample

[0147] Right: treated with Example 24-D1

[0148] FIG. 25 shows plaque pathology quantified as plaque density (plaques per pm2) in 10-month-old 5xFAD male mice.

[0149] DETAILED DESCRIPTION

[0150] Definitions

[0151] The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

[0152] Attorney Docket# COGN-01-PCT

[0153] The term “heteroatom” is art-recognized and refers to an atom of any element other than carbon or hydrogen. Illustrative heteroatoms include boron, nitrogen, oxygen, phosphorus, sulfur and selenium, and alternatively oxygen, nitrogen or sulfur.

[0154] The term “alkyl” as used herein is a term of art and refers to saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In certain embodiments, a straight-chain or branched-chain alkyl has about 30 or fewer carbon atoms in its backbone (e.g., C1-C30 for straight chain, C3-C30 for branched chain), and alternatively, about 20 or fewer, or 10 or fewer. In certain embodiments, the term “alkyl” refers to a C1-C10 alkyl group. In certain embodiments, the term “alkyl” refers to a Ci-Ce alkyl group, for example a Ci-Ce straight-chain alkyl group. In certain embodiments, the term “alkyl” refers to a C3-C12 branched-chain alkyl group. In certain embodiments, the term “alkyl” refers to a C3-Cx branched-chain alkyl group. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl.

[0155] The term “cycloalkyl” means mono- or bicyclic or bridged carbocyclic rings, each having from 3 to 12 carbon atoms, which can be completely saturated or which may can contain one or more units of unsaturation; but, for the avoidance of doubt, the degree of unsaturation does not result in an aromatic ring system. Certain cycloalkyls have from 5-12 carbon atoms in their ring structure, and may have 6-10 carbons in the ring structure. Preferably, cycloalkyl is (C3-C7)cycloalkyl, which represents a monocyclic saturated carbocyclic ring, having from 3 to 7 carbon atoms. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Bicyclic cycloalkyl ring systems include bridged monocyclic rings and fused bicyclic rings. Bridged monocyclic rings contain a monocyclic cycloalkyl ring where two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge of between one and three additional carbon atoms ( / .<?., a bridging group of the form -(CH2)M-, where w is 1, 2, or 3). Representative examples of bicyclic ring systems include, but are not limited to, bicyclo[l.l.l]pentane, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane. Fused bicyclic cycloalkyl ring systems contain a monocyclic cycloalkyl ring fused to either a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocycloalkyl, or a monocyclic heteroaryl. The bridged or fused bicyclic cycloalkyl is attached to the parent molecular moiety through any carbon atom contained within the monocyclic cycloalkyl ring. Cycloalkyl groups are optionallyAttorney Docket# COGN-01-PCT substituted. In certain embodiments, the fused bicyclic cycloalkyl is a 5 or 6 membered monocyclic cycloalkyl ring fused to either a phenyl ring, a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, a 5 or 6 membered monocyclic heterocycloalkyl, or a 5 or 6 membered monocyclic heteroaryl, wherein the fused bicyclic cycloalkyl is optionally substituted.

[0156] The term “(cycloalkyl)alkyl” as used herein refers to an alkyl group substituted with one or more cycloalkyl groups. An example of (cycloalkyl)alkyl is cyclohexylmethyl group.

[0157] The term “heterocycloalkyl” as used herein refers to a radical of a non-aromatic ring system, including, but not limited to, monocyclic, bicyclic, and tricyclic rings, which can be completely saturated or which can contain one or more units of unsaturation; but, for the avoidance of doubt, the degree of unsaturation does not result in an aromatic ring system, and having 3 to 12 atoms including at least one heteroatom, such as nitrogen, oxygen, or sulfur. For purposes of exemplification, which should not be construed as limiting the scope of this invention, the following are examples of heterocyclic rings: aziridinyl, azirinyl, oxiranyl, thiiranyl, thiirenyl, dioxiranyl, diazirinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, azetyl, oxetanyl, oxetyl, thietanyl, thietyl, diazetidinyl, dioxetanyl, dioxetenyl, dithietanyl, dithietyl, dioxalanyl, oxazolyl, thiazolyl, triazinyl, isothiazolyl, isoxazolyl, azepines, azetidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, oxopiperidinyl, oxopyrrolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, quinuclidinyl, thiomorpholinyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiomorpholinyl, 1,1-dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, and trithianyl. A heterocycloalkyl group is optionally substituted by one or more substituents as described below.

[0158] The term “(heterocycloalkyl)alkyl” as used herein refers to an alkyl group substituted with one or more heterocycloalkyl (i.e., heterocyclyl) groups.

[0159] The term “alkenyl” as used herein means a straight or branched chain hydrocarbon radical containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-l -heptenyl, and 3 -decenyl. The unsaturated bond(s) of the alkenyl group can be located anywhere in the moiety and can have either the (Z) or the (E) configuration about the double bond(s).

[0160] Attorney Docket# COGN-01-PCT

[0161] The term “alkynyl” as used herein means a straight or branched chain hydrocarbon radical containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.

[0162] The term “alkylene” is art-recognized, and as used herein pertains to a diradical obtained by removing two hydrogen atoms of an alkyl group, as defined above. In one embodiment an alkylene refers to a disubstituted alkane, i.e., an alkane substituted at two positions with substituents such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, fluoroalkyl (such as trifluromethyl), cyano, or the like. That is, in one embodiment, a “substituted alkyl” is an “alkylene”.

[0163] The term “amino” is a term of art and as used herein refers to both unsubstituted and substituted amines, e.g., a moiety that may be represented by the general formulas:

[0164]

[0165] wherein Ra, Rb, and Rc each independently represent a hydrogen, an alkyl, an alkenyl, -(CH2)X-Rd, or Ra and Rb, taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; Rd represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocyclyl or a polycyclyl; and x is zero or an integer in the range of 1 to 8. In certain embodiments, only one of Raor Rb may be a carbonyl, e.g., Ra, Rb, and the nitrogen together do not form an imide. In other embodiments, Raand Rb (and optionally Rc) each independently represent a hydrogen, an alkyl, an alkenyl, or -(CH2)X-Rd. In certain embodiments, the term “amino” refers to -NH2.

[0166] In certain embodiments, the term “alkylamino” refers to -NH(alkyl).

[0167] In certain embodiments, the term “dialkylamino” refers to -N(alkyl)2.

[0168] The term “amido”, as used herein, means -NHC(=O)-, wherein the amido group is bound to the parent molecular moiety through the nitrogen. Examples of amido include alkylamido such as CH3C(=O)N(H)- and CH3CH2C(=O)N(H)-.

[0169] The term “acyl” is a term of art and as used herein refers to any group or radical of the form RCO- where R is any organic group, e.g., alkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl. Representative acyl groups include acetyl, benzoyl, and malonyl.

[0170] Attorney Docket# COGN-01-PCT

[0171] The term “aminoalkyl” as used herein refers to an alkyl group substituted with one or more one amino groups. In one embodiment, the term “aminoalkyl” refers to an aminomethyl group.

[0172] The term “aminoacyl” is a term of art and as used herein refers to an acyl group substituted with one or more amino groups.

[0173] The term “aminothionyl” as used herein refers to an analog of an aminoacyl in which the O of RC(O)- has been replaced by sulfur, hence is of the form RC(S)-.

[0174] The term “azide” or “azido”, as used herein, means an -N3 group.

[0175] The term “carbonyl” as used herein refers to -C(=O)-.

[0176] The term “thiocarbonyl” as used herein refers to -C(=S)-.

[0177] The term “alkylthio” as used herein refers to alkyl-S-. The term “(alkylthio)alkyl” refers to an alkyl group substituted by an alkylthio group.

[0178] The term “carboxy”, as used herein, means a -CO2H group.

[0179] The term “aryl” is a term of art and as used herein refers to includes monocyclic, bicyclic and polycyclic aromatic hydrocarbon groups, for example, benzene, naphthalene, anthracene, and pyrene. Typically, an aryl group contains from 6-10 carbon ring atoms (i.e., (C6-Cio)aryl). The aromatic ring may be substituted at one or more ring positions with one or more substituents, such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, fluoroalkyl (such as trifluoromethyl), cyano, or the like. The term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are “fused rings”) wherein at least one of the rings is an aromatic hydrocarbon, e.g., the other cyclic rings may be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyl s. In certain embodiments, the term “aryl” refers to a phenyl group.

[0180] The term “arylene” means a diradical obtained by removing two hydrogen atoms of an aryl group, as defined above. In certain embodiments an arylene refers to a disubstituted arene, i.e., an arene substituted at two positions with substituents such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, fluoroalkyl (such as trifluoromethyl), cyano, or the like. That is, in certain embodiments, a “substituted aryl” is an “arylene”.

[0181] Attorney Docket# COGN-01-PCT

[0182] The term “heteroaryl” is a term of art and as used herein refers to a monocyclic, bicyclic, and polycyclic aromatic group having 3 to 12 total atoms including one or more heteroatoms such as nitrogen, oxygen, or sulfur in the ring structure. Exemplary heteroaryl groups include azaindolyl, benzo(b)thienyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzotri azolyl, benzoxadiazolyl, furanyl, imidazolyl, imidazopyridinyl, indolyl, indolinyl, indazolyl, isoindolinyl, isoxazolyl, isothiazolyl, isoquinolinyl, oxadiazolyl, oxazolyl, purinyl, pyranyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-d]pyrimidinyl, quinolinyl, quinazolinyl, triazolyl, thiazolyl, thiophenyl, tetrahydroindolyl, tetrazolyl, thiadiazolyl, thienyl, thiomorpholinyl, triazolyl or tropanyl, and the like. The “heteroaryl” may be substituted at one or more ring positions with one or more substituents such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, fluoroalkyl (such as trifluromethyl), cyano, or the like. The term “heteroaryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are “fused rings”) wherein at least one of the rings is an aromatic group having one or more heteroatoms in the ring structure, e.g., the other cyclic rings may be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls.

[0183] The term “heteroarylene” means a diradical obtained by removing two hydrogen atoms of a heteroaryl group, as defined above. In certain embodiments an heteroarylene refers to a disubstituted heteroarene, i.e., a heteroarene substituted at two positions with substituents such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, fluoroalkyl (such as trifluoromethyl), cyano, or the like. That is, in certain embodiments, a “substituted heteroaryl” is an “heteroarylene”.

[0184] The term “aralkyl” or “arylalkyl” is a term of art and as used herein refers to an alkyl group substituted with an aryl group, wherein the moiety is appended to the parent molecule through the alkyl group.

[0185] The term “heteroaralkyl” or “heteroarylalkyl” is a term of art and as used herein refers to an alkyl group substituted with a heteroaryl group, appended to the parent molecular moiety through the alkyl group.

[0186] Attorney Docket# COGN-01-PCT

[0187] The term “alkoxy” as used herein means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.

[0188] The term “alkoxyalkyl” refers to an alkyl group substituted by an alkoxy group.

[0189] The term “alkoxycarbonyl” means an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, represented by -C(=O)-, as defined herein. Representative examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxy carbonyl, and tert-butoxy carbonyl.

[0190] The term “alkyl carbonyl”, as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1 -oxopropyl, 2,2-dimethyl-l -oxopropyl, 1 -oxobutyl, and 1 -oxopentyl.

[0191] The term “arylcarbonyl”, as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of arylcarbonyl include, but are not limited to, benzoyl and (2-pyridinyl)carbonyl.

[0192] The term “alkyl carbonyl oxy” and “arylcarbonyloxy”, as used herein, means an alkylcarbonyl or arylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, and tert-butyl carbonyl oxy. Representative examples of arylcarbonyloxy include, but are not limited to phenyl carbonyl oxy.

[0193] The term “alkenoxy” or “alkenoxyl” means an alkenyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkenoxyl include, but are not limited to, 2-propen-l-oxyl (i.e., CH2=CH-CH2-O-) and vinyloxy (i.e., CH2=CH-O-).

[0194] The term “aryloxy” as used herein means an aryl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.

[0195] The term “heteroaryloxy” as used herein means a heteroaryl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.

[0196] The term “carbocyclyl” as used herein means a monocyclic or multicyclic (e.g., bicyclic, tricyclic, etc.) hydrocarbon radical containing from 3 to 12 carbon atoms that is completely saturated or has one or more unsaturated bonds, and for the avoidance of doubt, the degree of unsaturation does not result in an aromatic ring system (e.g., phenyl). Examples ofAttorney Docket# COGN-01-PCT carbocyclyl groups include 1 -cyclopropyl, 1-cyclobutyl, 2-cyclopentyl, 1 -cyclopentenyl, 3-cyclohexyl, 1 -cyclohexenyl and 2-cyclopentenylmethyl.

[0197] The term “cyano” is a term of art and as used herein refers to -CN.

[0198] The term “halo” is a term of art and as used herein refers to -F, -Cl, -Br, or -I.

[0199] The term “haloalkyl” as used herein refers to an alkyl group, as defined herein, wherein some or all of the hydrogens are replaced with halogen atoms.

[0200] The term “hydroxy” is a term of art and as used herein refers to -OH.

[0201] The term “hydroxyalkyl”, as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and 2-ethyl-4-hydroxyheptyl.

[0202] Certain compounds contained in compositions of the present disclosure may exist in particular geometric or stereoisomeric forms. In addition, compounds of the present disclosure may also be optically active. The present invention contemplates all such compounds, including cis- and trans-\ somers, (R)- and (k)-enantiomers, diastereoisomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.

[0203] If, for instance, a particular enantiomer of compound of the present invention is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.

[0204] It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, fragmentation, decomposition, cyclization, elimination, or other reaction.

[0205] Attorney Docket# COGN-01-PCT

[0206] The term “substituted” is also contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, those described herein above. The permissible substituents may be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and / or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. This invention is not intended to be limited in any manner by the permissible substituents of organic compounds.

[0207] " Substituted with deuterium" refers to the replacement of one or more hydrogen atoms with a corresponding number of deuterium atoms.

[0208] In certain embodiments, a compound of the invention is substituted by deuterium. For example, in an alkyl group, one or more hydrogen atoms may be replaced by a corresponding number of deuterium atoms.

[0209] It will be recognized that some variation of natural isotopic abundance occurs in a synthesized compound depending upon the origin of chemical materials used in the synthesis. Thus, a preparation of a compound of the invention will inherently contain small amounts of deuterated isotopologues. The concentration of naturally abundant stable hydrogen and carbon isotopes, notwithstanding this variation, is small and immaterial as compared to the degree of stable isotopic substitution of the deuterated compounds of this invention. See, for instance, Wada, E et al., Seikagaku, 1994, 66: 15; Gannes, LZ et al., Comp Biochem Physiol Mol Integr Physiol, 1998, 119:725.

[0210] In the compounds of this invention any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. The stable isotopes of hydrogen are (protium) and2H (deuterium). Unless otherwise stated, when a position is designated specifically as “H” or “hydrogen”, the position is understood to have hydrogen at its natural abundance isotopic composition. Also unless otherwise stated, when a position is designated specifically as “D” or “deuterium”, the position is understood to have deuterium at an abundance that is at least 3340 times greater than the natural abundance of deuterium, which is 0.015% (i.e., at least 50.1% incorporation of deuterium).

[0211] In certain embodiments, the optional substituents can include, for example, halogen, haloalkyl (such as fluoroalkyl or trifluoromethyl), hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl), thiocarbonyl (such as thioester, thioacetate, or thioformate), alkoxyl, alkenyloxy, alkynyloxy, phosphoryl, phosphate, phosphonate, phosphinate, aminoAttorney Docket# COGN-01-PCT

[0212] (including alkyl- and dialkylamino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, suifonamido, sulfonyl, silyl, silyloxy, heterocycloalkyl, (heterocycloalkyl)alkyl, cycloalkyl, (cycloalkyl)alkyl, alkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group.

[0213] For purposes of the invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 67th Ed., 1986-87, inside cover.

[0214] Other chemistry terms herein are used according to conventional usage in the art, as exemplified by The McGraw-Hill Dictionary of Chemical Terms (ed. Parker, S., 1985), McGraw-Hill, San Francisco, incorporated herein by reference). Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0215] The term “pharmaceutically acceptable salt or solvate” as used herein includes salts or solvates derived from inorganic or organic acids including, for example, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, phosphoric, formic, acetic, lactic, maleic, fumaric, succinic, tartaric, glycolic, salicylic, citric, methanesulfonic, benzenesulfonic, benzoic, malonic, trifluoroacetic, trichloroacetic, naphthalene-2-sulfonic, and other acids. Pharmaceutically acceptable salt forms can include forms wherein the ratio of molecules comprising the salt is not 1:1. For example, the salt may comprise more than one inorganic or organic acid molecule per molecule of base, such as two hydrochloric acid molecules per molecule of compound of Formula (I). As another example, the salt may comprise less than one inorganic or organic acid molecule per molecule of base, such as two molecules of compound of Formula (I) per molecule of tartaric acid.

[0216] The terms “carrier” and “pharmaceutically acceptable carrier” as used herein refer to a diluent, adjuvant, excipient, or vehicle with which a compound is administered or formulated for administration. Non-limiting examples of such pharmaceutically acceptable carriers include liquids, such as water, saline, and oils; and solids, such as gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating, flavoring, and coloring agents may be used. Other examples of suitable pharmaceutical carriers are described in Remington’s Pharmaceutical Sciences by E. W. Martin, herein incorporated by reference in its entirety.

[0217] The term “treat” as used herein means prevent, halt or slow the progression of, or eliminate a disease or condition in a subject. In one embodiment “treat” means halt or slowAttorney Docket# COGN-01-PCT the progression of, or eliminate a disease or condition in a subject. In one embodiment, “treat” means reduce at least one objective manifestation of a disease or condition in a subject.

[0218] The term “effective amount” as used herein refers to an amount that is sufficient to bring about a desired biological effect.

[0219] The term “therapeutically effective amount” as used herein refers to an amount that is sufficient to bring about a desired therapeutic effect.

[0220] The term “inhibit” as used herein means decrease by an objectively measurable amount or extent. In various embodiments “inhibit” means decrease by at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 95 percent compared to relevant control. In one embodiment “inhibit” means decrease 100 percent, i.e., halt or eliminate.

[0221] The term “subject” as used herein refers to a mammal. In various embodiments, a subject is a mouse, rat, rabbit, cat, dog, pig, sheep, horse, cow, or non-human primate. In certain embodiments, a subject is a human.

[0222] Compounds

[0223] In certain embodiments, the disclosure provides a compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof.

[0224]

[0225] wherein Ri is substituted or unsubstituted phenyl, heterocyclic, or pyridones groups. In one embodiment,

[0226] Attorney Docket# COGN-01-PCT

[0227]

[0228] R2 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl; and

[0229] R3 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkylcarbonyl, arylcarbonyl, aryloxy, heteroaryloxy, carbocyclyl, halo, haloalkyl, or hydroxy alkyl.

[0230] When Ri is substituted with

[0231]

[0232] R4 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl; and

[0233] A-E are independently selected from CH or N.

[0234] When Ri is substituted with

[0235] Attorney Docket# COGN-01-PCT

[0236]

[0237] Rs is alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, acyl, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, carbocyclyl, or haloalkyl; and

[0238] Re is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl.

[0239] When Ri is substituted with

[0240]

[0241] R7 is alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, acyl, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, carbocyclyl, or haloalkyl; and

[0242] Rs is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl.

[0243] Attorney Docket# COGN-01-PCT

[0244] When Ri is substituted with

[0245]

[0246] A-D are independently selected from CH, O, N, or NR$>, wherein:

[0247] R9 is alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkylene, acyl, aminoalkyl, carbonyl, aryl, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl.

[0248] In some embodiments, the compound of Formula (I) has the structure of Formula (la) as set forth below, or pharmaceutically accepted salt or solvate thereof.

[0249]

[0250] wherein:

[0251] R2 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl;

[0252] R3 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, aminoalkyl, carbonyl, aryl,

[0253] Attorney Docket# COGN-01-PCT arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkylcarbonyl, arylcarbonyl, aryloxy, heteroaryloxy, carbocyclyl, halo, haloalkyl, or hydroxyalkyl;

[0254] R4 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl; and

[0255] A-E are independently selected from CH or N.

[0256] With reference to Formula (la), R2 is substituted with H, OCH3, Cl, or CH3; R3 is substituted with H or CH3; and R4 is substituted with H, CH3, CF3, Cl, SO2CH3, CN, OCH3 or OCF3, as an example.

[0257] In some embodiments, the compound of Formula (I) has the structure of Formula (lb) as set forth below, or pharmaceutically acceptable salt or solvate thereof.

[0258]

[0259] wherein:

[0260] R2 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl;

[0261] Attorney Docket# COGN-01-PCT

[0262] R3 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkylcarbonyl, arylcarbonyl, aryloxy, heteroaryloxy, carbocyclyl, halo, haloalkyl, or hydroxyalkyl;

[0263] Rs is alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, acyl, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, carbocyclyl, or haloalkyl; and

[0264] Re is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl.

[0265] With reference to Formula (lb), R5 is substituted with CH3, CH(CH3)2, or CH2CF3; and Re is substituted with H or CH3, as an example.

[0266] In some embodiments, the compound of Formula (I) has the structure of Formula (Ic) as set forth below, or pharmaceutically acceptable salt or solvate thereof.

[0267]

[0268] wherein:

[0269] Attorney Docket# COGN-01-PCT

[0270] R2 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl;

[0271] R3 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkylcarbonyl, arylcarbonyl, aryloxy, heteroaryloxy, carbocyclyl, halo, haloalkyl, or hydroxyalkyl;

[0272] R7 is alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, acyl, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, carbocyclyl, or haloalkyl; and

[0273] Rs is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl.

[0274] With reference to Formula (Ic), R7 is substituted with CH3, CH(CH3)2, or CH2CF3; and Rs is substituted with H or CH3, as an example.

[0275] In some embodiments, the compound of Formula (I) has the structure of Formula (Id) as set forth below, or pharmaceutically acceptable salt or solvate thereof.

[0276] Attorney Docket# COGN-01-PCT

[0277]

[0278] wherein:

[0279] R2 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl;

[0280] R3 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkylcarbonyl, arylcarbonyl, aryloxy, heteroaryloxy, carbocyclyl, halo, haloalkyl, or hydroxyalkyl; and

[0281] A-D are independently selected from CH, O, N, or NR$>, wherein:

[0282] R9 is alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkylene, acyl, aminoalkyl, carbonyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, carbocyclyl, haloalkyl, or hydroxy alkyl.

[0283] With reference to Formula (Id), R$>is substituted with CH3, as an example.

[0284] Exemplary compounds of the disclosure are provided in Table 1. For each compound, stereoisomeric forms are specifically noted as D1 / D2 and E1ZE2. D1 / D2 are notations for diastereomeric pairs, and E1ZE2 are notations for enantiomeric pairs. The compounds of the disclosure are optionally substituted with deuterium at one or more positions.

[0285] Attorney Docket# COGN-01-PCT

[0286] Table 1. List of Exemplary Compounds and Structures

[0287]

[0288] Attorney Docket# COGN-01-PCT

[0289]

[0290] Attorney Docket# COGN-01-PCT

[0291]

[0292] Attorney Docket# COGN-01-PCT

[0293]

[0294] Attorney Docket# COGN-01-PCT

[0295]

[0296] Attorney Docket# COGN-01-PCT

[0297]

[0298] Attorney Docket# COGN-01-PCT

[0299]

[0300] Attorney Docket# COGN-01-PCT

[0301]

[0302] Attorney Docket# COGN-01-PCT

[0303]

[0304] Attorney Docket# COGN-01-PCT

[0305]

[0306] Attorney Docket# COGN-01-PCT

[0307]

[0308] Attorney Docket# COGN-01-PCT

[0309]

[0310] Attorney Docket# COGN-01-PCT

[0311]

[0312] Attorney Docket# COGN-01-PCT

[0313]

[0314] Attorney Docket# COGN-01-PCT

[0315]

[0316] Pharmaceutical Compositions

[0317] The disclosure provides pharmaceutical compositions, each comprising one or more compounds of the invention, or pharmaceutically acceptable salts or solvates thereof, and a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition comprises a compound of the invention and a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition comprises a plurality of compounds of the invention, or pharmaceutically acceptable salts or solvates thereof, and a pharmaceutically acceptable carrier.

[0318] Pharmaceutical compositions of the invention can be prepared by combining one or one or more additional pharmaceutically active agents, or pharmaceutically acceptable salts or solvates thereof, with a pharmaceutically acceptable carrier.

[0319] Attorney Docket# COGN-01-PCT

[0320] The pharmaceutical composition optionally comprises a second therapeutically active agent. The therapeutically active agent may include cholinesterase inhibitor, an NMDA receptor antagonist, and an anti-inflammatory agent. The cholinesterase inhibitor is selected from donepezil, rivastigmine, and galantamine, as example.

[0321] In one aspect, the compounds of the disclosure are in the form of a pharmaceutically acceptable salt, wherein the pharmaceutically acceptable salt is derived from an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, tartaric acid, methanesulfonic acid, and benzenesulfonic acid. In another aspect, the pharmaceutically acceptable salt is a hydrochloride salt. In another aspect, the compounds of the disclosure are in the form of a solvate. In another aspect, the solvate is a hydrate.

[0322] In one aspect, the compounds of the disclosure have a molecular weight of less than 500 Da. In another aspect, the compounds have a molecular weight of about 400 Da. The compounds of the disclosure are capable of crossing the blood-brain barrier. The compounds are suitable for oral administration.

[0323] In one aspect, the pharmaceutical compositions of the disclosure are formulated for oral administration. The dosage form is selected from a tablet, a capsule, a pill, a powder, a granule, a solution, a suspension, an emulsion, a syrup, and an elixir.

[0324] In another aspect, the pharmaceutical compositions of the disclosure are formulated for parenteral administration, wherein the formulation is administered by a route selected from intravenous injection, intramuscular injection, subcutaneous injection, and intraperitoneal injection.

[0325] In another aspect, the pharmaceutical composition is formulated for intranasal administration.

[0326] Method of Use

[0327] The present disclosure provides methods of treating, delaying progression of, or preventing degenerative cognitive disorders by administering to a subject in need thereof a therapeutically effective amount of a compound of the invention. The degenerative

[0328] Attorney Docket# COGN-01-PCT

[0329] cognitive disorders include, such as Alzheimer’s Disease (AD), Parkinson’s Disease, and Lewy Body Dementia.

[0330] The disclosure further provides methods of treating, delaying progression of, or preventing Alzheimer’s Disease (AD) by administering to a subject in need thereof a therapeutically effective amount of a compound of the invention.

[0331] The disclosure provides compounds, and pharmaceutically acceptable salts or solvates thereof, that are useful for treating, delaying progression of, or preventing a disease or condition in which reducing amyloid-P (Ap) species and / or modulating amyloid precursor protein APP) processing is beneficial, including disorders whose treatment would benefit from inhibiting or reducing Ap production in a cell. In further embodiments, the invention provides a method of reducing Ap protein in a cell, comprising contacting the cell with an effective amount of a compound of the invention, thereby reducing one or more Ap species (including A l-40, A i-42, and / or oligomeric AJ3) and, in certain embodiments, reducing APP processing intermediates including APP C-terminal fragments (APP-CTFs). The cell may be in vitro or ex vivo, or may be in a mammalian body, e.g., a human body. In certain embodiments, administration of a compound of the invention further preserves, restores, or enhances synaptic integrity, including increasing or preserving pre-synaptic and post-synaptic markers, and may reduce neuroinflammation and / or microgliosis, including decreasing markers such as IB Al; in some embodiments, such synaptic marker increases are observed following chronic dosing (e.g., about two months), including in non -transgenic control animals, consistent v / ith enhanced synaptic maintenance and / or plasticity. In certain aspects, the invention provides a compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, for use as a medicament.

[0332] In certain embodiments, the invention provides a method of treating, delaying progression of, or preventing Alzheimer’s disease, including treatment of prodromal AD or mild cognitive impairment due to AD, as well as broader neurode enerative or cognitive disorders such as age-related cognitive decline. Administration of the compound enhances synaptic integrity by increasing one or more synaptic markers in brain tissue, including elevations in presynaptic proteins (e.g., synaptophysin, synapsin) and postsynaptic scaffolding proteins (e.g, PSD95, Homer), and in some implementations produces a coordinated enhancement across both presynaptic and postsynaptic compartments. These pro-synaptic effects are observed in disease-model animals and in non-transgenic healthyAttorney Docket# COGN-01-PCT

[0333] animals, supporting a direct pharmacological mechanism independent of baseline pathology.

[0334] In additional embodiments, administration modulates the amyloid pathway by reducing A^l-42 levels in hippocampal and / or cortical tissue, decreasing amyloid plaque burden or plaque density, and lowering APP C -terminal fragments (APP-CTFs). The compound may further disrupt fibrillar Ap in vitro or ex vivo, as evidenced by reduced ThT fluorescence and partial defibrillation of Ap fibrils. In certain embodiments, the compound protects neuronal cells from Ap-induced cytotoxicity, wherein co-treatment increases cell viability relative to Ap alone, and reduces Ap -associated neurotoxicity in vitro and / or in vivo. The method may additionally involve activation of pro-survival signaling pathways, including increased pAKT (Ser473 ), an elevated pAKT / AKT ratio, and increased inhibitory' pGSK3p (Ser9), thereby engaging the AKT-GSK3p signaling axis in CNS tissue.

[0335] In further embodiments, administration reduces pathological tau phosphorylation, including reductions in pTaul81 / total tau and pTau217 / total tau. The compound also attenuates neuroinflammation by reducing IBA1 levels and decreasing microglial activation. Collectively, these effects support a multimodal, disease-modifying profile characterized by concurrent reduction of amyloid pathology, improvement of synaptic integrity, suppression of neuroinflammation, and modulation of key signaling pathways. The invention further encompasses methods of treating Alzheimer’s disease using a CNS-penetrant compound that achieves target-relevant CNS pharmacodynamics, including unbound brain exposure sufficient to modulate the AKT-GSK3p axis, amyloid-related biomarkers, and / or synaptic markers.

[0336] Formulations, Routes of Administration, and Dosing

[0337] The compounds of the invention, and pharmaceutically acceptable salts or solvates thereof, can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient, in a variety of forms adapted to the chosen route of administration, e.g., orally, intranasally, or parenterally by intravenous, intraperitoneal, intramuscular, topical, or subcutaneous routes. Additional routes of administration are also contemplated by the disclosure.

[0338] Thus, the present compounds or pharmaceutically acceptable salts or solvates thereof may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets,Attorney Docket# COGN-01-PCT

[0339] or may be incorporated directly with the food of the patient's diet. For oral therapeutic administration, the active compound (i.e., a compound of the invention or a pharmaceutically acceptable salt or solvate thereof), may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2% to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.

[0340] The tablets, troches, pills, capsules, and the like may also contain the following diluents and carriers: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices.

[0341] The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound can be prepared in water or physiologically acceptable aqueous solution, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

[0342] The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active compound which are adapted for the extemporaneous preparation of sterile injectable or infusibleAttorney Docket# COGN-01-PCT

[0343] solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

[0344] Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation can include vacuum drying and the freeze drying techniques, which yield a powder of the active compound plus any additional desired ingredient present in the previously sterile-filtered solutions.

[0345] Additional rout of administration includes intranasal delivery.

[0346] Useful dosages of the compounds of the invention, or pharmaceutically acceptable salts or solvates thereof, can be determined, at least initially, by comparing their in vitro activity and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known in the art; for example, see U. S. Pat. No. 4,938,949 (incorporated herein by reference).

[0347] The amount of the compound, or pharmaceutically acceptable salt or solvate thereof, required for use in treatment will vary not only with the particular compound or salt selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.

[0348] In general, however, a suitable dose will be in the range of from about 0.5 to about 100 mg / kg body weight of the recipient per day, e.g., from about 3 to about 90 mg / kg of body weight per day, from about 6 to about 75 mg per kilogram of body weight per day,Attorney Docket# COGN-01-PCT

[0349] from about of 10 to about 60 mg / kg of body weight per day, or from about 15 to about 50 mg / kg of body weight per day.

[0350] Compounds of the invention, or pharmaceutically acceptable salts or solvates thereof, can be conveniently formulated in unit dosage form; for example, containing 5 to 1000 mg, 10 to 750 mg, or 50 to 500 mg of active compound per unit dosage form. In one embodiment, the invention provides a composition comprising a compound of the invention, or pharmaceutically acceptable salt or solvate thereof, formulated in such a unit dosage form. The desired dose may conveniently be presented in a single dose or as divided doses to be administered at appropriate intervals, for example, as two, three, four or more subdoses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations.

[0351] Compounds of the invention, or pharmaceutically acceptable salts or solvates thereof, can also be administered in combination with one or more other therapeutic agents. In certain embodiments, such additional therapeutic agents comprise agents useful for treating, delaying progression of, or preventing neurodegenerative, neuroinflammatory, or cognitive disorders, including disorders associated with amyloid pathology, altered APP processing, synaptic dysfunction, and / or neuroinflammation. Non-limiting examples include Alzheimer’s disease (including sporadic and familial Alzheimer’s disease), mild cognitive impairment (MCI) due to Alzheimer’s disease, prodromal Alzheimer’s disease, cerebral amyloid angiopathy (CAA), Down syndrome-associated Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia, frontotemporal dementia, vascular cognitive impairment and vascular dementia, traumatic brain injury (including chronic traumatic encephalopathy), age-related cognitive decline and age-related memory impairment, and other Ap- and / or tau-associated neurodegenerative conditions.

[0352] Other delivery systems can include time-release, delayed release, or sustained release delivery systems such as are well-known in the art. Such systems can avoid repeated administrations of the active compound, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. Use of a long-term sustained release implant may be desirable. Long-term release, as used herein, means that the delivery system or is implant constructed and arranged to deliver therapeutic levels of the active compound for at least 30 days, and preferably 60 days.

[0353] Attorney Docket# COGN-01-PCT

[0354] It will be understood by one of ordinary skill in the relevant arts that other suitable modifications and adaptations to the compositions and methods described herein are readily apparent from the description of the invention contained herein in view of information known to the ordinarily skilled artisan, and may be made without departing from the scope of the invention or any embodiment thereof.

[0355] Examples

[0356] Having now described the present disclosure in detail, the same will be more clearly understood by reference to the following examples, which are included herewith for purposes of illustration only and are not intended to be limiting of the invention.

[0357] SYNTHETIC METHODS AND SCHEMES OF THE COMPOSITIONS

[0358] The following examples represent synthetic routes to the compounds of the disclosure.

[0359] Attorney Docket# COGN-01-PCT

[0360] Scheme 1. Synthesis of Key Diol Intermediates

[0361]

[0362] Attorney Docket# COGN-01-PCT

[0363] Scheme 2. Suzuki Coupling

[0364]

[0365] Attorney Docket# COGN-01-PCT

[0366] Scheme 3. Reverse Suzuki Coupling

[0367]

[0368] Details of the synthetic methods are provided herein.

[0369] Preparation of intermediates (17?,25,4s)-4-(4-bromo-2-methoxyphenoxy)cvclopentane-l,2-diol (1-1) and -4-(4-bromo-2-methoxyphenoxy)cvclopentane-l,2-diol (1-1**).

[0370]

[0371] Attorney Docket# COGN-01-PCT

[0372] 4-bromo-l-(cyclopent-3-en-l-yloxy)-2-methoxybenzene (3)

[0373] In a stirred solution of cyclopent-3 -en-l-ol (1) (8 g, 95.10 mmol) in toluene (150 mL) was added 4-bromo-2-methoxy-phenol (2) (21.45 g, 104.6 mmol) under a nitrogen atmosphere. The solution was stirred at room temperature, and then triphenylphosphine (PPhs) (47.02 g, 142.7 mmol) was added and allowed the reaction mixture to stir at room temperature for 15 min. cooled the reaction mass to 0 °C and diethyl azodicarboxylate (DEAD) (40% in toluene) (52.24 mL, 142.7 mmol) was added in a dropwise manner. The reaction mixture was stirred at room temperature for 16 h, monitored by TLC (20% EtOAc / heptane, 0.8 Rf). Upon completion, the reaction was quenched by adding water (50 mL). The product was extracted with EtOAc, and the organic layer was dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure. The crude product was purified by combi-flash column chromatography (silica gel, 230-400 mesh) and eluted with 10-20% EtOAc / heptane to obtain 4-bromo-l -(cyclopent-3 -en-l-yloxy)-2-methoxybenzene (3, 26 g, 91% yield) as a white solid.

[0374] ¹H NMR (400 MHz, DMSO-d₆) 6 = 7.09 - 7.02 (m, 2H), 6.88 (d, J= 8.8 Hz, 1H), 5.73 (br s, 2H), 5.01-4.98 (m, 1H), 3.76 - 3.72 (m, 4H), 2.76 (dd, J= 16.8, 6.4 Hz, 2H), 2.38 (d, J = 17.6 Hz, 2H).

[0375] (ll?,2N,4s)-4-(4-bromo-2-methoxyphenoxy)cyclopentane-l,2-diol (1-1) and (lR,2S,4r)~ 4-(4-bromo-2-methoxyphenoxy)cyclopentane-l,2-diol (1-1**)

[0376] In a stirred solution of 4-bromo-l -(cyclopent-3 -en-l-yloxy)-2-methoxybenzene (3) (6.4 g, 24 mmol) in acetone (200 mL) and water (12 mL) was added osmium tetroxide solution 4 wt% in water (OsO4) (7.2 mL, 1.13 mmol) followed by 7V-methylmorpholine 7V-oxide (NMO) (12 mL, 105.63 mmol) under an inert atmosphere. The mixture was stirred at room temperature for 1 h, with reaction progress monitored by TLC (50% EtOAc / heptane, 0.1 Rf). Upon completion, the reaction was quenched by 0.2% aq. sodium thiosulfate solution and extracted with EtOAc and washed with water. The organic layer was dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure to obtain the crude. The crude product was purified by column chromatography (silica gel, 230-400 mesh) and eluted with 70-100% EtOAc / heptane to obtain (l / ?,2, S',4.s)-4-(4-bromo-2-methoxyphenoxy)cyclopentane-l,2-diol (1-1, 3.2 g, 44% yield) and (U?,25,4r)-4-(4-bromo-2-methoxyphenoxy)cyclopentane-l,2-diol (1-1**, 0.83 g, 12% yield).

[0377] 1-1: 'H NMR (400 MHz, DMSO-d6) 6 = 7.08 (d, J= 2.4 Hz, 1H), 7.02 (dd, J= 2.3, 8.4 Hz, 1H), 6.81 (d, J= 8.6 Hz, 1H), 4.79-4.75 (m, 1H), 4.51 (d, J= 4.2 Hz, 2H), 4.03 - 3.97 (m,

[0378] Attorney Docket# COGN-01-PCT

[0379] 1H), 3.75 (s, 3H), 2.08 - 1.99 (m, 2H), 1.84 - 1.76 (m, 2H) ppm; LCMS: 99% [M+18]+= 320.1. Chiral HPLC: 99%. (Note: NOESY data supported the assigned structure).

[0380] 1-1**: ¹H NMR (401 MHz, DMSO-d6) 6 = 7.08 (d, J= 2.3 Hz, 1H), 7.01 (dd, J= 2.3, 8.6 Hz, 1H), 6.80 (d, J= 8.7 Hz, 1H), 4.60 - 4.54 (m, 1H), 4.51 (d, J= 4.5 Hz, 2H), 3.80 - 3.77 (m, 2H), 3.75 (s, 3H), 2.27 - 2.20 (m, 2H), 1.74-1.68 (m, 2H) ppm; LCMS: 97% [M+18]+= 320.0. Chiral HPLC: 96%. (Note: NOESY data supported the assigned structure).

[0381] Preparation of intermediates -4-(2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2-

[0382]

[0383] dioxaborolan-2-yl)phenoxy) cyclopentane- 1,2-diol (1-2) and (17?,2N,4r)-4-(2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy) cyclopentane- 1,2-diol (1-.

[0384]

[0385]

[0386] To a degassed solution of 1-1 or 1-1** in 1,4-dioxane (5-10 mL) was added potassium acetate (3 eq.), bis(pinacolato)diboron (1 eq.) and [l,l'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) (0.1-0.15 eq.) at room temperature. The resulting reaction mixture was allowed to stir at 100°C for 8 h. The reaction progress was monitored by TLC (50% EtOAc in / / -heptane). After completion of the reaction, the reaction mixture was cooled, filtered over a celite bed and washed with EtOAc. The combined filtrate was washed with water, dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure to obtain the crude product boronate esters which were used in subsequent reaction without further purification.

[0387] (ll?,2N,4s)-4-(2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy) cyclopentane- 1,2-diol (1-2)

[0388] Prepared from 1-1 (220 mg) to obtain 1-2 (220 mg). LCMS: 72.5%, [M+18]+= 368.1.

[0389] (ll?,2N,4r)-4-(2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy) cyclopentane- 1,2-diol (1-2**)

[0390] Attorney Docket# COGN-01-PCT

[0391] Prepared from 1-1** (300 mg) to obtain 1-2** (290 mg). LCMS: 77.2%, [M+H]+= 351.1.

[0392] Preparation of intermediates ( 1 / .2. S.4v)-4-(4-broiiioi)lieiioxy)cvcloi)entane-l.2-diol (I- and (l / ?,25,4r)-4-(4-l -1.2-diol (1-3**

[0393]

[0394] Synthesis of l-bromo-4-(cyclopent-3-en-l-yloxy)benzene (5)

[0395] In a stirred solution of cyclopent-3 -en-l-ol (1, 2g, 23.78 mmol) in toluene (38 mL) was added 4-bromophenol (4, 4.52 g, 26.1 mmol) under a nitrogen atmosphere. The solution was stirred at room temperature, and then triphenylphosphine (PPhs) (9.34 g, 28.3 mmol) was added and stirred at room temperature for 15 min. Then cooled the reaction mass to 0 °C, diethyl azodi carb oxy late (DEAD) (40% in toluene) (5.64 mL, 28.3 mmol) was added in a dropwise manner. The resulting reaction mixture was allowed to warm to room temperature and stirred for 16 h. The progress of the reaction was monitored by TLC (20% EtOAc / heptane, 0.8 Rf). Upon completion, the reaction was quenched by adding water (50 mL). The product was extracted with EtOAc, the organic layer was dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure. The crude product was purified by combi-flash column chromatography (silica gel, 100-200 mesh, eluent: 10-20% EtOAc in n-heptane) to get l-bromo-4-(cy cl opent-3 -en-l-yloxy)benzene (5, 4.6 g, 73% yield) as a colourless liquid.1H NMR (400 MHz, DMSO-d6): 8 = 7.43 (d, J= 9.1 Hz, 2H), 6.88 (d, J= 9.1 Hz, 2H), 5.75 (s, 2H), 5.04 (br t, J= 6.8 Hz, 1H), 2.79 (br dd, J= 6.8, 16.6 Hz, 2H), 2.45 - 2.30 (m, 2H) ppm.

[0396] (ll?,25',4s)-4-(4-bromophenoxy)cyclopentane-l,2-diol (1-3) and (ll?,25',4r)-4-(4-bromophenoxy)-cyclopentane-l,2-diol (1-3**)

[0397] To a stirred solution of l-bromo-4-(cy cl opent-3 -en-l-yloxy)benzene (12, 4.6 g, 19 mmol) in acetone (152 mL) and water (9.2 mL) was added osmium tetroxide solution 4 wt% in water (OSO4) (6 mL, 0.95 mmol) followed by A-methylmorpholine A-oxide (NMO) (9.2 mL, 83.6 mmol) under an inert atmosphere. The resulting reaction mixture was stirred at room temperature for 1 h. The progress of the reaction was monitored by TLC (50% EtOAc / heptane, 0.1 Rf). Upon completion, the reaction was quenched by 0.2% aq. sodiumAttorney Docket# COGN-01-PCT

[0398] thiosulfate solution, extracted with EtOAc and washed with water. The organic layer was dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure to obtain the crude. The crude product was purified by column chromatography (silica gel, 230-400 mesh, eluent: 70-100% EtOAc in / / -heptane) to obtain (lA,25,45)-4-(4-bromophenoxy)cyclopentane-l,2-diol (1-3, 1 g, 19% yield) and (lA,25,4r)-4-(4-bromophenoxy)cyclopentane-l,2-diol (1-3**), 2 g, 38% yield).

[0399] 1-3; 'H NMR (400 MHz, DMSO-d6) 6 = 7.41 (br d, J= 8.8 Hz, 2H), 6.82 (br d, J= 8.8 Hz, 2H), 4.82 (br s, 1H), 4.58 - 4.47 (m, 2H), 4.00 (br s, 2H), 2.14 - 2.01 (m, 2H), 1.76 - 1.8 (m, 2H) ppm; LCMS: 99% [M-H]’ = 371.1. Chiral HPLC: 100%. (Note: NOESY data supported the assigned structure).

[0400] 1-3**: 'H NMR (400 MHz, DMSO-d6) 6 = 7.45 - 7.37 (m, 2H), 6.84 - 6.78 (m, 2H), 4.66 - 4.57 (m, 1H), 4.53 (d, J= 4.4 Hz, 2H), 3.83 - 3.74 (m, 2H), 2.29 - 2.21 (m, 2H), 1.74 -1.65 (m, 2H) ppm; LCMS: 91% [M+H]+= 373.14. Chiral HPLC: 97%. (Note: NOESY data supported the assigned structure).

[0401] Preparation of intermediates -4-(4-bromo-2-chloroDhenoxy)cvcloDentane-

[0402]

[0403] 1,2-diol (1-4) and ( 1 / L2. S.4r)-4-(4-broiiio-2-chloroi)henoxy)cvcloi)eiitane-l,2-diol (I-

[0404]

[0405] Synthesis of 4-bromo-2-chloro-l-(cyclopent-3-en-l-yloxy)benzene (7)

[0406] To a stirred solution of cyclopent-3 -en-l-ol (1, 2g, 23.30 mmol) in toluene (38 mL) was added 4-bromo-2-chlorophenol (6, 5.45 g, 25.7 mmol) under nitrogen atmosphere. The solution was stirred at room temperature, and then triphenylphosphine (PPhs) (10 g, 30.34 mmol) was added and allowed the reaction mixture to stir at room temperature for 15 min. Then cooled the reaction mass to 0 °C and diethyl azodicarboxylate (DEAD) (40% in toluene) (5.64 mL, 30.34 mmol) was added in a dropwise manner. The reaction mixture was stirred at room temperature for 16 h. Progress of the reaction was monitored by TLC (20% EtOAc / heptane, 0.8 Rf). Upon completion, the reaction was quenched by adding water (50 mL). The product was extracted with EtOAc, and the organic layer was dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure. The crudeAttorney Docket# COGN-01-PCT

[0407] product was purified by combi-flash column chromatography (silica gel, 100 - 200 mesh; eluent: 10% EtOAc / heptane) to get 4-bromo-2-chl oro-1 -(cyclopent-3 -en-l-yloxy)benzene (7, 4.5 g, 64% yield) as a colourless liquid. 'H NMR (400 MHz, DMSO-d6) 6 = 7.66 (d, J = 2.6 Hz, 1H), 7.48 (dd, J= 2.5, 8.9 Hz, 1H), 7.12 (d, J= 8.9 Hz, 1H), 5.79 - 5.74 (m, 2H), 5.15 - 5.10 (m, 1H), 2.83 (dd, J= 6.8, 16.6 Hz, 2H), 2.44 - 2.37 (m, 2H) ppm.

[0408] (ll?,2N,4s)-4-(4-bromo-2-chlorophenoxy)cyclopentane-l,2-diol (1-4) and (lR,2S,4r)-4-(4-bromo-2-chlorophenoxy)cyclopentane-l,2-diol (1-4**)

[0409] To a stirred solution of 4-bromo-2-chl oro-1 -(cyclopent-3 -en-l-yloxy)benzene (7) (3 g, 9.87 mmol) in acetone (100 mL) and water (6 mL) was added osmium tetroxide solution 4 wt% in water (OSO4) (3.2 mL, 0.5 mmol) followed by A-methylmorpholine A -oxi de (NMO) (5.5 mL, 43.42 mmol) under an inert atmosphere. The resulting reaction mixture was stirred at room temperature for 1 h. Progress of the reaction was monitored by TLC (50% EtOAc / heptane, 0.1 Rf). Upon completion, the reaction was quenched by 0.2% aq. sodium thiosulfate solution, extracted with EtOAc and washed with water. The organic layer was dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (silica gel, 230-400 mesh, eluent: 70-100% EtOAc / heptane) to obtain a mixture of 1-4 and 1-4** as a brown liquid. 'H NMR (400 MHz, DMSO-d6) 6 = 7.67 - 7.61 (m, 1H), 7.48 - 7.41 (m, 1H), 7.06 - 6.99 (m, 1H), 4.94 - 4.87 (m, 1H), 4.72 - 4.54 (m, 2H), 4.07 - 3.77 (m, 2H), 2.14 - 2.03 (m, 2H), 1.88 - 1.71 (m, 2H) ppm; LCMS: 98% [M+H]+= 307; Chiral HPLC: 73.2% + 25.4%.

[0410] The mixture of 1-4 and 1-4** (2.5 g, 8 mmol) was purified by Chiral SFC method [Column name: Chiral PAK IG (30 x 250 mm, 5pm); mobile phase A: CO2; mobile phase B: 0.1 % methanolic ammonia in MeOH; Flow rate: 120g - 30%, 100 bar] to obtain (lA,25,45)-4-(4-bromo-2-chlorophenoxy)cyclopentane-l,2-diol (1-4, 1.6 g, 65% yield) as white solid and (lA,2£,4s)-4-(4-bromo-2-chlorophenoxy)cyclopentane-l,2-diol (1-4**, 0.52 g, 21%, yield) as white solid.

[0411] 1-4: 'H NMR (400 MHz, DMSO-d6) 6 = 7.64 (d, J= 2.4 Hz, 1H), 7.44 (dd, J= 2.8, 9.2 Hz, 1H), 7.03 (br d, J= 8.8 Hz, 1H), 4.92 - 4.88 (m, 1H), 4.5 (d, J= 4.4 Hz, 2H) 4.02 (d, J= 4 Hz, 2H), 2.12 - 2.05 (m, 2H), 1.84-1.80 (m, 2H) ppm; LCMS: 98% [M+45]+= 351.04;

[0412] Chiral HPLC: 97%. (Note: NOESY data supported the assigned structure).

[0413] Attorney Docket# COGN-01-PCT

[0414] 1-4**: 'H NMR (400 MHz, DMSO-d6) 6 = 7.64 (br s, 1H), 7.45 (br d, J= 8.8 Hz, 1H), 7.01 (br d, J= 8.8 Hz, 1H), 4.69 (br s, 1H), 4.57 (br s, 2H), 3.80 (br s, 2H), 2.22-2.38 (m, 2H), 1.65-1.85 ppm (m, 2H) ppm; LCMS: 99.3% [M-H]‘ = 306.9; Chiral HPLC: 100%.

[0415] (Note: NOESY data supported the assigned structure).

[0416]

[0417] 2. S.4v)-4-(4-bromo-2-m

[0418]

[0419] 1,2-diol

[0420]

[0421] 2. S.4r)-4-(4-bromo-2-m

[0422]

[0423] -1.2-diol (I- 5**

[0424]

[0425] Synthesis of 4-bromo-l-(cyclopent-3-en-l-yloxy)-2-methylbenzene (9)

[0426] In a stirred solution of cyclopent-3 -en-l-ol (1, 1.5 g, 17.48 mmol) in toluene (15 mL) was added 4-bromo-2 -methylphenol (8, 2.5 g, 13.1 mmol) under a nitrogen atmosphere. The solution was stirred at room temperature, triphenylphosphine (PPhs) (6 g, 18.2 mmol) was added and the reaction mixture was allowed to stir at room temperature for 15 min. The reaction mixture was cooled to 0 °C and diethyl azodi carb oxy late (DEAD) (40% in toluene) (3.18 mL, 18.2 mmol) was added in a dropwise manner. The reaction mixture was stirred at room temperature for 16 h. The progress of the reaction was monitored by TLC (20% EtOAc / heptane, 0.8 Rf). Upon completion, the reaction was quenched by adding water (50 mL). The product was extracted with EtOAc, and the organic layer was dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure. The crude product was purified by combi-flash column chromatography (silica gel, 100-200 mesh; eluent: 10% EtOAc / heptane to get 4-bromo-l -(cyclopent-3 -en-l-yloxy)-2 -methylbenzene (9, 2.4 g, 65% yield) as colourless liquid. 'H NMR (400 MHz, DMSO-d6) 6 = 7.34 - 7.26 (m, 2H), 6.88 (d, J= 8.6 Hz, 1H), 5.75 (s, 2H), 5.03 (br t, J= 6.8 Hz, 1H), 2.87 - 2.74 (m, 2H), 2.42 - 2.35 (m, 2H), 2.08 (s, 3H) ppm.

[0427] (ll?,2N,4s)-4-(4-bromo-2-methylphenoxy)cyclopentane-l,2-diol (1-5) and ( 1 / L2. S.4r )-4- (4-bromo-2-methylphenoxy)cyclopentane-l,2-diol (1-5**)

[0428] Attorney Docket# COGN-01-PCT

[0429] To a stirred solution of 4-bromo-l -(cyclopent-3 -en-l-yloxy)-2-methylbenzene (9, 2.5 g, 9.4 mmol) in acetone (90 mL) and water (5 mL) was added osmium tetroxide solution 4 wt% in water (OsO4) (4 mL, 0.6 mmol) followed by N-methylmorpholine N-oxide (NMO) (3 mL, 41.36 mmol) under an inert atmosphere. The mixture was stirred at room temperature for 1 h, with reaction progress monitored by TLC (50% EtOAc / heptane, 0.1 Rf). Upon completion, the reaction was quenched by 0.2% aq. sodium thiosulfate solution and extracted with EtOAc and washed with water. The organic layer was dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure to obtain the crude. The crude product was purified by column chromatography (silica gel, 230-400 mesh; eluent: 70-100% EtOAc / heptane to obtain a mixture of 1-5 and 1-5**, 2.46 g, 90% yield) as yellow solid. Purification by Chiral SFC (Column name: CHIRALPAK IG (30 x 250 mm, 5pm); mobile phase A: CO2; mobile phase B: 0.1 % ammonia in MeOH; Flow rate: 90 g - 30%, 100 bar) gave (lA,2£,4s)-4-(4-bromo-2-methylphenoxy)cyclopentane-l,2-diol (1-5, 1.2 g, 48% yield) and (lA,25,4r)-4-(4-bromo-2-methylphenoxy)cyclopentane-l,2-diol (1-5**, 0.70 g, 19%, yield) as white solids.

[0430] 1-5: 'H NMR (400 MHz, DMSO-d6) 6 = 7.30 - 7.25 (m, 2H), 6.78 (d, J= 8.4 Hz, 1H), 4.82 - 4.79 (m, 1H), 4.51 (d, J= 4.4 Hz, 2H), 4.03 - 3.98 (m, 2H), 2.13 - 2.03 (m, 5H), 1.83 - 1.78 (m, 2H) ppm; LCMS: 93% [M+H]+= 287.0. Chiral HPLC: 95%. (NOESY data supported the assigned structure).

[0431] 1-5**: 'H NMR (400 MHz, DMSO-d6) 6 = 7.30 - 7.24 (m, 2H), 6.78 (d, J= 8.8 Hz, 1H), 4.62 - 4.59 (m, 1H), 4.48 (d, J= 4.8 Hz, 2H), 3.81 - 3.78 (m, 2H), 2.28 - 2.22 (m, 2H), 2.10 (s, 3H), 1.74 - 1.68 (m, 2H) ppm; LCMS: 93% [M+H]+= 287.0. Chiral HPLC: 93%. (NOESY data supported the assigned structure).

[0432]

[0433] Attorney Docket# COGN-01-PCT

[0434]

[0435] 2,6-dimethylhepta-l,6-dien-4-ol (12)

[0436] To a stirred solution of ethyl formate (10, 5.0 g, 66 mmol) in diethyl ether (20 mL) at 0 °C, 2-methylallylmagnesuim chloride solution (11, 0.5 mol / L) in THF (270 mL, 100 mmol, 0.5 mol / L) was added. The resulting reaction mixture was allowed to stir at room temperature for 2 h. The progress of the reaction was monitored by TLC (2% EtOAc in heptane). After completion of the reaction, the reaction mixture was quenched with saturated aq. ammonium chloride solution and extracted with diethyl ether. The organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure (bath temperature below 20 °C, the compound was highly volatile). The crude product was purified by column chromatography (using silica gel, 100-200 mesh size, eluent: 1-2% EtOAc in / / -heptane) to afford 2,6-dimethylhepta-l,6-dien-4-ol (12, 3.5 g, 34% yield) as colourless liquid. 'H NMR (400 MHz, CDCh) 6 = 4.88 (s, 2H), 4.80 (s, 2H), 3.88 - 3.83 ( m, 1H), 2.29 - 2.09 (m, 4H), 1.78 (s, 6H) ppm.

[0437] 4-bromo-2-methoxy-l-[3-methyl-l-(2-methylallyl)but-3-enoxy] benzene (13)

[0438] To a stirred solution of 2,6-dimethylhepta-l,6-dien-4-ol (12, 2.0 g, 10 mmol) in THF (10 mL) at room temperature was added 4-bromo-2-methoxy-phenol (2, 1.0 g, 4.7 mmol) was added under a nitrogen atmosphere. The solution was stirred at room temperature, and then triphenylphosphine (PPFu) (1.5 g, 5.6 mmol) was added and stirred at room temperature for 15 min. Then cooled the reaction mass to 0 °C, diethyl azodi carb oxy late (DEAD) (40% in toluene) (1.0 mL, 7.6 mmol) was added in a dropwise manner. The resulting reaction mixture was allowed to warm to room temperature and stirred for 16 h. The progress of the reaction was monitored by TLC (20% EtOAc / heptane, 0.8 Rf). Upon completion, the reaction was quenched by adding water (50 mL). The product was extracted with EtOAc, and the organic layer was dried over anhydrous sodium sulphate, filtered, and concentratedAttorney Docket# COGN-01-PCT

[0439] under reduced pressure. The crude product was purified by combi-flash column chromatography (silica gel, 100-200 mesh, eluent: 10-20% EtOAc in / / -heptane) to afford 4-bromo-2-methoxy-l-[3-methyl-l-(2-methylallyl)but-3-enoxy]benzene (13, 700 mg, 41% yield) as a pale-yellow liquid.1H NMR (400 MHz, DMSO-d6) 8 = 7.10 (s, 1H), 7.07 - 6.99 (m, 1H), 6.99 - 6.91 (m, 1H), 4.87 - 4.70 (m, 4H), 4.65 - 4.56 (m, 1H), 3.75 (s, 3H), 2.36 -2.20 (m, 4H), 1.76 (s, 6H) ppm; LCMS: 93%, [M+2]+= 325.09

[0440] 4-bromo-l-(3,4-dimethylcyclopent-3-en-l-yl)oxy-2-methoxy-benzene (14)

[0441] In a degassed solution of l-bromo-4-[3 -methyl- 1 -(2 -methylallyl)but-3-enoxy]benzene (13, 1.5 g, 4.8 mmol) in toluene (100 mL) was added (l,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene)di chloro (phenylmethylene)(tricyclohexylphosphine)ruthenium

[0442] (Grubbs-Hovey da 2ndgen) (150 mg, 0.17 mmol) at room temperature. The reaction mixture was stirred for at 100 °C for 4 hours. The progress of the reaction was monitored by TLC (2% EtOAc / n- heptane). After completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with diethyl ether. The organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel, 100-200 mesh, eluent: 5-10% EtOAc in / / -heptane) to afford 4-bromo-l -(3, 4-dimethylcy cl opent-3 -en-l-yl)oxy-2-m ethoxybenzene (14, 700 mg, 46% yield) as an off-white solid.1H NMR (400 MHz, DMSO-de) 6 = 7.11 - 6.99 (m, 2H), 6.84 (br d, J= 8.8 Hz, 1H), 4.87 (br s, 1H), 3.74 (s, 3H), 2.79 - 2.69 (m, 2H), 2.35 - 2.26 (m, 2H), 1.60 (s, 6H) ppm; LCMS: 93%, [M+2] = 325.09.

[0443] (lR,2S,4s)-4-(4-bromo-2-methoxyphenoxy)-l,2-dimethylcyclopentane-l,2-diol (1-6) and (lR,2S,4r)-4-(4-bromo-2-methoxyphenoxy)-l,2-dimethylcyclopentane-l,2-diol (I-6**)

[0444] To a stirred solution of 4-bromo-l -(3, 4-dimethylcy cl opent-3 -en-l-yl)oxy-2-m ethoxybenzene (14) (1.5 g, 4.8 mmol) in acetone (50 mL) and water (2 mL) was added osmium tetroxide solution (OsO4) (3.0 mL, 4 wt% in water) followed by N-methylmorpholine N-oxide (NMO) (3 mL, 50 wt% in water) under an inert atmosphere. The mixture was stirred at room temperature for 6 h, with reaction progress monitored by TLC (50% EtOAc / heptane, 0.1 Rf). Upon completion, the reaction was quenched by 0.2% aq. sodium thiosulfate solution and extracted with EtOAc and washed with water. The organic layer was dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure to obtain the crude. The crude product was purified by column chromatographyAttorney Docket# COGN-01-PCT

[0445] (silica gel, 100-200 mesh, eluent: 40-50% EtOAc in ^-heptane) to obtain a mixture 1-6 and 1-6** (1.1 g, 68% yield) as an off-white sticky oil. LCMS: 99%, [M+Na]+ = 357.05.

[0446] The mixture was purified by chiral preparative SFC (Column name: Chiral PAK IC (30 x 250 mm, 5p); mobile phase A: CO2; mobile phase B: 0.1 % methanolic ammonia in methanol; Flow rate: 90g, 15%, 100 bar) to afford (lA,2£,4 )-4-(4-bromo-2-methylphenoxy)cyclopentane-l,2-diol (1-6, 510 mg) as a white gummy solid and (lA,25,4r)-4-(4-bromo-2-methylphenoxy)cyclopentane-l,2-diol (1-6**, 236 mg) as pale yellow gummy solid.

[0447] 1-6: 'H NMR (400 MHz, DMSO-d6) 6 = 7.08 (d, J= 2.0 Hz, 1H), 7.02 (dd, J= 2.4 Hz, 8.4 Hz, 1H), 6.78 (d, J= 8.8, 1H), 4.73 - 4.71 (m, 1H), 4.23 (s, 2H), 3.76 (s, 3H), 2.34 - 2.28 (m, 2H), 1.70 - 1.66 (m, 2H), 1.13 (s, 6H); LCMS: 97%, [M+Na]+ = 354.17; Chiral HPLC: 100%. (Note: NOESY data supported the assigned structure).

[0448] 1-6**: 'H NMR (400 MHz, DMSO-d6) 6 = 7.06 (d, J= 2 Hz, 1H), 7.01 (dd, J= 2.4 Hz, 8.4 Hz, 1H), 6.79 (d, J= 8.8 Hz, 1H), 4.60 - 4.53 (m, 1H), 4.22 (s, 2H), 3.74 (s, 3H), 2.17 -2.11 (m, 2H), 1.98 - 1.94 (m, 2H), 1.04 (s, 6H); LCMS: 94%, [M+Na]+ = 355.02; Chiral HPLC: 96%. (Note: NOESY data supported the assigned structure).

[0449] Preparation of intermediates (lR,2R)-4-(4-bromo-2-methoxyphenoxy)-l,2-dimethylcvdopentane-l,2-diol (1-7) and (lR,2R)-4-(4-bromo-2-methoxyphenoxy)-l,2-dimethylcvdopentane-l,2-diol (1-7**).

[0450]

[0451] 3-(4-bromo-2-methoxy-phenoxy)-l,5-dimethyl-6-oxabicyclo[3.1.0]hexane (15)

[0452] In a stirred solution of 4-bromo-l -(3, 4-dimethylcy cl opent-3 -en-l-yl)oxy-2-m ethoxybenzene (14) (100 mg, 0.32 mmol) in dichloromethane (3 mL) at 0 °C, was added 3-chloroperoxybenzoic acid (95 mg, 0.52 mmol). The resulting reaction mixture was stirred at room temperature for 16 h. The progress of the reaction was monitored by TLC (50% EtOAc / w-heptane). After completion of the reaction, the reaction mixture was extracted withAttorney Docket# COGN-01-PCT

[0453] di chloromethane, washed with sodium bicarbonate solution, the organic layer was separated and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel, 100-200 mesh, eluent: 40-50% EtOAc in / / -heptane to afford 3-(4-bromo-2-methoxy-phenoxy)-l,5-dimethyl-6-oxabicyclo[3.1.0]hexane (15, 90 mg, 87% yield) as pale yellow gummy solid.

[0454] 'H NMR (400 MHz, DMSO-d6) 6 = 7.09 (s, 1H), 7.00 (br d, J= 8.4 Hz, 1H), 6.89 (br d, J = 8.4 Hz, 1H), 4.36 - 4.33 (m, 1H), 3.75 (s, 3H), 2.56 - 2.53 (m, 2H), 1.80 - 1.74 (m, 2H), 1.31 (s, 6H) ppm; LCMS: 97%, 97% [M+23]+= 337.06.

[0455] (lR,2R)-4-(4-bromo-2-methoxyphenoxy)-l,2-dimethylcyclopentane-l,2-diol (1-7) and (lR,2R)-4-(4-bromo-2-methoxyphenoxy)-l,2-dimethylcyclopentane-l,2-diol (1-7**)

[0456] In a stirred solution of 3-(4-bromo-2-methoxy-phenoxy)-l,5-dimethyl-6-oxabicyclo[3.1.0]hexane (15) (900 mg, 2.82 mmol) in THF (10 mL), water (2.5 mL) and trifluoroacetic acid (0.5 mL) were added at room temperature. The resulting reaction mixture was stirred at 100°C for 16 h. The progress of the reaction was monitored by TLC (100% EtoAc). After completion of the reaction, the reaction mixture was allowed to cool to room temperature and extracted with EtOAc. The organic layer was washed with sodium bicarbonate solution (30 mL) and the organic layer was separated, dried over anhydrous sodium sulphate, and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel, 100-200 mesh, eluent: 80-100% EtOAc in / / -heptane to afford a mixture of 1-7 and 1-7** (800 mg, 76.3% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-cL) 6 = 6.97 - 6.85 (m, 2H), 6.76 (d, J= 8.8, 1H), 4.72 - 4.66 (m, 1H), 4.36 (s, 1H), 4.30-4.20 (m, 1H), 3.74 (s, 3H), 2.35 - 2.30 (m, 1H), 2.16 - 2.03 (m, 2H), 1.71 (dd, J=2.4, 14.4 Hz, 1H), 1.13 (d, J = 14.0 Hz, 6H)ppm; LCMS: 98%, [M+Na]+= 355.21.

[0457] The mixture was purified by chiral preparative SFC (Column name: Chiral PAK IC (30 x 250 mm, 5p); mobile phase A: CO2; mobile phase B: 0.1 % methanolic ammonia in methanol; Flow rate: 90g, 15%, 100 bar) to afford (lA,2£,4 )-4-(4-bromo-2-methylphenoxy)cyclopentane-l,2-diol (1-7, 510 mg) as a white solid and (lA,25,4r)-4-(4-bromo-2-m ethylphenoxy )cy cl opentane-l,2-diol (1-7**, 236 mg) as a pale yellow solid.

[0458] 1-7: 'H NMR (400 MHz, DMSO-cL) 6 = 7.08 (d, J= 2.0 Hz, 1H), 7.02 (dd, J= 2.4 Hz, 8.4 Hz, 1H), 6.78 (d, J= 8.8, 1H), 4.73 - 4.71 (m, 1H), 4.23 (s, 2H), 3.76 (s, 3H), 2.34 - 2.28

[0459] Attorney Docket# COGN-01-PCT

[0460] (m, 2H), 1.70 - 1.66 (m, 2H), 1.13 (s, 6H); LCMS: 97%, [M+Na]+ = 354.1; Chiral HPLC:

[0461] 99%. Absolute stereochemistry was confirmed by x-ray crystallography.

[0462] 1-7**: 'H NMR (400 MHz, DMSO-d6) 6 = 7.06 (d, J= 2 Hz, 1H), 7.01 (dd, J = 2.4 Hz, 8.4 Hz, 1H), 6.79 (d, J= 8.8 Hz, 1H), 4.60 - 4.53 (m, 1H), 4.22 (s, 2H), 3.74 (s, 3H), 2.17 -2.11 (m, 2H), 1.98 - 1.94 (m, 2H), 1.04 (s, 6H); LCMS: 94%, [M+Na]+ = 355.02; Chiral HPLC: 96%

[0463]

[0464] -4-(4-broino-2-m

[0465]

[0466] 1,2-diol (1-8) and -4-(4-bromo-2-methoxyphenoxy)cvclopentane-l,2-diol (1-8**)

[0467]

[0468] 3-(4-bromo-2-methoxyphenoxy)-6-oxabicyclo [3.1.0] hexane (16)

[0469] To a stirred solution of 4-bromo-l -(cyclopent-3 -en-l-yloxy)-2-methoxybenzene (3) (5 g, 16.72 mmol) in dichloromethane (50 mL) was added 3-chloroperoxybenzoic acid (4.79 g, 26.4 mmol) at 0 °C and the reaction mixture was stirred at room temperature for 16 h. The progress of the reaction was monitored by TLC (30% EtOAc / w-heptane). After completion of the reaction, the reaction mixture was extracted with dichloromethane and the residue was washed with sodium carbonate solution (30 mL). The organic layer was separated dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure to obtain the crude product. This was purified by combi-flash column chromatography (silica gel, 100-200 mesh, eluent: 10-15% EtOAc / w-heptane) to afford 3-(4-bromo-2-methoxyphenoxy)-6-oxabicyclo[3.1.0]hexane (16, mixture of two isomers) 2.7 g, 56% yield a pale yellow liquid.

[0470] (17?,27?)-4-(4-bromo-2-methoxyphenoxy)cyclopentane-l,2-diol (1-8) and (15',25)-4-(4-bromo-2-methoxyphenoxy)cyclopentane-l,2-diol (1-8**).

[0471] To a stirred solution of 3-(4-bromo-2-methoxyphenoxy)-6-oxabicyclo[3.1.0]hexane (16) (2 mg, 5.2 mmol) in 1,4-dioxane (30 mL) and water (5 mL) was added hexacarbonylmolybdenum(O) (16 mg, 0.064 mmol) at room temperature and allowed the reaction mixture to stir at 95 °C for 16 h. The progress of the reaction was monitored byAttorney Docket# COGN-01-PCT

[0472] TLC (100% EtOAc). After completion of the reaction, the reaction mixture was extracted with EtOAc (100 mL) and washed with water (100 mL), organic layer was separated and concentrated under reduced pressure to afford crude which was purified by combi-flash column chromatography (silica gel, 100-200 mesh, eluent: 70-80% in EtOAc in / / -heptane to afford a mixture of 1-8 and 1-8** (580 mg, 32% yield) as white solid.1H NMR (400 MHz, DMSO-d6) 6 = 7.08 (s, 1H), 7.02 (br d, J= 8.7 Hz, 1H), 6.81 (br d, J= 8.3 Hz, 1H), 4.77 (br s, 2H), 4.71 (br s, 1H), 3.89 (br s, 1H), 3.75 (s, 3H), 2.46 - 2.38 (m, 2H), 1.96 - 1.87 (m, 2H), 1.54 - 1.44 (m, 1H) ppm; LCMS: 91% [M+H]+= 303.16. Chiral HPLC: 50% + 49%.

[0473] The crude mixture was purified by chiral SFC [Column: CHIRALPAK IG (250 x 30 mm) 5p particle size, mobile phase A: CO2, Mobile Phase B:0.1% methanolic ammonia in methanol) to obtain (lA,2A)-4-(4-bromo-2-methoxyphenoxy)cyclopentane-l,2-diol (1-8, Peak-1) (610 mg, 39% yield) and (15,25)-4-(4-bromo-2-methoxyphenoxy)cyclopentane-1,2-diol (1-8**, Peak-2) (700 mg, 45% yield)

[0474] 1-8: 'H NMR (400 MHz, CDCI3) 8 = 7.10 - 6.92 (m, 2H), 6.76 (d, J = 8.5 Hz, 1H), 4.92 (br t, J= 5.6 Hz, 1H), 4.40 (br s, 1H), 4.04 (br s, 1H), 3.82 (s, 3H), 2.90 (br d, J= 8.6 Hz, 1H), 2.46 - 2.31 (m, 1H), 2.30 - 2.26 (m, 1H), 2.03 - 1.88 (m, 2H), 1.73 (br d, J= 3.1 Hz, 1H) ppm; Chiral HPLC: 96%.

[0475] 1-8**: 'H NMR (400 MHz, CDCI3) 6 = 7.09 - 6.93 (m, 3H), 6.76 (d, J= 8.5 Hz, 1H), 4.92 (br t, J= 5.5 Hz, 1H), 4.40 (br d, J= 2.4 Hz, 1H), 4.05 - 3.97 (m, 1H), 2.89 (br d, J= 8.8 Hz, 1H), 2.47 - 2.31 (m, 1H), 2.31 - 2.23 (m, 1H), 2.04 - 1.90 (m, 2H), 1.71 (d, J= 3.1 Hz, 1H) ppm; Chiral HPLC: 96%. Absolute stereochemistry was confirmed by x-ray crystallography.

[0476] -4-(2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-

[0477]

[0478] yl)phenoxy)cvclopentane-l,2-diol (1-9) and (IN, 2l)-4-(2-methoxy-4-(4, 4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)phenoxy)cvclopentane- 1,2-diol (1-9 * *).

[0479]

[0480] Attorney Docket# COGN-01-PCT

[0481] To a degassed solution of 1-8 or 1-8** in 1,4-dioxane (5 mL) was added potassium acetate (3 mmol), bis(pinacolato)diboron (1 mmol) and [l,l'-bis(diphenylphosphino)ferrocene] dichloropalladium(II) (0.01 mol) were added at room temperature. The resulting reaction mixture was allowed to stir at 100°C for 8 h. The reaction progress was monitored by TLC (50% EtOAc in / / -heptane, 0.4 Rf). After completion of the reaction, the reaction mixture was filtered over a celite bed and washed with EtOAc. The combined filtrate was washed with water, dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure to obtain the crude product boronate esters which were used in subsequent reactions without further purification.

[0482] (ll?,21?)-4-(2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy)cyclopentane- 1,2-diol (1-9)

[0483] Prepared from 1-8 (200 mg, 0.65 mmol) to obtain 1-9 (520 mg). LCMS: 84.1%, [M+H]+= 351.1.

[0484] (15',25)-4-(2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy)cyclopentane- 1,2-diol (1-9* *)

[0485] Prepared from 1-8** (205 mg, 0.66 mmol) to obtain 1-9** (510 mg). LCMS: 72.6%, [M+H]+= 351.45

[0486]

[0487]

[0488] Step-1: Synthesis of 4-bromo-l-(cyclopent-3-en-l-yloxy)-2-(trifluoromethyl)benzene (18).

[0489] To a stirred solution of cyclopent-3 -en-l-ol (1, 2.0 g, 23.30 mmol) in toluene (38 mL) was added 4-bromo-2-(trifluoromethyl)phenol (17, 6.18 g, 25.60 mmol) followed by triphenylphosphine (9.35 g, 34.90 mmol) under a nitrogen atmosphere at room temperature. After stirring at room temperature for 15 min, diethyl azodicarboxylate (DEAD) (40% in

[0490] Attorney Docket# COGN-01-PCT

[0491] toluene) (5.6 mL, 34.95 mmol) was added at 0°C in a dropwise manner. The resulting reaction mixture was allowed to warm to room temperature and stirred for 16 h. The progress of the reaction was monitored by TLC (20% EtOAc in heptane, Rf= 0.8). After the completion of reaction, the reaction mixture was quenched with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layer was dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure. The crude compound was purified by combi-flash column chromatography by eluting with 10-20% EtOAc in heptane to afford 4-bromo-l -(cyclopent-3 -en-l-yloxy)-2-(trifluoromethyl)benzene (18, 3.70 g, 49% yield) as a colorless liquid.

[0492] 'H NMR (400 MHz, DMSO-d6): 6 = 7.78 (dd, J= 8.80, 2.40 Hz, 1H), 7.71 (d, J= 3.60 Hz, 1H), 7.23 (d, J= 8.80 Hz, 1H), 5.75-5.71 (m, 2H), 5.20-5.17 (m, 1H), 2.84-2.79 (m, 2H), 2.41-2.35 (m, 2H).

[0493] Step-2: Synthesis of (ll?,25',4s)-4-(4-bromo-2-(trifluoromethyl)phenoxy)cyclopentane-1,2-diol (1-10) and (17?,25',4r)-4-(4-bromo-2-(trifluoromethyl)phenoxy)cyclopentane-1,2-diol (1-10**).

[0494] To a stirred solution of 4-bromo-l -(cyclopent-3 -en-l-yloxy)-2-(trifluoromethyl)benzene (18, 3.5 g, 11 mmol) in acetone (115 mL) and water (7.0 mL) was added osmium tetroxide solution (OsO4) (4 wt% in water) (4.3 mL, 0.68 mmol) followed by N-methylmorpholine N-oxide (NMO) (7.0 mL) under an inert atmosphere. The resulting reaction mixture was stirred at room temperature for 1 h. The progress of the reaction was monitored by TLC (50% EtOAc in heptane, Rf = 0.1). After the completion of the reaction, the reaction mixture was quenched with 0.2% aq. sodium thiosulfate solution (25 mL), extracted with DCM (2 x 100 mL) and washed with water (2 x 50 mL). The combined organic layer was dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure to obtain the crude product which was purified by combi-flash chromatography by eluting with 50-90% EtOAc in heptane to afford crude mixture of 4-(4-bromo-2-(trifluoromethyl)phenoxy)cyclopentane-l,2-diols (2.90 g, 75% yield) as a white solid. The mixture of diols (2.90 g) was separated through chiral SFC (Column: Chiral Pak IG (30 x 250 mm), 5 p particle size; mobile phase A: CO2; mobile phase B: 0.1 % methanolic ammonia in MeOH; flow rate: 100 mL) to afford (l / ,2, S',4.s)-4-(4-bromo-2-(trifluoromethyl)phenoxy)cyclopentane-l,2-diol (1-10, 2.50 g, 86% yield) as an off-white solid and (lA,25',4r)-4-(4-bromo-2-(trifluoromethyl)phenoxy)cyclopentane-l,2-diol (I-10**, 0.11 g, 3.60% yield) as an off-white solid.

[0495] Attorney Docket# COGN-01-PCT

[0496] 1-10: 'H-NMR (400 MHz, DMSO-d6): 3 = 7.76 (dd, J= 8.80, 2.40 Hz, 1H), 7.71 (d, J = 2.40 Hz, 1H), 7.16 (d, J= 8.80 Hz, 1H), 5.02-4.99 (m, 1H), 4.56 (d, J= 4.40 Hz, 2H), 4.00-3.97 (m, 2H), 2.12-2.06 (m, 2H), 1.83-1.80 (m, 2H).19F NMR (377 MHz, DMSO-d6): 3 = -61.46. LC-MS: 99.88%; [(M-H) + HCOOH]+= 385.26. Chiral HPLC: 99.81%. Note:

[0497] NOESY data supported the assigned structure.

[0498] 1-10**: 'H-NMR (400 MHz, DMSO-d6): 3 = 7.76 (dd, J= 8.80, 2.40 Hz, 1H), 7.71 (d, J = 2.40 Hz, 1H), 7.14 (d, J= 9.20 Hz, 1H), 4.79-4.72 (m, 1H), 4.51 (d, J= 4.80 Hz, 2H), 3.82-3.77 (m, 2H), 2.34-2.27 (m, 2H), 1.77-1.71 (m, 2H).19F NMR (377 MHz, DMSO-d6): 3 = -62.38. LC-MS purity: 99.88%; [M-H] ’ = 338.80. Chiral HPLC: 100%. Note: NOESY data supported the assigned structure.

[0499] Preparation of (l / .2. S.4v)-4-(4-broiiio-2-(trinuoroiiiethoxy)i)henoxy)cvcloi)eiitane-1.2-diol (1-11) and -4-(4-bromo-2-(trifluoromethoxy)Dhenoxy)cvcloDentane-l,2-

[0500]

[0501] diol (1-11**).

[0502]

[0503] Step-1: Synthesis of 4-bromo-l-(cyclopent-3-en-l-yloxy)-2-(trifluoromethoxy)benzene (20).

[0504] To a stirred solution of cyclopent-3 -en-l-ol (1, 2.0 g, 23.78 mmol) in toluene (38 mL) was added 4-bromo-2-(trifluoromethoxy)phenol (19, 6.73 g, 26.2 mmol) followed by triphenylphosphine (9.54 g, 35.00 mmol) under a nitrogen atmosphere at room temperature. After stirring at room temperature for 15 min, diethyl azodicarboxylate (DEAD) (40% in toluene) (5.6 mL, 34.95 mmol) was added at 0°C in a dropwise manner. The resulting reaction mixture was allowed to warm to room temperature and stirred for 16 h. The progress of the reaction was monitored by TLC (20% EtOAc in heptane; Rf= 0.8). After the completion of reaction, the reaction mixture was quenched with water (50 mL). The product was extracted with EtOAc, and the organic layer was dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure. The crude product was purified by combi-flash column chromatography by eluting with 10-20% EtOAc in heptane to afford 4-bromo-Attorney Docket# COGN-01-PCT

[0505] 1 -(cyclopent-3 -en-l-yloxy)-2-(trifluorom ethoxy )benzene (20, 7.47 g, 97.2% yield) as a white solid.

[0506] 'H NMR (400 MHz, DMSO-d6): 3 = 7.59-7.54 (m, 2H), 7.22 (d, J= 8.80 Hz, 1H), 5.75 (s, 2H), 5.15-5.13 (m, 1H), 2.85-2.79 (m, 2H), 2.40-2.36 (m, 2H).

[0507] Step-2: Synthesis of (ll?,2N,4s)-4-(4-bromo-2- (trifluoromethoxy)phenoxy)cyclopentane-l,2-diol (1-11) and (ll?,2N,4r)-4-(4-bromo-2-(trifluoromethoxy)phenoxy)cyclopentane-l,2-diol (1-11**).

[0508] To a stirred solution of 4-bromo-l -(cyclopent-3 -en-l-yloxy)-2-(trifluoromethoxy)benzene (20, 7.0 g, 21.66 mmol) in acetone (233 mL) and water (15 mL) was added osmium tetroxide solution (OsO4) (4 wt% in water) (8.20 mL, 1.30 mmol) followed by A-methylmorpholine A-oxide (NMO) (14 mL) under an inert atmosphere. The resulting reaction mixture was stirred at room temperature for 1 h. The progress of the reaction was monitored by TLC (50% EtOAc in heptane; Rf = 0.1). After the completion of the reaction, the reaction mixture was quenched with 0.2% aq. sodium thiosulfate solution (40 mL). The aqueous solution was extracted with di chloromethane (3 * 100 mL) and washed with water. The combined organic layer was dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure. The crude compound was purified through combi-flash chromatography by eluting with 60-70% EtOAc in heptane to afford a mixture of 1-11 and 1-11** (5.2 g, 67%) as a white solid. The mixture of diols (3.0 g) was separated through chiral SFC (Column: Chiral Pak IG (30 x 250 mm), 5 p particle size; mobile phase A: CO2; mobile phase B: 0.1 % methanolic ammonia in MeOH; flow rate: 100 bar) to afford (lA,25,45)-4-(4-bromo-2-(trifluorom ethoxy )phenoxy)cy cl opentane-l,2-diol (1-11, 1.90 g, 57% yield) as an off-white solid and (lA,2£,4r)-4-(4-bromo-2-(trifluoromethoxy)phenoxy)cyclopentane-l,2-diol (I-11**, 300 mg, 8.75% yield) as an off-white solid.

[0509] 1-11: ’H-NMR (400 MHz, DMSO-d6): 3 = 7.57 (s, 1H), 7.52 (dd, J= 8.80, 2.40 Hz, 1H), 7.13 (d, J= 8.80 Hz, 1H), 4.95-4.92 (m, 1H), 4.55 (d, J= 4.0 Hz, 2H), 4.0-3.98 (m, 2H), 2.12-2.06 (m, 2H), 1.82-1.78 (m, 2H).19F NMR (377 MHz, DMSO-d6): 3 = -57.38. LC-MS: 94.47%; [(M-H) + HCOOH]+= 401.16. Chiral HPLC: 100%. Note: NOESY data supported the assigned structure.

[0510] 1-11**: 'H-NMR (400 MHz, DMSO-d6): 3 = 7.56 (s, 1H), 7.52 (dd, J= 8.80, 2.40 Hz, 1H), 7.11 (d, 9.20 Hz, 1H), 4.73-4.67 (m, 1H), 4.53 (d, 3.60 Hz, 2H), 3.81-3.77 (m,

[0511] Attorney Docket# COGN-01-PCT

[0512] 2H), 2.33-2.26 (m, 2H), 1.79-1.72 (m, 2H).19F NMR (377 MHz, DMSO-d6): S = -57.23.

[0513] LC-MS purity: 99.65%; [(M-H) +HCOOH]+= 401.19. Chiral HPLC: 99.62%. Note:

[0514] NOESY data supported the assigned structure.

[0515] Preparation of (l / .2. S.4s)-4-(2-niethyl-4-(4.4.5.5-tetr:iniethyl-1.3.2-dioxaborolan-2-yl)Dhenoxy)cvclopentane-l,2-diol (1-12) and (LR,2. Sl,4r)-4-(2-niethyl-4-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)phenoxy)cvcloDentane- 1,2-diol (I- 12 * *):

[0516]

[0517] Synthesis of (17?,2N,4s)-4-(2-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy)cyclopentane- 1,2-diol (1-12)

[0518] To a degassed solution of (17?,2£,4s)-4-(4-bromo-2-methylphenoxy)cyclopentane-l,2-diol (1-5, 100 mg, 0.34 mmol) in 1,4-dioxane (8.0 mL) were added potassium acetate (102.5 mg, 1.03 mmol), bis(pinacolato)diboron (176.3 mg, 0.67 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) [PdCh(dppf)] (25.4 mg, 0.03 mmol). The resulting reaction mixture was stirred at 100 °C for 8 h. The progress of reaction was monitored by TLC (50% EtOAc in heptane, Rf = 0.5). After the completion of reaction, the reaction mixture was filtered over a celite bed and washed with EtOAc (30 mL). The combined filtrate was evaporated under reduced pressure to afford the crude compound (lA,2£,4s)-4-(2-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy)cyclopentane-l,2-diol (1-12, 300 mg, crude) as a brown sticky compound which was used in the next step without further purification.

[0519] LC-MS: 81.90%; [M+H]+= 335.12.

[0520] Synthesis of (17?,2N,4r)-4-(2-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy)cyclopentane-l,2-diol (1-12**).

[0521] To a degassed solution of (lA,25,4r)-4-(4-bromo-2-methylphenoxy)cyclopentane-l,2-diol (1-5**, 100 mg, 0.33 mmol) in 1,4-dioxane (8.0 mL) were added potassium acetate (80 mg.

[0522] Attorney Docket# COGN-01-PCT

[0523] 0.81 mmol), bis(pinacolato)diboron (140 mg, 0.53 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) [PdC12(dppf)] (25 mg, 0.03 mmol). The resulting reaction mixture was stirred at 100 °C for 8 h. The progress of reaction was monitored by TLC (50% EtOAc in heptane, Rf = 0.4). After the completion of reaction, the reaction mixture was filtered through a celite bed and washed with EtOAc (3 x 30 mL). The combined filtrate was evaporated under reduced pressure to afford the crude compound (lA,25,4r)-4-(2-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy)cyclopentane-l,2-diol (1-12**, 220 mg, crude) as a brown colour solid which was used in the next step without further purification.

[0524] LC-MS: 81.90%; [M+H]+= 335.14.

[0525] Preparation of (l / .2. S.4v)-4-(4-(4.4.5.5-tetraiiietliyl-1.3.2-di()x:iborolan-2-yl)Dhenoxy)cvclopentane-l,2-diol (1-13) and Synthesis o -4-(4-(4.,4.,5.,5-

[0526]

[0527] tetramethyl- 1,3,2-dioxaborolan-2-yl)Dhenoxy)cvclopentane- 1,2-diol (I- 13 * *):

[0528]

[0529] Synthesis of (ll?,25',4s)-4-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy)cyclopentane- 1,2-diol (1-13).

[0530] To a degassed solution of (lA,25,45)-4-(4-bromophenoxy)cyclopentane-l,2-diol (1-3, 100 mg, 0.36 mmol) in 1,4-dioxane (8.0 mL) was added potassium acetate (111 mg, 1.09 mmol), bis(pinacolato)diboron (190 mg, 0.73 mmol), and [l,l'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) [PdC12(dppf)] (27 mg, 0.04 mmol). The resulting reaction mixture was stirred at 100 °C for 8 h. The progress of reaction was monitored by TLC (50% EtOAc in heptane; Rf= 0.5). After the completion of reaction, the reaction mixture was filtered over a celite bed and washed with EtOAc (50 mL) and filtrate was concentrated under reduced pressure to obtain (lA,2£,4s)-4-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy)cyclopentane-l,2-diol (1-13, 270 mg, crude) as a brown sticky compound which was used in the next step without further purification.

[0531] Attorney Docket# COGN-01-PCT

[0532] LC-MS: 74.67%, [M+H]+= 321.3.

[0533] Synthesis of (17?,25',4r)-4-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy)cyclopentane-l,2-diol (1-13**).

[0534] To a degassed solution of (lA,25,4r)-4-(4-bromophenoxy)cyclopentane-l,2-diol (1-3**, 200 mg, 0.71 mmol) in 1,4-dioxane (5 mL) was added potassium acetate (215.38 mg, 2.12 mmol), bis(pinacolato)diboron (371.34 mg, 1.43 mmol), and [1,1'-bis(diphenylphosphino)ferrocene-]dichloropalladium(II) [PdC12(dppf)] (53.40 mg, 0.072 mmol). The resulting reaction mixture was stirred at 100 °C for 8 h. The progress of reaction was monitored by TLC (50% EtOAc in heptane; Rf = 0.4). After the completion of reaction, the reaction mixture was filtered over a celite bed and washed with EtOAc (100 mL) and filtrate was concentrated under reduced pressure to obtain (1A, 2S, 4r)-4-(4-(4, 4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy)cyclopentane-l,2-diol (1-13**, 600 mg, crude yield) as a brown sticky compound which was used in the next step without further purification.

[0535] LC-MS: 60.74 %, [M+H]+= 321.23.

[0536] Preparation of (l / .2. S.4v)-4-(2-chloro-4-(4.4.5.5-tetraniethyl-1.3.2-dioxaborolan-2-yl)Dhenoxy)cvclopentane-l,2-diol (1-14) and (LR,2. Sl,4r)-4-(2-chloro-4-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)Dhenoxy)cvclopentane- 1,2-diol (1-14**):

[0537]

[0538] Synthesis of (17?,25',4s)-4-(2-chloro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy)cyclopentane- 1,2-diol (I- 14).

[0539] To a degassed solution of (17?,2£,4s)-4-(4-bromo-2-chlorophenoxy)cyclopentane-l,2-diol (1-4, 100 mg, 0.32 mmol) in 1,4-dioxane (8.0 mL) was added potassium acetate (95 mg, 0.97 mmol), bis(pinacolato)diboron (165 mg, 0.63 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) [PdC12(dppf)] (24 mg, 0.02 mol).

[0540] Attorney Docket# COGN-01-PCT

[0541] The resulting reaction mixture was stirred at 100 °C for 8 h. The progress of reaction was monitored by TLC (50% EtOAc in heptane; Rf = 0.4). After the completion of reaction, the reaction mixture was filtered through a celite bed and washed with EtOAc. The combined filtrate was concentrated under reduced pressure to afford (lA,25,45)-4-(2-chloro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy)cyclopentane-l,2-diol (1-14, 320 mg, crude yield) as a brown sticky compound which was used for the next step without further purification.

[0542] Synthesis of (17?,25',4r)-4-(2-chloro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy)cyclopentane- 1,2-diol (1-14**)

[0543] To a degassed solution of (lA,25,4r)-4-(4-bromo-2-chlorophenoxy)cyclopentane-l,2-diol (1-4**, 100 mg, 0.30 mmol) in 1,4-dioxane (5 mL) were added potassium acetate (110 mg, 1.11 mmol), bis(pinacolato)diboron (180 mg, 0.69 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) [PdC12(dppf)] (30 mg, 0.04 mmol). The resulting reaction mixture was stirred at 100 °C for 8 h. The progress of reaction was monitored by TLC (50% EtOAc in heptane, Rf = 0.4). After the completion of reaction, the reaction mixture was filtered through a celite bed and washed with EtOAc. The combined filtrate was concentrated under reduced pressure to afford (lA,25,4r)-4-(2-chloro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy)cyclopentane-l,2-diol (1-14**, 260 mg, crude yield) as a brown sticky compound. The crude compound was used in the next step without further purification.

[0544] of Final

[0545]

[0546]

[0547] To a degassed solution of the corresponding aryl halide (typically 30-150 mg, 1.0 eq) in DMF (final concentration ~ 0.1 M) was added the appropriate aryl boronic acid or boronic ester (1.5 eq), potassium phosphate tribasic (2.5 eq) and [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II), complex with dichloromethane (0.1 eq), and the reaction mixture was stirred at 80-100 °C for 16 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was filtered over a celite bed and washed with EtOAc. The combined filtrate was washed with water, dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified through reverse phase chromatography (using C18 gold column or preparative HPLC) and the product fractionsAttorney Docket# COGN-01-PCT

[0548] were lyophilized to afford corresponding products.

[0549] of Final

[0550]

[0551]

[0552] To a degassed solution of the corresponding aryl halide (typically 30-150 mg, 1.0 eq) in 1,4-dioxane / water (final concentration ~ 0.1 M) was added the appropriate arylboronic acid or arylboronate ester (1.5 eq), potassium carbonate (2.5 eq) and (2-Dicyclohexylphosphino-2',4',6'-triisopropyl-l, 1 '-biphenyl) [2-(2 '-amino- 1, 1 '-biphenyl)]palladium(II) methanesulfonate (XPhos Pd G3, 0.1 eq), and the reaction mixture was stirred at 70-80 °C for 1 to 4 h. Reaction progress was monitored by TLC. After completion of the reaction, the reaction mixture was filtered through a celite bed and washed with EtOAc. The combined filtrate was washed with water, dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to obtain the crude residue. The crude mixture was purified through reverse phase chromatography (using a Cl 8 gold column) or preparative HPLC. The pure fractions were collected and lyophilized to afford corresponding products.

[0553] Synthesis of Final Compounds

[0554] (17?,27?)-4-((3'-chloro-3-methoxy-[l,r-biphenyl]-4-yl)oxy)cyclopentane-l,2-diol

[0555]

[0556] The reaction was carried out according to general procedure A using 1-8 (50 mg, 0.163 mmol), 3-chlorophenylboronic acid (39 mg, 0.244 mmol), potassium phosphate tribasic (54 mg, 0.249 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (15 mg, 0.023 mmol) in DMF (4 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC [column: X-Bridge C18 (250 x 30 mm) 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 70; gradient (time / %B): 0 / 10,3 / 10,10 / 35,20 / 55,30 / 65,40 / 75,50 / 99 to afford (lA,2A)-4-((3'-chloro-3-methoxy-[l, T-Attorney Docket# COGN-01-PCT

[0557] biphenyl]-4-yl)oxy)cyclopentane-l,2-diol (Example 1-E1 (21 mg, 38.4% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-A) 6 = 7.71 (t, J= 1.8 Hz, 1H), 7.62 (d, J= 7.8 Hz, 1H), 7.45 (t, J= 7.9 Hz, 1H), 7.39 - 7.33 (m, 1H), 7.26 - 7.17 (m, 2H), 6.94 (d, J= 8.4 Hz, 1H), 4.83 - 4.75 (m, 3H), 3.92 (br s, 1H), 3.85 (s, 3H), 3.82 - 3.76 (m, 1H), 2.47 - 2.43 (m, 1H), 2.07 - 1.86 (m, 2H), 1.57 - 1.51 (m, 1H) ppm; LCMS: 99%, [M+Na]+= 357.18;

[0558] HPLC: 99%

[0559] (15',25)-4-((3'-chloro-3-methoxy-[l,l'-biphenyl]-4-yl)oxy)cyclopentane-l,2-diol

[0560]

[0561] The reaction was carried out according to general procedure A using 1-8** (30 mg, 0.096 mmol), 3-chlorophenylboronic acid (23 mg, 0.15 mmol), potassium phosphate tribasic (52 mg, 0.24 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (8 mg, O. Olmmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC [column: X-Bridge CSH C18(150 x 19 mm), 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 65; gradient (time / %B): 0 / 10,3 / 10,10 / 35,20 / 55,30 / 65,40 / 75,50 / 99 to afford (15,2S)-4-((3'-chloro-3-methoxy-[l, T-biphenyl]-4-yl)oxy)cyclopentane-l,2-diol (Example 1-E2) (10 mg, 30% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 7.71 (t, J= 1.8 Hz, 1H), 7.62 (d, J= 7.9 Hz, 1H), 7.45 (t, J= 7.8 Hz, 1H), 7.40 - 7.32 (m, 1H), 7.27 - 7.16 (m, 2H), 6.94 (d, J= 8.3 Hz, 1H), 4.83 - 4.72 (m, 3H), 3.95 - 3.89 (m, 1H), 3.85 (s, 3H), 3.82 - 3.76 (m, 1H), 2.47 -2.44 (m, 1H), 2.04 - 1.90 (m, 2H), 1.58 - 1.49 (m, 1H) ppm; LCMS: 99%, [M+18]+= 352.15; HPLC: 99%.

[0562] 4'-(((31?,41?)-3,4-dihydroxycyclopentyl)oxy)-3'-methoxy-[l,l'-biphenyl]-3-carbonitrile

[0563] (Example 2-E1)

[0564] Attorney Docket# COGN-01-PCT

[0565]

[0566] The reaction was carried out according to general procedure A using 1-8 (50 mg, 0.16 mmol), 3-cyanophenylboronic acid (37 mg, 0.24 mmol), potassium phosphate tribasic (89 mg, 0.41 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (14 mg, 0.01 mmol) in DMF (4 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC [column: X-Select C18 (250 x 30 mm), 5p particle size; mobile phase A O mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 30; gradient (time / %B): 0 / 10,3 / 10,10 / 35,20 / 55,30 / 65,40 / 75,50 / 99 to afford (4'-(((37?,47?)-3,4-dihydroxycyclopentyl)oxy)-3'-methoxy-[l,r-biphenyl]-3-carbonitrile (Example 2-E1, (16 mg, 30% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 5 = 8.16 (t, J= 1.6 Hz, 1H), 8.03 - 7.98 (m, 1H), 7.77 - 7.73 (m, 1H), 7.66 - 7.59 (m, 1H), 7.31 (d, J= 2.1 Hz, 1H), 7.26 (dd, J= 2.2, 8.3 Hz, 1H), 6.96 (d, J= 8.4 Hz, 1H), 4.84 - 4.75 (m, 3H), 3.96 - 3.89 (m, 1H), 3.86 (s, 3H), 3.82 - 3.75 (m, 1H), 2.46 - 2.43 (m, 1H), 2.04 - 1.91 (m, 2H), 1.59 -1.50 (m, 1H) ppm; LCMS: 99%, [M+Na]+= 348.22; HPLC: 99%.

[0567] 4'-(((35',45)-3,4-dihydroxycyclopentyl)oxy)-3'-methoxy-[l,l'-biphenyl]-3-carbonitrile

[0568]

[0569]

[0570] The reaction was carried out according to general procedure A using 1-8** (50 mg, 0.16 mmol), 3-cyanophenylboronic acid (36 mg, 0.24 mmol), potassium phosphate tribasic (87 mg, 0.40 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (14 mg, 0.016 mmol) in DMF (4 mL) at 100 °C for 16 h.

[0571] Attorney Docket# COGN-01-PCT

[0572] The crude product was purified by preparative HPLC [column: X-Select CSH Cl 8, 250 x 30 mm), 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 90; gradient (time / %B): 0 / 10,3 / 10,15 / 35,35 / 60,60 / 98 to afford (4'-(((35,45)-3,4-dihydroxycyclopentyl)oxy)-3'-methoxy-[l, T-biphenyl]-3-carbonitrile (Example 2-E2) (26 mg, 48% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-cL) 6 = 8.18 - 8.14 (m, 1H), 8.01 (d, J= 8.6 Hz, 1H), 7.75 (d, J= 7.8 Hz, 1H), 7.65 - 7.61 (m, 1H), 7.31 (d, J=2.1 Hz, 1H), 7.28 - 7.23 (m, 1H), 6.96 (d, J= 8.4 Hz, 1H), 4.78 (br t, J= 3.8 Hz, 3H), 3.95 - 3.89 (m, 1H), 3.86 (s, 3H), 3.82 - 3.76 (m, 1H), 2.47 (br s, 1H), 1.97 (br d, J= 6.6 Hz, 2H), 1.58 - 1.51 (m, lH)ppm; LCMS:

[0573] 99%, [M+H]+= 326.21; HPLC: 95%.

[0574] (ll?,21?)-4-((3-methoxy-3'-(methylsulfonyl)-[l,l'-biphenyl]-4-yl)oxy)cyclopentane-l,2-

[0575]

[0576] The reaction was carried out according to general procedure A using 1-8 (30 mg, 0.10 mmol), (3-(methylsulfonyl)phenyl)boronic acid (33 mg, 0.147 mmol), potassium phosphate tribasic (54 mg, 0.24 mmol) and [l,lr-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (9 mg, 0.010 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC [column: X-Select C18, 250 x 30 mm),5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 50; gradient (time / %B): 0 / 10,3 / 10,10 / 35,20 / 55,30 / 65,40 / 75,50 / 99 to afford (U?,27?)-4-((3 -m ethoxy-3 '-(methylsulfonyl)-[ 1, 1 '-biphenyl]-4-yl)oxy)cyclopentane- 1,2-diol (Example 3-E1 (23 mg, 62% yield) as an off-white solid.1H NMR (400 MHz, DMSO-d6) 5 = 8.13 - 8.10 (m, 1H), 8.03 - 7.99 (m, 1H), 7.87 - 7.82 (m, 1H), 7.73 - 7.67 (m, 1H), 7.30 - 7.24 (m, 2H), 6.99 (d, J= 8.4 Hz, 1H), 4.84 - 4.76 (m, 3H), 3.93 (br d, J= 5.0 Hz, 1H), 3.86 (s, 3H), 3.79 (br d, J= 3.9 Hz, 1H), 3.29 (br s, 3H), 2.44 - 2.42 (m, 1H), 2.02 -1.95 (m, 2H), 1.58 - 1.52 (m, 1H) ppm; LCMS: 99%, [M+18]+= 396.10; HPLC: 99%.

[0577] Attorney Docket# COGN-01-PCT

[0578] (15',25)-4-((3-methoxy-3'-(methylsulfonyl)-[l,l'-biphenyl]-4-yl)oxy)cyclopentane-l,2-

[0579]

[0580]

[0581] The reaction was carried out according to general procedure A using 1-8** (30 mg, 0.10 mmol), 3-(methylsulfonyl)phenylboronic acid (30 mg, 0.146 mmol), potassium phosphate tribasic (52 mg, 0.24 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (8 mg, 0.01 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC [column: X-Bridge CSH C18 (150 x 19 mm),5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 55; gradient (time / %B): 0 / 10,3 / 10, 10 / 35,20 / 55,30 / 65,40 / 75,50 / 99 to afford (l£,25 -4-((3-methoxy-3'-(methylsulfonyl)-[l, T-biphenyl]-4-yl)oxy)cyclopentane-1,2-diol (Example 3-E2, 15 mg, 40% yield) as an off-white solid.1H NMR (400 MHz, DMSO-cL) 6 = 8.11 (s, 1H), 8.01 (br d, J= 7.8 Hz, 1H), 7.88 - 7.82 (m, 1H), 7.74 - 7.67 (m, 1H), 7.31 - 7.23 (m, 2H), 6.99 (d, J= 8.4 Hz, 1H), 4.87 - 4.74 (m, 3H), 3.96 - 3.89 (m, 1H), 3.86 (s, 3H), 3.82 - 3.76 (m, 1H), 2.42 (br s, 1H), 2.03 - 1.93 (m, 2H), 1.60 - 1.50 (m, 1H) ppm; LCMS: 99%, [M+18]+= 396.10; HPLC: 99%.

[0582] (ll?,21?)-4-((3-methoxy-3'-(trifluoromethyl)-[l,l'-biphenyl]-4-yl)oxy)cyclopentane-

[0583]

[0584] The reaction was carried out according to general procedure A using 1-8 (30 mg, 0.0979 mmol), 3-(trifluoromethyl)phenylboronic acid (28 mg, 0.14 mmol), potassium phosphateAttorney Docket# COGN-01-PCT

[0585] tribasic (54 mg, 0.24 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (9 mg, 0.01 mmol) in DMF (3 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC [column: X-Bridge C18 (250 x 30 mm); 5p particle size mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 60; gradient (time / %B): 0 / 10,3 / 10,10 / 35,20 / 55,30 / 65,40 / 75,50 / 99 to afford (U?,27?)-4-((3 -m ethoxy-3 '-(trifluoromethyl)-[ 1, 1 '-biphenyl]-4-yl)oxy)cyclopentane- 1,2-diol (Example 4-E1 (25 mg, 68.9% yield) as an off-white gummy solid. 'H NMR (400 MHz, DMSO-d6) 6 = 7.99 - 7.92 (m, 2H), 7.69 - 7.63 (m, 2H), 7.31 - 7.22 (m, 2H), 6.97 (d, J= 8.4 Hz, 1H), 4.84 - 4.76 (m, 3H), 3.96 - 3.90 (m, 1H), 3.86 (s, 3H), 3.82 - 3.76 (m, 1H), 2.47 - 2.44 (m, 1H), 2.04 - 1.91 (m, 2H), 1.59 - 1.51 (m, 1H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -60.91; LCMS: 99%, [M+18]+= 386.05; HPLC: 98%.

[0586] (lN,25)-4-((3-methoxy-3'-(trifluoromethyl)-[l,l'-biphenyl]-4-yl)oxy)cyclopentane-l,2-

[0587]

[0588] The reaction was carried out according to general procedure A using 1-8** (30 mg, 0.09 mmol), 3-(trifluoromethyl)phenylboronic acid (28 mg, 0.14 mmol), potassium phosphate tribasic (54 mg, 0.24 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (8 mg, 0.01 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC [column: X-Bridge C18 (250 x 30 mm) 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 25; loading (mg / injection):50; gradient (time / %B): 0 / 10,3 / 10,10 / 35,20 / 55,30 / 65,40 / 75,50 / 99 to afford (15,25)-4-((3-methoxy-3'-(trifluoromethyl)-[l,r-biphenyl]-4-yl)oxy)cyclopentane-l,2-diol (Example 4-E2, 27 mg, 75% yield) as an off-white solid.1H NMR (400 MHz, DMSO-de) 8 = 7.99 - 7.92 (m, 2H), 7.69 - 7.63 (m, 2H), 7.30 - 7.21 (m, 2H), 6.96 (d, J= 8.3 Hz, 1H), 4.85 - 4.75 (m, 3H), 3.95 - 3.89 (m, 1H), 3.85 (s, 3H), 3.82 - 3.76 (m, 1H), 2.43 (br s, 1H),Attorney Docket# COGN-01-PCT

[0589] 2.03 - 1.91 (m, 2H), 1.57 - 1.51 (m, 1H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -60.88 ppm; LCMS: 99%, [M+18]+= 386.10; HPLC: 99%.

[0590] (ll?,21?)-4-((3-methoxy-3'-(trifluoromethoxy)-[l,l'-biphenyl]-4-yl)oxy)cyclopentane-

[0591]

[0592] The reaction was carried out according to general procedure A using 1-8 (30 mg, 0.09 mmol), (3-(trifluoromethoxy)phenyl)boronic acid (31 mg, 0.15), potassium phosphate tribasic (53 mg, 0.25 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (9 mg, 0.010 mmol) in DMF (3 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC [column: X-Bridge C18 (250 x 30 mm) 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 65; gradient (time / %B): 0 / 10,3 / 10,10 / 35,20 / 55,30 / 65,40 / 75,50 / 99 to afford (U?,27?)-4-((3 -m ethoxy-3 '-(trifluoromethoxy)-[ 1, 1 '-biphenyl]-4-yl)oxy)cyclopentane- 1,2-diol (Example 5-E1, 23 mg, 60% yield) as an off-white solid.1H NMR (400 MHz, DMSO-d6) 6 = 7.70 (d, J= 8.3 Hz, 1H), 7.62 (s, 1H), 7.55 (t, J= 8.0 Hz, 1H), 7.32 - 7.26 (m, 1H), 7.25 (d, = 2.0 Hz, 1H), 7.21 (dd, J= 2.1, 8.3 Hz, 1H), 6.95 (d, = 8.4 Hz, 1H), 4.84 - 4.73 (m, 3H), 3.95 - 3.88 (m, 1H), 3.85 (s, 3H), 3.79 (br s, 1H), 2.46 - 2.42 (m, 1H), 2.05 - 1.90 (m, 2H), 1.58 - 1.48 (m, 1H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -60.91 ppm;

[0593] LCMS: 99%, [M+18]+= 402.10; HPLC: 99%.

[0594] (lN,25)-4-((3-methoxy-3'-(trifluoromethoxy)-[l,l'-biphenyl]-4-yl)oxy)cyclopentane- 1,2-diol (Example 5-E2)

[0595] Attorney Docket# COGN-01-PCT

[0596]

[0597] The reaction was carried out according to general procedure A using 1-8** (30 mg, 0.09 mmol), (3-(trifluoromethoxy)phenyl)boronic acid (31 mg, 0.15), potassium phosphate tribasic (52 mg, 0.24 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (8 mg, 0.09 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC [column: X-Bridge C18 (250 x 30 mm) 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 25; loading (mg / inj ection): 59; gradient (time / %B): 0 / 10,3 / 10,10 / 35,20 / 55,30 / 65,40 / 75,50 / 99 to afford (15,25)-4-((3-methoxy-3'-(trifluoromethoxy)-[l,r-biphenyl]-4-yl)oxy)cyclopentane-l,2-diol (Example 5-E2, 18 mg, 47% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 7.70 (d, J= 8.4 Hz, 1H), 7.62 (s, 1H), 7.55 (t, J= 8.0 Hz, 1H), 7.30 (br d, J= 8.0 Hz, 1H), 7.25 (d, J= 2.0 Hz, 1H), 7.21 (dd, J= 2.1, 8.4 Hz, 1H), 6.95 (d, J= 8.4 Hz, 1H), 4.84 - 4.73 (m, 3H), 3.96 - 3.89 (m, 1H), 3.85 (s, 3H), 3.82 - 3.76 (m, 1H), 2.04 - 1.90 (m, 2H), 1.58 - 1.50 (m, 1H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -56.92 ppm; LCMS:

[0598] 99%, [M+Na]+= 407.10; HPLC: 98%.

[0599] (ll?,21?)-4-(2-methoxy-4-(pyridin-3-yl)phenoxy)cyclopentane-l,2-diol (Example 6-E1)

[0600]

[0601] The reaction was carried out according to general procedure A using 1-8 (30 mg, 0.09 mmol), pyri din-3 -ylboronic acid (18 mg, 0.14), potassium phosphate tribasic (54 mg, 0.09 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (9 mg, 0.09 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Bridge C18 (250 x 30 mm) 5p particle size;

[0602] Attorney Docket# COGN-01-PCT

[0603] mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 60; gradient (time / %B):

[0604] 0 / 10,3 / 10,10 / 35,20 / 55,30 / 65,40 / 75,50 / 99) to afford (17?,27?)-4-(2-methoxy-4-(pyridin-3-yl)phenoxy)cyclopentane-l,2-diol (Example 6-E1, 29 mg, 98.1% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.88 (d, J= 1.9 Hz, 1H), 8.51 (dd, J= 1.5, 4.8 Hz, 1H), 8.05 (td, J= 1.8, 8.2 Hz, 1H), 7.46 - 7.42 (m, 1H), 7.28 (d, J= 2.1 Hz, 1H), 7.22 (br dd, J= 2.1, 8.3 Hz, 1H), 6.97 (d, J= 8.4 Hz, 1H), 4.85 - 4.74 (m, 3H), 3.96 - 3.87 (m, 1H), 3.85 (s, 3H), 3.82 - 3.76 (m, 1H), 2.47 - 2.44 (m, 1H), 2.04 - 1.88 (m, 2H), 1.60 - 1.49 (m, 1H) ppm; LCMS: 99%, [M+H]+= 302.20; HPLC: 99%.

[0605] (15',25)-4-(2-methoxy-4-(pyridin-3-yl)phenoxy)cyclopentane-l,2-diol (Example 6-E2)

[0606]

[0607] The reaction was carried out according to general procedure A using 1-8** (30 mg, 0.09 mmol), pyri din-3 -ylboronic acid (18 mg, 0.14), potassium phosphate tribasic (54 mg, 0.09 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (9 mg, 0.09 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC [column: X-Bridge C18 (250 x 30 mm) 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 25; loading (mg / inj ection): 11; gradient (time / %B): 0 / 5,3 / 5,25 / 45,45 / 60,60 / 98 to afford (15,25)-4-(2-methoxy-4-(pyridin-3-yl)phenoxy)cyclopentane-l,2-diol (Example 6-E2) (20 mg, 68% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.88 (d, J= 1.7 Hz, 1H), 8.51 (dd, J= 1.6, 4.8 Hz, 1H), 8.08 - 8.02 (m, 1H), 7.48 - 7.41 (m, 1H), 7.28 (d, J = 2.1 Hz, 1H), 7.23 (dd, J= 2.0, 8.3 Hz, 1H), 6.97 (d, J= 8.4 Hz, 1H), 4.82 - 4.76 (m, 3H), 3.95 - 3.89 (m, 1H), 3.85 (s, 3H), 3.81 - 3.77 (m, 1H), 2.04 - 1.92 (m, 2H), 1.54 (td, J= 4.3, 13.9 Hz, 1H) ppm, (Note: one aliphatic proton is merged with DMSO peak); LCMS: 99%, [M+H]+= 302.20; HPLC: 99%.

[0608] (ll?,21?)-4-(4-(5-chloropyridin-3-yl)-2-methoxyphenoxy)cyclopentane-l,2-diol (Example 7-E1)

[0609] Attorney Docket# COGN-01-PCT

[0610]

[0611] The reaction was carried out according to general procedure A using 1-8 (150 mg, 0.49 mmol), (5-chloropyridin-3-yl)boronic acid (119 mg, 0.741 mmol), potassium phosphate tribasic (266 mg, 1.22 mmol) and [l,l'-bis(diphenylphosphino)ferrocene] dichloropalladium(II), complex with dichloromethane (41 mg, 0.05 mmol) in DMF (7 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC [column: X-select CSH C18 (250 x 30 mm), 5p particle size; mobile phase A: 0.1% formic acid in water mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 102; gradient (time / %B): 0 / 10,3 / 10,15 / 35,35 / 60,60 / 98 to afford (U?,27?)-4-(4-(5-chloropyridin-3-yl)-2-methoxyphenoxy)cyclopentane-l,2-diol (Example 7-E1, 50 mg, 29% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.86 (d, J= 1.9 Hz, 1H), 8.55 (d, J= 2.1 Hz, 1H), 8.24 (t, J= 2.1 Hz, 1H), 7.34 (d, J= 2.1 Hz, 1H), 7.30 (dd, J= 2.2, 8.3 Hz, 1H), 6.97 (d, J= 8.4 Hz, 1H), 4.84 - 4.73 (m, 3H), 3.95 - 3.89 (m, 1H), 3.87 - 3.84 (m, 3H), 3.81 -3.76 (m, 1H), 2.48 - 2.45 (m, 1H), 2.06 - 1.90 (m, 2H), 1.57 - 1.51 (m, 1H) ppm; LCMS:

[0612] 99%, [M+H]+= 336.17; HPLC: 99%.

[0613] (15',25)-4-(4-(5-chloropyridin-3-yl)-2-methoxyphenoxy)cyclopentane-l,2-diol

[0614]

[0615] The reaction was carried out according to general procedure A using 1-8** (150 mg, 0.49 mmol), (5-chloropyridin-3-yl)boronic acid (119 mg, 0.741 mmol), potassium phosphate tribasic (266 mg, 1.22 mmol) and [l,l'-bis(diphenylphosphino)ferrocene] dichloropalladium(II) complex with dichloromethane (41 mg, 0.05 mmol) in DMF (7 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC [column: X-BridgeAttorney Docket# COGN-01-PCT

[0616] CSH C18 (150 x 19mm), 5p particle size; mobile phase A: 0.1% formic acid in water mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 100; gradient (time / %B): 0 / 10,3 / 10,15 / 35,35 / 65,60 / 98 to afford (15,25)-4-(4-(5-chloropyridin-3-yl)-2-methoxyphenoxy)cyclopentane-l,2-diol (Example 7-E2) (52 mg, 31% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.86 (d, J= 2.0 Hz, 1H), 8.55 (d, J= 2.3 Hz, 1H), 8.24 (t, J= 2.1 Hz, 1H), 7.37 - 7.27 (m, 2H), 6.97 (d, J= 8.5 Hz, 1H), 4.86 - 4.75 (m, 3H), 3.95 - 3.88 (m, Hz, 1H), 3.86 (s, 3H), 3.83 - 3.76 (m, 1H), 2.47 - 2.42 (m, 1H), 2.06 - 1.89 (m, 2H), 1.57 - 1.51 (m, 1H) ppm; LCMS: 97%, [M+H]+= 336.17; HPLC:

[0617] 98%.

[0618] (ll?,21?)-4-(2-methoxy-4-(5-(trifluoromethyl)pyridin-3-yl)phenoxy)cyclopentane-l,2-

[0619]

[0620] The reaction was carried out according to general procedure A using 1-8 (30 mg, 0.09 mmol), (5-(trifluoromethyl)pyridin-3-yl)boronic acid (28 mg, 0.14 mmol), potassium phosphate tribasic (54 mg, 0.24 mmol) and [l,l'-bis(diphenylphosphino)ferrocene] dichloropalladium(II), complex with dichloromethane (9 mg, 0.010 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC [column: X-Bridge C18 (250 x 30 mm) 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 60; gradient (time / %B): 0 / 10,3 / 10,10 / 35,20 / 55,30 / 65,40 / 75,50 / 99 to afford (17?,27?)-4-(2-methoxy-4-(5-(trifluoromethyl)pyri din-3 -yl)phenoxy)cy cl opentane-l,2-diol (Example 8-E1 (25 mg, 68.9% yield) as an off-white gummy solid.1H NMR (400 MHz, DMSO-de) 8 = 9.22 - 9.18 (m, 1H), 8.89 (s, 1H), 8.44 (s, 1H), 7.43 - 7.34 (m, 2H), 7.00 (d, J= 8.5 Hz, 1H), 4.86 - 4.75 (m, 3H), 3.93 (m, 1H), 3.87 (s, 3H), 3.84 - 3.75 (m, 1H), 2.47 - 2.44 (m, 1H), 2.05 - 1.92 (m, 2H), 1.57 - 1.51 (m, 1H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -60.68; LCMS:

[0621] 98%, [M+H]+370.27; HPLC: 95%.

[0622] Attorney Docket# COGN-01-PCT

[0623] (15',25)-4-(2-methoxy-4-(5-(trifluoromethyl)pyridin-3-yl)phenoxy)cyclopentane-l,2-

[0624]

[0625] The reaction was carried out according to general procedure A using 1-8** (30 mg, 0.09 mmol), (5-(trifluoromethyl)pyridin-3-yl)boronic acid (27 mg, 0.14 mmol), potassium phosphate tribasic (52 mg, 0.24 mmol) and [l,l'-bis(diphenylphosphino)ferrocene] dichloropalladium(II), complex with dichloromethane (8 mg, 0.010 mmol) in DMF (2 mL) at 100 °C for 16 h.. The crude product was purified by preparative HPLC (column: X-B ridge C18 (250 x 30 mm) 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 22; loading (mg / injection):50; gradient (time / %B): 0 / 10,3 / 10,10 / 35,20 / 55,30 / 65,40 / 75,50 / 99 to afford (15,2S)-4-(2-methoxy-4-(5-(trifluoromethyl)pyri din-3 -yl)phenoxy)cy cl opentane-l,2-diol (Example 8-E2) (17 mg, 47% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 7.99 - 7.92 (m, 2H), 7.69 - 7.63 (m, 2H), 7.30 - 7.21 (m, 2H), 6.96 (d, J= 8.3 Hz, 1H), 4.85 - 4.75 (m, 3H), 3.95 - 3.89 (m, 1H), 3.85 (s, 3H), 3.82 - 3.76 (m, 1H), 2.43 (br s, 1H), 2.03 - 1.91 (m, 2H), 1.57 - 1.51 (m, 1H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -61.83 ppm; LCMS: 99%, [M+H]+= 370.20; HPLC: 98%.

[0626] (ll?,21?)-4-(2-methoxy-4-(5-(trifluoromethoxy)pyridin-3-yl)phenoxy)cyclopentane-

[0627]

[0628] The reaction was carried out according to general procedure A using 1-9 (126 mg, 0.30 mmol), 3-bromo-5-(trifluoromethoxy)pyridine (50 mg, 0.20), potassium phosphate tribasic (110 mg, 0.50 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II),Attorney Docket# COGN-01-PCT

[0629] complex with dichloromethane (17 mg, 0.02 mmol) in DMF (2 mL) at 100 °C for 5 h. The crude product was purified by preparative HPLC [column: XTIMATE C18 (250 x 20 mm), 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 15; loading (mg / inj ection): 30; gradient (time / %B): 0 / 15,3 / 15,10 / 25,35 / 35 to afford (lA,2A)-4-(2-methoxy-4-(5-(trifluoromethoxy)pyridin-3-yl)phenoxy)cyclopentane-l,2-diol (Example 9-E1 (13 mg, 16% yield) as an off-white solid.

[0630] 'H NMR (400 MHz, DMSO-d6) 6 = 8.98 (d, J= 1.9 Hz, 1H), 8.60 (d, J= 1.4 Hz, 1H), 8.18 (s, 1H), 7.39 - 7.29 (m, 2H), 6.99 (d, J= 8.5 Hz, 1H), 4.86 - 4.77 (m, 3H), 3.96 - 3.89 (m, 1H), 3.86 (s, 3H), 3.83 - 3.75 (m, 1H), 2.46 - 2.41 (m, 1H), 2.05 - 1.91 (m, 2H), 1.57 - 1.51 (m, 1H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -56.99 ppm; LCMS: 96%, [M+H]+= 386.05; HPLC: 99%.

[0631] (lN,25)-4-(2-methoxy-4-(5-(trifluoromethoxy)pyridin-3-yl)phenoxy)cyclopentane-l,2-diol (Example 9-E2)

[0632]

[0633] The reaction was carried out according to general procedure A using 1-9** (150 mg, 0.30 mmol), 3-bromo-5-(trifluoromethoxy)pyridine (50 mg, 0.20), potassium phosphate tribasic (110 mg, 0.50 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (17 mg, 0.02 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: XTIMATE C18 (250 x 20 mm),5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 15; loading (mg / inj ection): 30; gradient (time / %B): 0 / 15,3 / 15,10 / 25,35 / 35 to afford (15',25)-4-(2-methoxy-4-(5-(trifluoromethoxy)pyridin-3-yl)phenoxy)cyclopentane-l,2-diol (Example 9-E2) (7 mg, 8% yield) as an off-white gummy solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.97 (d, J= 1.8 Hz, 1H), 8.60 (s, 1H), 8.21 - 8.16 (m, 1H), 7.36 (d, J= 2.1 Hz, 2H), 7.32 (dd, J= 2.1, 8.3 Hz, 1H), 6.98 (d, = 8.4 Hz, 1H), 4.86 - 4.76 (m, 3H), 3.93 - 3.89 (m, 1H), 3.86 (s, 3H), 3.83 - 3.76 (m, 1H), 2.46 -Attorney Docket# COGN-01-PCT

[0634] 2.41 (m, 1H), 2.04 - 1.91 (m, 2H), 1.57 - 1.51 (m, 1H ppm;19F NMR (377 MHz, DMSO- d6) 6 = -56.99 ppm; LCMS: 99%, [M+H]+= 386.05; HPLC: 99%.

[0635] 4'-(((31?,41?)-3,4-dihydroxycyclopentyl)oxy)-3'-methoxy-[l,l'-biphenyl]-3-carbonitrile

[0636]

[0637]

[0638] The reaction was carried out according to general procedure A using 1-8 (30 mg, 0.09 mmol), (5-cyanopyridin-3-yl)boronic acid (22 mg, 0.14 mmol), potassium phosphate tribasic (54 mg, 0.25 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (9 mg, 0.01 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC [column: X-Select C18 (250 x 30 mm), 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 20; loading (mg / inj ection): 46; gradient (time / %B): 0 / 10,3 / 10,10 / 35,20 / 55,30 / 65,40 / 75,50 / 99 to afford 4'-(((37?,4 / ?)-3,4-dihydroxycyclopentyl)oxy)-3'-methoxy-[l, T-biphenyl]-3-carbonitrile (Example 10-E1 (15 mg, 46% yield) as an off-white solid.1H NMR (400 MHz, DMSO- d6) 8 = 9.19 (d, J= 2.3 Hz, 1H), 8.93 (d, J= 1.9 Hz, 1H), 8.65 (t, J= 2.1 Hz, 1H), 7.46 - 7.26 (m, 2H), 6.99 (d, J= 8.5 Hz, 1H), 4.90 - 4.71 (m, 3H), 3.96 - 3.89 (m, 1H), 3.86 (s, 3H), 3.83 - 3.75 (m, 1H), 2.46 - 2.43 (m, 1H), 2.04 - 1.91 (m, 2H), 1.59 - 1.50 (m, 1H) ppm; LCMS: 99%, [H]+= 327.22; HPLC: 99%.

[0639] 5-(4-(((35',45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)nicotinonitrile

[0640] (Example 10-E2)

[0641] Attorney Docket# COGN-01-PCT

[0642]

[0643] The reaction was carried out according to general procedure A using 1-8** (30 mg, 0.09 mmol), (5-cyanopyridin-3-yl)boronic acid (21 mg, 0.14 mmol), potassium phosphate tribasic (52 mg, 0.24 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (8 mg, 0.01 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC [column: X-Select CSH C18(250 x 30 mm), 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 20; loading (mg / inj ection): 29; gradient (time / %B): 0 / 10,3 / 10,10 / 35,20 / 55,30 / 65,40 / 75,50 / 99 to afford 5 -(4-(((3 A’, 4A’)-3, 4-dihydroxycy cl opentyl)oxy)-3-methoxyphenyl)nicoti nonitrile

[0644] (Example 10-E2) (26 mg, 48% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 9.19 (d, J= 2.3 Hz, 1H), 8.93 (d, J= 1.9 Hz, 1H), 8.65 (t, J= 2.1 Hz, 1H), 7.40 (d, J= 2.1 Hz, 1H), 7.37 - 7.33 (m, 1H), 6.99 (d, J= 8.5 Hz, 1H), 4.85 - 4.75 (m, 3H), 3.95 -3.88 (m, 1H), 3.86 (s, 3H), 3.84 - 3.75 (m, 1H), 2.49 - 2.26 (m, 1H), 2.02 - 1.92 (m, 2H), 1.57 - 1.51 (m, 1H) ppm; LCMS: 99%, [M+H]+= 327.20; HPLC: 98%.

[0645] (ll?,21?)-4-(2-methoxy-4-(pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 11-

[0646]

[0647] The reaction was carried out according to general procedure A using 1-8 (30 mg, 0.09 mmol), 4-pyridylboronic acid (18 mg, 0.244 mmol), potassium phosphate tribasic (54 mg, 0.24 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with di chloromethane (9 mg, 0.01 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC [column: X-select CSH C18 (250 x 3.0 mm) 5pAttorney Docket# COGN-01-PCT

[0648] particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 21; gradient (time / %B): 0 / 10,3 / 10,15 / 35,35 / 60,60 / 98 to afford (U?,27?)-4-(2-methoxy-4-(pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 11-E1 (9 mg, 30% yield) as an off-white solid.

[0649] 'H NMR (400 MHz, DMSO-d6) 6 = 8.60 - 8.55 (m, 2H), 7.72 - 7.67 (m, 2H), 7.37 - 7.32 (m, 2H), 6.99 (d, J= 9.0 Hz, 1H), 4.88 - 4.73 (m, 3H), 3.92 - 3.90 (m, 1H), 3.86 (s, 3H), 3.82 - 3.76 (m, 1H), 2.36 - 3.42 (m, 1H), 2.0 - 1.95 (m, 2H), 1.57 - 1.51 (m, 1H) ppm;

[0650] LCMS: 99%, [M+H]+= 302.20; HPLC: 99%.

[0651] (15',25)-4-(2-methoxy-4-(pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 11-E2)

[0652]

[0653] The reaction was carried out according to general procedure A using 1-8** (30 mg, 0.09 mmol), 4-pyridylboronic acid (18 mg, 0.244 mmol), potassium phosphate tribasic (52 mg, 0.24 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with di chloromethane (8 mg, 0.01 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC [column: X-select CSH C18, (50 * 3.0 mm) 2.5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 25; gradient (time / %B): 0 / 10,3 / 10,15 / 35,35 / 60,60 / 98 to afford (15,25)-4-(2-methoxy-4-(pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 11-E2) (7 mg, 23% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.60 - 8.55 (m, 2H), 7.71 - 7.67 (m, 2H), 7.37 -7.32 (m, 2H), 6.99 (d, J = 9.0 Hz, 1H), 4.86 - 4.72 (m, 3H), 3.95 - 3.88 (m, 1H), 3.86 (s, 3H), 3.82 - 3.76 (m, 1H), 2.45 - 2.41 (m, 1H), 2.04 - 1.94 (m, 2H), 1.57 - 1.53 (m, 1H) ppm;

[0654] LCMS: 96%, [M+H]+= 302.20; HPLC: 98%.

[0655] (ll?,21?)-4-(2-methoxy-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 12-E1)

[0656] Attorney Docket# COGN-01-PCT

[0657]

[0658] The reaction was carried out according to general procedure A using 1-8 (30 mg, 0.09 mmol), (2-(trifluoromethyl)pyridin-4-yl)boronic acid (28 mg, 0.14 mmol), potassium phosphate tribasic (54 mg, 0.24 mmol) and [l,l'-bis(diphenylphosphino)ferrocene] dichloropalladium(II), complex with di chloromethane (9 mg, 0.01 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC [column: X-select CSH C18, (50 mm x 3.0 mm) 2.5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 57; gradient (time / %B): 0 / 10,3 / 10,15 / 35,35 / 60,60 / 98 to afford (U?,27?)-4-(2-methoxy-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 12-E1 (14 mg, 38% yield) as an off-white solid. 'HNMR (400 MHz, DMSO-d6) 8 = 8.83 - 8.70 (m, 1H), 8.22 - 8.13 (m, 1H), 8.03 (dd, J= 1.3, 5.2 Hz, 1H), 7.70 - 7.30 (m, 2H), 7.09 - 6.92 (m, 1H), 4.95 - 4.70 (m, 3H), 4.00 - 3.86 (m, 4H), 3.82 - 3.69 (m, 1H), 2.08 - 1.86 (m, 2H), 1.60 -1.47 (m, 1H) ppm; LCMS: 99%, [M+H]+= 370.10; HPLC: 99%.

[0659] Note: One aliphatic proton was merged in DMSO peak.

[0660] (15',25)-4-(2-methoxy-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-l,2-

[0661]

[0662] The reaction was carried out according to general procedure A using 1-8** (30 mg, 0.09 mmol), (2-(trifluoromethyl)pyridin-4-yl)boronic acid (28 mg, 0.14 mmol), potassium phosphate tribasic (52 mg, 0.24 mmol) and [l,l'-bis(diphenylphosphino)ferrocene] dichloropalladium(II), complex with di chloromethane (8 mg, 0.01 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC [column: X-selectAttorney Docket# COGN-01-PCT

[0663] CSH C18, 50 * 3.0 mm, 2.5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 46; gradient (time / %B): 0 / 10,3 / 10,15 / 35,35 / 60,60 / 98 to afford (15,2S)-4-(2-methoxy-4-(2- (trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 12-E2) (13 mg, 36% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.75 (d, J= 5.1 Hz, 1H), 8.17 (s, 1H), 8.03 (d, J= 5.1 Hz, 1H), 7.50 - 7.44 (m, 2H), 7.01 (d, J= 8.9 Hz, 1H), 4.88 - 4.80 (m, 3H), 3.97 - 3.89 (m, 1H), 3.88 (s, 3H), 3.84 - 3.76 (m, 1H), 2.04 - 1.95 (m, 2H), 1.57- 1.51 (m, 1H) ppm; LCMS: 99%, [M+H]+= 370.10. Note: One aliphatic proton was merged in DMSO peak.

[0664] (ll?,2N,4s)-4-((3'-chloro-3-methoxy-[l,l'-biphenyl]-4-yl)oxy)cyclopentane-l,2-diol

[0665]

[0666] The reaction was carried out according to general procedure A using 1-1 (100 mg, 0.33 mmol), (3-chlorophenyl)boronic acid (77 mg, 0.49 mmol), potassium phosphate tribasic (174 mg, 0.82 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (26 mg, 0.03 mmol) in DMF (4 mL) at 80 °C for 16 h. The crude product was purified by reverse phase chromatography (using Cl 8 gold column) and product fractions were eluted with 0.1% formic acid in water in 40-50% acetonitrile to afford (17?,25',4s)-4-((3'-chloro-3-methoxy-[l, T-biphenyl]-4-yl)oxy)cyclopentane-l,2-diol (Example 13-D1, 23 mg, 20% yield) as an off white solid.1H NMR (400 MHz, DMSO- d6) 6 = 7.71 (br s, 1H), 7.62 (br d, J= 7.6 Hz, 1H), 7.45 (t, J= 8.0 Hz, 1H), 7.36 (br d, J = 8.0 Hz, 1H), 7.26 - 7.16 (m, 2H), 6.93 (d, J= 8.4 Hz, 1H), 4.87 - 4.83 (m, 1H), 4.52 (d, J = 4.2 Hz, 2H), 4.07 - 4.00 (m, 2H), 3.84 (s, 3H), 2.10 - 2.04 (m, 2H), 1.85 - 1.82 (m, 2H) ppm; LCMS: 96%, [M+H]+= 335.19; HPLC: 96%.

[0667] (ll?,2N,4r)-4-((3'-chloro-3-methoxy-[l,l'-biphenyl]-4-yl)oxy)cyclopentane-l,2-diol

[0668] (Example 13-D2)

[0669] Attorney Docket# COGN-01-PCT

[0670]

[0671] The reaction was carried out according to general procedure A using 1-1** (100 mg, 0.33 mmol), (3-chlorophenyl)boronic acid (77 mg, 0.49 mmol), potassium phosphate tribasic (174 mg, 0.82 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (26 mg, 0.03 mmol) in DMF (4 mL) at 100 °C for 16 h. The crude product was purified by reverse phase chromatography (using Cl 8 gold column) and product fractions were eluted with 0.1% formic acid in water in 40-50% acetonitrile to afford (17?,25',4r)-4-((3'-chloro-3-methoxy-[l,r-biphenyl]-4-yl)oxy)cyclopentane-l,2-diol (Example 13-D2, 7 mg, 6% yield) as an off white solid.1H NMR (400 MHz, DMSO-de) 8 = 7.71 (br s, 1H), 7.62 (br d, J= 7.6 Hz, 1H), 7.44 (t, J= 8.0 Hz, 1H), 7.37 - 7.33 (m, 1H), 7.23 (br s, 1H), 7.19 (dd, J= 8.4, 2.0 Hz, 1H), 6.93 (d, J = 8.4 Hz, 1H), 4.66 - 4.63 (m, 1H), 4.48 (d, J= 4.4 Hz, 2H), 3.86 - 3.80 (m, 5H), 2.31 - 2.24 (m, 2H), 1.79 - 1.73 (m, 2H) ppm;

[0672] LCMS: 99%, [M+H]+= 335.21.

[0673] 4'-(((ls,31?,45)-3,4-dihydroxycyclopentyl)oxy)-3'-methoxy-[l,l'-biphenyl]-3-

[0674]

[0675]

[0676] The reaction was carried out according to general procedure A using 1-1 (100 mg, 0.33 mmol), (3-cyanophenyl)boronic acid (72 mg, 0.48 mmol), potassium phosphate tribasic (174 mg, 0.82 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (27 mg, 0.03 mmol) in DMF (4 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH Cl 8 (50 mmx3.0Attorney Docket# COGN-01-PCT

[0677] mm) 2.5p, particle size; mobile phase A: 2.5 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 15 mL; loading(mg / inj ection): 40; gradient (time / %B): 0 / 10,3 / 10,15 / 50,27 / 60,35 / 99) to afford 4'-(((l,37?,45)-3,4-dihydroxycyclopentyl)oxy)-3'-methoxy-[l,r-biphenyl]-3-carbonitrile. (Example 14-D1, 18 mg, 16% yield) as an off white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.16 (s, 1H), 8.01 (d, J= 8.0 Hz, 1H), 7.76 (d, J= 8.0 Hz, 1H), 7.62 (t, J= 8.0 Hz, 1H), 7.31 (d, J= 2.4 Hz, 1H), 7.25 (dd, J= 8.4, 2.0 Hz, 1H), 6.96 (d, J= 8.4 Hz, 1H), 4.88 - 4.84 (m, 1H), 4.52 (d, J= 4.0 Hz, 2H), 4.04 - 3.99 (m, 2H), 3.85 (s, 3H), 2.11 - 2.05 (m, 2H), 1.86 - 1.82 (m, 2H) ppm. LCMS: 99%, [M-H]’ = 324.15; HPLC: 99%.

[0678] 4'-(((lr,31?,45)-3,4-dihydroxycyclopentyl)oxy)-3'-methoxy-[l,l'-biphenyl]-3-

[0679]

[0680]

[0681] The reaction was carried out according to general procedure A using 1-1** (100 mg, 0.33 mmol), (3-cyanophenyl)boronic acid (72 mg, 0.48 mmol), potassium phosphate tribasic (174 mg, 0.82 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (27 mg, 0.032 mmol) in DMF (4 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH Cl 8 (50 mmx3.0 mm) 2.5p, particle size; mobile phase A: 2.5 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 22 mL; loading (mg / inj ection): 120; gradient (time / %B): 0 / 5,3 / 5,10 / 15,40 / 60,41 / 99,45 / 99) to afford 4'-(((lr,37?,45)-3,4-dihydroxycyclopentyl)oxy)-3'-methoxy-[l, T-biphenyl]-3-carbonitrile. (Example 14-D2, 38 mg, 42% yield) as an off white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.16 (s, 1H), 8.01 (d, J= 8.0 Hz, 1H), 7.75 (d, J= 7.6 Hz, 1H), 7.62 (t, J= 8.0 Hz, 1H), 7.31 (d, J= 2.0 Hz, 1H), 7.25 (dd, J= 8.4, 2.0 Hz, 1H), 6.95 (d, J= 8.4 Hz, 1H), 4.71 - 4.62 (m, 1H), 4.48 (d, J= 4.4 Hz, 2H), 3.89 - 3.78 (m, 5H), 2.35 - 2.22 (m, 2H), 1.80 - 1.72 (m, 2H) ppm; LCMS: 99% [M+H]+= 326.2;

[0682] HPLC: 99%

[0683] Attorney Docket# COGN-01-PCT

[0684] (ll?,25',4s)-4-((3-methoxy-3'-(methylsulfonyl)-[l,l'-biphenyl]-4-yl)oxy)cyclopentane-

[0685]

[0686]

[0687] The reaction was carried out according to general procedure A using 1-1 (100 mg, 0.33 mmol), (3-(methylsulfonyl)phenyl)boronic acid (100 mg, 0.49 mmol), potassium phosphate tribasic (174 mg, 0.82 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloro-palladium(II), complex with di chloromethane (27 mg, 0.03 mmol) in DMF (4 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (50 mm x3.0 mm) 2.5p, particle size; mobile phase A: 2.5 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 8 mL; loading (mg / inj ection): 50; Gradient(Time / %B): 0 / 10,3 / 10,15 / 50,27 / 60,35 / 99) to afford ( 1R, 2S, 4s)-4-((3-m ethoxy-3 (methylsulfonyl)-[l,l'-biphenyl]-4-yl)oxy)cyclopentane-l,2-diol (Example 15-D1, 36 mg, 28% yield) as an off white solid. 'H NMR (400 MHz, DMSO-cL) 8 = 8.11 (t, J = 1.6 Hz, 1H), 8.01 (br d, J= 7.6 Hz, 1H), 7.84 (dd, J= 7.6, 0.8 Hz, 1H), 7.70 (t, J= 7.6 Hz, 1H), 7.32 - 7.23 (m, 2H), 6.98 (d, J= 8.4 Hz, 1H), 4.73 - 4.40 (m, 3H), 3.90 - 3.78 (m, 5H), 2.32 - 2.24 (m, 2H), 1.79 - 1.72 (m, 2H) ppm (Note: 3 protons-singlet merged in solvent peak, visible in ^NMR-CDsOD at 3.18 ppm); LCMS: 99% [M-H]’ = 377.10; HPLC: 99%

[0688] (ll?,25',4r)-4-((3-methoxy-3'-(methylsulfonyl)-[l,l'-biphenyl]-4-yl)oxy)cyclopentane-

[0689]

[0690] Attorney Docket# COGN-01-PCT

[0691] The reaction was carried out according to general procedure A using 1-1** (100 mg, 0.33 mmol), (3-(methylsulfonyl)phenyl)boronic acid (100 mg, 0.490 mmol), potassium phosphate tribasic (174 mg, 0.82 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (27 mg, 0.03 mmol) in DMF (4 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (50 mm x3.0 mm) 2.5p, particle size; mobile phase A: 2.5 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 20 mL; loading (mg / inj ection): 70; gradient (time / %B):

[0692] 0 / 10,3 / 10,10 / 30,30 / 65,40 / 85,50 / 99) to afford (U?,25,4r)-4-((3-methoxy-3'-(methylsulfonyl)-[l,l'-biphenyl]-4-yl)oxy)cyclopentane-l,2-diol (Example 15-D2, 21 mg, 20% yield) as an off white solid. 'H NMR (400 MHz, DMSO-cL) 8 = 8.11 (t, J = 1.6 Hz, 1H), 8.01 (br d, J= 7.6 Hz, 1H), 7.85 (br d, J= 7.6 Hz, 1H), 7.70 (t, J= 7.6 Hz, 1H), 7.30 -7.23 (m, 2H), 6.98 (d, J= 8.4 Hz, 1H), 4.93 - 4.84 (m, 1H), 4.66 - 4.40 (m, 2H), 4.06 - 3.99 (m, 2H), 3.85 (s, 3H), 2.14 - 2.04 (m, 2H), 1.89 - 1.80 (m, 2H) ppm Note: 3 protons-singlet merged in solvent peak. LCMS: 99% [M-H]’= 377.10; HPLC: 99%

[0693] (ll?,25',4s)-4-((3-methoxy-3'-(trifluoromethyl)-[l,l'-biphenyl]-4-yl)oxy)cyclopentane-

[0694]

[0695] The reaction was carried out according to general procedure A using 1-1 (50 mg, 0.16 mmol), (3-(trifluoromethyl)phenyl)boronic acid (47 mg, 0.24 mmol), potassium phosphate tribasic (90 mg, 0.42 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloro-palladium(II), complex with dichloromethane (14 mg, 0.02 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (50 mm x 3.0 mm) 2.5p, particle size; mobile phase A: 2.5 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 25 mL; loading (mg / inj ection): 25; gradient (time / %B): 0 / 10,3 / 10,15 / 35,45 / 60,60 / 98) to afford (l / ?,2£,4 )-4-((3-methoxy-3'-(trifluoromethyl)-[l, T-biphenyl]-4-yl)oxy)cyclopentane-l,2-diol (Example 16-D1, 12 mg,Attorney Docket# COGN-01-PCT

[0696] 19.4% yield) as an off white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 7.99 - 7.92 (m, 2H), 7.68 - 7.64 (m, 2H), 7.29 - 7.22 (m, 2H), 6.96 (d, J= 8.4 Hz, 1H), 4.88 - 4.85 (m, 1H), 4.52 (d, J= 4.4 Hz, 2H), 4.07 - 4.00 (m, 2H), 3.85 (s, 3H), 2.11 - 2.04 (m, 2H), 1.87 - 1.83 (m, 2H) ppm;19F NMR (376.66 MHz, DMSO-d6) 6 = -60.91 ppm; LCMS: 97%, [M-H]’ = 367.1; HPLC: 97%.

[0697] (ll?,2N,4r)-4-((3-methoxy-3'-(trifluoromethyl)-[l,l'-biphenyl]-4-yl)oxy)cyclopentane-

[0698]

[0699] The reaction was carried out according to general procedure A using 1-1** (50 mg, 0.16 mmol), (3-(trifluoromethyl)phenyl)boronic acid (46 mg, 0.24 mmol), potassium phosphate tribasic (46 mg, 0.24 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloro-palladium(II), complex with dichloromethane (14 mg, 0.02 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (50 mm x3.0 mm) 2.5p, particle size; mobile phase A: 2.5 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 20 mL; loading (mg / inj ection): 30; gradient (time / %B): 0 / 10,3 / 10,10 / 30,30 / 65,40 / 85,50 / 99) to afford (U?,2S,4r)-4-((3-methoxy-3'-(trifluoromethyl)-[l, T-biphenyl]-4-yl)oxy)cyclopentane-l,2-diol (Example 16-D2, 12 mg, 24% yield) as an off white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 7.99 - 7.92 (m, 2H), 7.68 - 7.63 (m, 2H), 7.30 - 7.21 (m, 2H), 6.95 (d, J= 8.4 Hz, 1H), 4.69 - 4.63 (m, 1H), 4.48 - 4.45 (m, 2H), 3.85 - 3.79 (m, 5H), 2.31 - 2.25 (m, 2H), 1.80- 1.73 (m, 2H) ppm;19F NMR (376.66 MHz, DMSO-d6) 6 = -62.06 ppm; LCMS: 99%, [M+H]+= 369.19; HPLC: 99%.

[0700] (ll?,2N,4s)-4-((3-methoxy-3'-(trifluoromethoxy)-[l,l'-biphenyl]-4-yl)oxy)cyclopentane-l,2-diol (Example 17-D1)

[0701] Attorney Docket# COGN-01-PCT

[0702]

[0703] The reaction was carried out according to general procedure A using 1-1 (30 mg, 0.09 mmol), (3-(trifluoromethoxy)phenyl)boronic acid (30 mg, 0.15 mmol), potassium phosphate tribasic (90 mg, 0.24 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloro-palladium(II), complex with dichloromethane (8 mg, 0.01 mmol) in DMF (1 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm x30 mm) 5p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 15 mL; loading (mg / inj ection): 5; gradient (time / %B): 0 / 10,3 / 10,15 / 50,27 / 60,35 / 99) to afford

[0704]

[0705] ((3 -m ethoxy-3 '-(trifluoromethoxy)-[ 1, 1 '-biphenyl]-4-yl)oxy)cy clopentane- 1,2-diol (Example 17-D1, 8 mg, 21% yield) as an off white solid. LCMS: 99.7%, [M-l]'= 383.05.

[0706] (ll?,25',4r)-4-((3-methoxy-3'-(trifluoromethoxy)-[l,l'-biphenyl]-4-yl)oxy)cyclopentane-l,2-diol (Example 17-D2)

[0707]

[0708] The reaction was carried out according to general procedure A using 1-1** (30 mg, 0.09 mmol), (3-(trifluoromethoxy)phenyl)boronic acid (30 mg, 0.14 mmol), potassium phosphate tribasic (90 mg, 0.24 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloro-palladium(II), complex with dichloromethane (8 mg, 0.01 mmol) in DMF (1 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm x30 mm) 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 22 mL; loading (mg / inj ection): 45; gradient (time / %B): 0 / 10,3 / 10,10 / 30,40 / 70,41 / 99,45 / 99) toAttorney Docket# COGN-01-PCT

[0709] afford (U?,25',4r)-4-((3-methoxy-3'-(trifluoromethoxy)-[l,r-biphenyl]-4-yl)oxy)cyclopentane-l,2-diol (Example 17-D2, 8 mg, 20% yield) as an off white solid.

[0710] LCMS: 99%, [M+H]+= 385.17.

[0711] (ll?,2»S,4s)-4-(2-methoxy-4-(pyridin-3-yl)phenoxy)cyclopentane-l,2-diol (Example 18-

[0712]

[0713] The reaction was carried out according to general procedure A using 1-1 (50 mg, 0.16 mmol), pyri din-3 -ylboronic acid (27 mg, 0.22 mmol), potassium phosphate tribasic (51 mg, 0.37 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloro-palladium(II), complex with dichloromethane (12 mg, 0.014 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by reverse phase chromatography (using Cl 8 gold column) and product fractions were eluted with 0.1% formic acid in water in 40-50% acetonitrile to afford (17?,25',45)-4-(2-methoxy-4-(pyridin-3-yl)phenoxy)cyclopentane-l,2-diol (Example 18-D1, 22 mg, 49% yield) as an off white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.88 (dd, J = 2.4, 0.4 Hz, 1H), 8.51 (dd, J = 4.4, 1.6 Hz, 1H), 8.07 - 8.03 (m, 1H), 7.46 - 7.42 (m, 1H), 7.28 (d, J= 2.0 Hz, 1H), 7.22 (dd, J= 8.0, 2.0 Hz, 1H), 6.96 (d, J= 8.4 Hz, 1H), 4.89 - 4.84 (m, 1H), 4.52 (d, J= 4.4 Hz, 2H), 4.05 - 4.00 (m, 2H), 3.84 (s, 3H), 2.11 - 2.03 (m, 2H), 1.89 - 1.81 (m, 2H) ppm; LCMS: 99%, [M+H]+=302.2; HPLC: 95%.

[0714] (ll?,25',4r)-4-(2-methoxy-4-(pyridin-3-yl)phenoxy)cyclopentane-l,2-diol (Example 18-

[0715]

[0716] Attorney Docket# COGN-01-PCT

[0717] The reaction was carried out according to general procedure A using 1-1** (100 mg, 0.27 mmol), (3-pyridylboronic acid (49 mg, 0.41 mmol), potassium phosphate tribasic (146 mg, 0.68 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloro-palladium(II), complex with di chloromethane (22 mg, 0.027 mmol) in DMF (4 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm * 30 mm) 5p particle size; mobile phase A: 0.1% trifluoroacetic acid in water, mobile phase B: acetonitrile; flow: 25 mL; loading (mg / inj ection): 20; gradient (time / %B): 0 / 0,5 / 0,10 / 5,15 / 10,20 / 15,25 / 20,30 / 25,60 / 99) to afford (17?,25,4r)-4-(2-methoxy-4-(pyridin-3-yl)phenoxy)cyclopentane-l,2-diol (Example 18-D2, 28 mg, 33% yield) as an off white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 9.02 (d, J = 1.6 Hz, 1H), 8.63 (d, J = 4.8 Hz, 1H), 8.37 (br d, J= 8.4 Hz, 1H), 7.69 (br dd, J= 8.0, 5.2 Hz, 1H), 7.34 (d, J= 2.0 Hz, 1H), 7.29 (dd, J= 8.4, 2.0 Hz, 1H), 6.99 (d, J= 8.4 Hz, 1H), 4.72 - 4.64 (m, 1H), 3.86 (s, 3H), 3.84 - 3.78 (m, 2H), 2.33 - 2.24 (m, 2H), 1.81 - 1.73 (m, 2H) ppm; LCMS: 98%, [M+H]+=302.1; HPLC: 99%.

[0718] (ll?,2»S,4s)-4-(4-(5-chloropyridin-3-yl)-2-methoxyphenoxy)cyclopentane-l,2-diol

[0719]

[0720] The reaction was carried out according to general procedure A using 1-1 (150 mg, 0.33 mmol), (5-chloropyridin-3-yl)boronic acid (116 mg, 0.73 mmol), potassium phosphate tribasic (274 mg, 1.22 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (41mg, 0.05 mmol) in DMF (6 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm * 30 mm) 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 22 mL; loading (mg / inj ection): 100; gradient (time / %B):

[0721] 0 / 10,3 / 10,10 / 35,20 / 55,30 / 65,40 / 75,50 / 99) to afford (17?,25,45)-4-(4-(5-chloropyridin-3-yl)-Attorney Docket# COGN-01-PCT

[0722] 2-methoxyphenoxy)cyclopentane-l,2-diol (Example 19-D1, 98 mg, 59% yield) as an white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.87 (d, J= 2.0 Hz, 1H), 8.55 (d, J= 2.3 Hz, 1H), 8.24 (t, J= 2.1 Hz, 1H), 7.34 (d, J= 2.1 Hz, 1H), 7.30 (dd, J= 2.2, 8.3 Hz, 1H), 6.97 (d, J= 8.4 Hz, 1H), 4.91 - 4.84 (m, 1H), 4.53 (d, J= 4.0 Hz, 2H), 3.99-4.06 (m, 2H), 3.85 (s, 3H), 2.13 - 2.04 (m, 2H), 1.89 - 1.81 (m, 2H) ppm; LCMS: 99%, [M+H]+= 336.2.

[0723] (ll?,2»S,4r)-4-(4-(5-chloropyridin-3-yl)-2-methoxyphenoxy)cyclopentane-l,2-diol

[0724]

[0725] The reaction was carried out according to general procedure A using 1-1** (150 mg, 0.33 mmol), (5-chloropyridin-3-yl)boronic acid (116 mg, 0.73 mmol), potassium phosphate tribasic (265 mg, 1.22 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (41mg, 0.05 mmol) in DMF (6 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm * 30 mm) 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 20 mL; loading (mg / inj ection): 80; gradient (time / %B):

[0726] 0 / 10,3 / 10,10 / 35,20 / 55,30 / 65,40 / 75,50 / 99) to afford (17?,25,4r)-4-(4-(5-chloropyridin-3-yl)-2-methoxyphenoxy)cyclopentane-l,2-diol (Example 19-D2, 79 mg, 45% yield) as an white solid. 'HNMR (400 MHz, DMSO-d6) 8 = 8.86 (d, J= 1.9 Hz, 1H), 8.55 (d, J= 2.3 Hz, 1H), 8.23 (t, J= 2.1 Hz, 1H), 7.34 (d, J= 2.1 Hz, 1H), 7.29 (dd, J= 2.1, 8.3 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 4.72 - 4.63 (m, 1H), 4.49 (d, J= 4.3 Hz, 2H), 3.85 (s, 3H), 3.83 - 3.76 (m, 2H), 2.33 - 2.25 (m, 2H), 1.73-1.80 (m, 2H) LCMS: 95%, [M+H]+= 336.17; HPLC: 98%.

[0727] (ll?,2»S,4s)-4-(2-methoxy-4-(5-(trifluoromethyl)pyridin-3-yl)phenoxy)cyclopentane-1,2-diol (Example 20-D1)

[0728] Attorney Docket# COGN-01-PCT

[0729]

[0730] The reaction was carried out according to general procedure A using 1-1 (50 mg, 0.16 mmol), (5-(trifluoromethyl)pyridin-3-yl)boronic acid (49 mg, 0.41 mmol), potassium phosphate tribasic (47 mg, 0.24 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloro-palladium(II), complex with dichloromethane (13 mg, 0.02 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm * 30 mm) 5p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 20 mL; loading (mg / inj ection): 70; gradient (time / %B): 0 / 20,3 / 20,10 / 40,35 / 60) to afford (I / ?,2A',4.s)-4-(2-methoxy-4-(5-(trifluoromethyl)pyridin-3-yl)phenoxy)cyclopentane-l,2-diol (Example 20-Dl, 27 mg, 44% yield) as an off white solid. 'H NMR (400 MHz, DMSO-d6) 8 = 9.20 (d, J = 2.0 Hz, 1H), 8.89 (d, J= 1.1 Hz, 1H), 8.44 (s, 1H), 7.40 (d, J= 2.1 Hz, 1H), 7.36 (dd, J = 2.1, 8.4 Hz, 1H), 6.99 (d, J= 8.4 Hz, 1H), 4.91 - 4.86 (m, 1H), 4.50 (d, J= 4.4 Hz, 2H), 4.06 - 4.00 (m, 2H), 3.86 (s, 3H), 2.13 - 2.04 (m, 2H), 1.89 - 1.80 (m, 2H) ppm; LCMS: 99%, [M+H]+=370.25; HPLC: 95%.

[0731] (ll?,25,4r)-4-(2-methoxy-4-(5-(trifluoromethyl)pyridin-3-yl)phenoxy)cyclopentane-

[0732]

[0733]

[0734] The reaction was carried out according to general procedure A using 1-1** (100 mg, 0.32 mmol), (5-(trifluoromethyl)pyridin-3-yl)boronic acid (94 mg, 0.49 mmol), potassiumAttorney Docket# COGN-01-PCT

[0735] phosphate tribasic (175 mg, 0.82 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloro-palladium(II), complex with dichloromethane (27 mg, 0.03 mmol) in DMF (4 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm * 30 mm) 5p particle size; mobile phase A: 0.1% trifluoroacetic acid in water, mobile phase B: acetonitrile; flow: 20 mL; loading (mg / inj ection): 70; gradient (time / %B): 0 / 20,3 / 20,10 / 40,35 / 60) to afford (1R, 2S, 4r)-4-(2 -methoxy -4-(5-(trifluoromethyl)pyridin-3-yl)phenoxy)cyclopentane-l, 2-diol (Example 20-D2, 38 mg, 30% yield) as an off white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 9.20 (d, J= 1.8 Hz, 1H), 8.89 (s, 1H), 8.44 (s, 1H), 7.42 - 7.33 (m, 2H), 6.99 (d, J= 8.4 Hz, 1H), 4.76 - 4.62 (m, 1H), 3.87 (s, 3H), 3.80 (br d, J= 3.9 Hz, 2H), 2.36 - 2.20 (m, 2H), 1.84 - 1.73 (m, 2H) ppm; LCMS: 99%, [M+H]+= 370.25; HPLC: 99%.

[0736] (ll?,2»S,4s)-4-(2-methoxy-4-(5-(trifluoromethoxy)pyridin-3-yl)phenoxy)cyclo pentane-

[0737]

[0738] The reaction was carried out according to general procedure A using 1-2 (86 mg, 0.24 mmol), 3-bromo-5-(trifluoromethoxy)pyridine (50 mg, 0.20 mmol), potassium phosphate tribasic (109 mg, 0.50 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloro-palladium(II), complex with dichloromethane (16 mg, 0.02mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm * 30 mm) 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 22 mL; loading (mg / inj ection): 70; gradient (time / %B): 0 / 15,3 / 15,10 / 35,35 / 55 to afford (l / ?,2£,4 )-4-(2-methoxy-4-(5- (trifluorom ethoxy )pyri din-3 -yl)phenoxy)cy cl opentane-l,2-diol (Example 21-D1, 18 mg, 22% yield) as an off white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.97 (d, J= 1.9 Hz, 1H), 8.62 - 8.58 (m, 1H), 8.19 - 8.16 (m, 1H), 7.36 (d, J= 2.1 Hz, 1H), 7.34 - 7.30 (m, 1H), 7.00 - 6.96 (m, 1H), 4.92 - 4.84 (m, 1H), 4.51 (d, J= 4.4 Hz, 2H), 4.06 - 3.99 (m, 2H), 3.85Attorney Docket# COGN-01-PCT

[0739] (s, 3H), 2.13 - 2.05 (m, 2H), 1.88 - 1.81 (m, 2H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -56.99 ppm; LCMS: 99%, [M+H]+= 386.1; HPLC: 99%.

[0740] (ll?,2N,4r)-4-(2-methoxy-4-(5-(trifluoromethoxy)pyridin-3-yl)phenoxy)cyclopentane-1,2-diol (Example 21-D2)

[0741]

[0742] The reaction was carried out according to general procedure A using 1-2** (86 mg, 0.24 mmol), 3-bromo-5-(trifluoromethoxy)pyridine (50 mg, 0.20 mmol), potassium phosphate tribasic (109 mg, 0.50 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloro-palladium(II), complex with dichloromethane (16 mg, 0.02mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm * 30 mm) 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 20 mL; loading (mg / inj ection): 50; gradient (time / %B): 0 / 15,3 / 15,10 / 35,35 / 55 to afford (l / ?,2£,4 )-4-(2-methoxy-4-(5- (trifluorom ethoxy )pyri din-3 -yl)phenoxy)cy cl opentane-l,2-diol (Example 21-D2, 13 mg, 16% yield) as an off white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.98 (d, J= 1.8 Hz, 1H), 8.60 (s, 1H), 8.18 (s, 1H), 7.36 (d, J= 1.9 Hz, 1H), 7.32 (dd, J= 2.0, 8.4 Hz, 1H), 6.98 (d, J= 8.5 Hz, 1H), 4.72 - 4.64 (m, 1H), 4.50 (br d, J= 0.9 Hz, 2H), 3.86 (s, 3H), 3.78-3.84 (m, 2H), 2.33 - 2.27 (m, 2H), 1.72-1.81 (m, 2H) ppm;19F NMR (377 MHz, DMSO-d6) 8 = -58.14 ppm; LCMS: 99%, [M+H]+= 386.1; HPLC: 99%.

[0743] 5-(4-(((ls,37?,4 )-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)nicotinonitrile

[0744] (Example 22-D1)

[0745] Attorney Docket# COGN-01-PCT

[0746]

[0747] The reaction was carried out according to general procedure A using 1-1 (30 mg, 0.09 mmol), (5-cyanopyridin-3-yl)boronic acid (22 mg, 0.14 mmol), potassium phosphate tribasic (53 mg, 0.25 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloro-palladium(II), complex with dichloromethane (8 mg, 0.01 mmol) in DMF (1 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm * 30 mm) 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 22 mL; loading (mg / inj ection): 34; gradient (time / %B): 0 / 10,3 / 10,10 / 30,27 / 45,28 / 99,33 / 99 to afford 5-(4-(((ls,37?,4S)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)nicotinonitrile (Example 22-D1, 12 mg, 35.6% yield) as an off white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 9.20 (d, J= 2.3 Hz, 1H), 8.94 (d, J= 1.8 Hz, 1H), 8.65 (t, J= 2.1 Hz, 1H), 7.40 (d, J= 2.1 Hz, 1H), 7.35 (dd, J = 2.1, 8.4 Hz, 1H), 6.99 (d, J= 8.4 Hz, 1H), 4.92 - 4.86 (m, 1H), 4.52 (d, J= 4.3 Hz, 2H), 4.03 (br d, J = 3.9 Hz, 2H), 3.85 (s, 3H), 2.13 - 2.05 (m, 2H), 1.88-1.81 (m, 2H) ppm;

[0748] LCMS: 98%, [M+H]+=327.22.

[0749] 5-(4-(((lr,31?,45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)nicotinonitrile

[0750]

[0751] The reaction was carried out according to general procedure A using 1-1** (30 mg, 0.09 mmol), (5-cyanopyridin-3-yl)boronic acid (22 mg, 0.14 mmol), potassium phosphate tribasic (53 mg, 0.25 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloro-

[0752] Attorney Docket# COGN-01-PCT

[0753] palladium(II), complex with dichloromethane (8 mg, 0.01 mmol) in DMF (1 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Bridge C18 (150 * 19 mm), 5 p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 15 mL; loading (mg / inj ection): 10; gradient (time / %B): 0 / 10,3 / 10,15 / 50,27 / 60,35 / 99 to afford 5-(4-(((lr,37?,45)-3,4-dihydroxycyclopentyl)oxy)-3- methoxyphenyl)nicotinonitrile (Example 22-D2, 11 mg, 33% yield) as an off white solid.XH NMR (400 MHz, DMSO-d6) 8 = 9.20 (d, J= 2.3 Hz, 1H), 8.94 (d, J= 2.0 Hz, 1H), 8.66 (t, J= 2.1 Hz, 1H), 7.39 (d, J= 2.1 Hz, 1H), 7.35 (dd, J= 2.2, 8.3 Hz, 1H), 6.98 (d, J= 8.4 Hz, 1H), 4.72 - 4.64 (m, 1H), 4.52 (d, J= 4.5 Hz, 2H), 3.86 (s, 3H), 3.81 (br d, J= 4.3, 8.7 Hz, 2H), 2.34 - 2.25 (m, 2H), 1.72-1.79 (m, 2H) ppm; LCMS: 99%, [M+H]+=327.14.

[0754] (ll?,2»S,4s)-4-(2-methoxy-4-(pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 23-

[0755]

[0756] The reaction was carried out according to general procedure A using 1-1 (30 mg, 0.09 mmol), pyridin-4-ylboronic acid (18 mg, 0.15 mmol), potassium phosphate tribasic (53 mg, 0.25 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloro-palladium(II), complex with dichloromethane (8 mg, 0.01 mmol) in DMF (1 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm * 30 mm) 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 22 mL; loading (mg / inj ection): 34; gradient (time / %B): 0 / 5,3 / 5,10 / 20,25 / 40,26 / 99,30 / 99 to afford (l. R,2£,4 )-4-(2-methoxy-4-(pyridin-4- yl)phenoxy)cyclopentane-l,2-diol (Example 23-D1, 12 mg, 39% yield) as an off white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.60 - 8.56 (m, 2H), 7.72 - 7.66 (m, 2H), 7.36 - 7.32 (m, 2H), 7.00 - 6.96 (m, 1H), 4.84-4.93 (m, 1H), 4.50 (d, J= 4.3 Hz, 2H), 4.03 (bd, J = 4.3, 8.3 Hz, 2H), 3.87 - 3.83 (m, 3H), 2.13 - 2.05 (m, 2H), 1.90 - 1.81 (m, 2H) ppm;

[0757] LCMS: 97%, [M+H]+= 302.1; HPLC: 96%.

[0758] Attorney Docket# COGN-01-PCT

[0759] (ll?,2»S,4r)-4-(2-methoxy-4-(pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 23-

[0760]

[0761] The reaction was carried out according to general procedure A using 1-1** (30 mg, 0.09 mmol), pyridin-4-ylboronic acid (18 mg, 0.15 mmol), potassium phosphate tribasic (53 mg, 0.25 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloro-palladium(II), complex with dichloromethane (8 mg, 0.01 mmol) in DMF (1 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm * 30 mm) 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 22 mL; loading (mg / inj ection): 50; gradient (time / %B): 0 / 10,3 / 10,10 / 25,25 / 45,28 / 99,32 / 99 to afford (17?,25,4r)-4-(2-methoxy-4-(pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 23-D2, 12 mg, 47% yield) as an off white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.60 - 8.56 (m, 2H), 7.72 - 7.66 (m, 2H), 7.36 - 7.32 (m, 2H), 7.00 - 6.96 (m, 1H), 4.84-4.93 (m, 1H), 4.50 (d, J= 4.3 Hz, 2H), 4.03 (br d, J = 4.3, 8.3 Hz, 2H), 3.87 - 3.83 (m, 3H), 2.13 - 2.05 (m, 2H), 1.90 - 1.81 (m, 2H) ppm;

[0762] LCMS: 99%, [M+H]+= 302.1.

[0763] (ll?,2»S,4s)-4-(2-methoxy-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-

[0764]

[0765] The reaction was carried out according to general procedure A using 1-1 (30 mg, 0.09 mmol), (2-(trifluoromethyl)pyridin-4-yl)boronic acid (28 mg, 0.15 mmol), potassium

[0766] Attorney Docket# COGN-01-PCT

[0767] phosphate tribasic (53 mg, 0.25 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloro-palladium(II), complex with dichloromethane (8 mg, 0.01 mmol) in DMF (1 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm * 30 mm) 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 22 mL; loading (mg / inj ection): 59; gradient (time / %B): 0 / 15,3 / 15,10 / 30,28 / 60,29 / 99,33 / 99 to afford ( l / ?,2A',4.s)-4-(2-methoxy-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-1,2-diol (Example 24-D1, 14 mg, 38% yield) as an off white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.75 (d, J= 5.1 Hz, 1H), 8.16 (s, 1H), 8.03 (br d, J= 4.0 Hz, 1H), 7.51 -7.42 (m, 2H), 7.01 (d, J= 9.0 Hz, 1H), 4.94 - 4.86 (m, 1H), 4.51 (d, J= 4.3 Hz, 2H), 4.03 (br d, J= 3.8 Hz, 2H), 3.87 (s, 3H), 2.15 - 2.07 (m, 2H), 1.91 - 1.80 (m, 2H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -66.27 ppm; LCMS: 99%, [M+H]+= 370.23; HPLC: 98%.

[0768] (ll?,2N,4r)-4-(2-methoxy-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-

[0769]

[0770]

[0771] The reaction was carried out according to general procedure A using 1-1** (30 mg, 0.09 mmol), (2-(trifluoromethyl)pyridin-4-yl)boronic acid (28 mg, 0.15 mmol), potassium phosphate tribasic (53 mg, 0.25 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloro-palladium(II), complex with dichloromethane (8 mg, 0.01 mmol) in DMF (1 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm * 30 mm) 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 22 mL; loading (mg / inj ection): 80; gradient (time / %B):

[0772] 0 / 10,3 / 10,10 / 35,20 / 55,30 / 65,40 / 75,50 / 99 to afford (17?,25,4r)-4-(2-methoxy-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 24-D2, 18 mg, 59% yield) as an off white solid. 'H NMR (400 MHz, DMSO-d6) 8 = 8.75 (d, J = 5.3 Hz, 1H), 8.16 (s, 1H), 8.03 (br d, J = 3.9 Hz, 1H), 7.51 - 7.41 (m, 2H), 7.00 (d, J = 9.0 Hz, 1H),Attorney Docket# COGN-01-PCT

[0773] 4.74 - 4.65 (m, 1H), 4.50 (d, J = 4.5 Hz, 2H), 3.88 (s, 3H), 3.85 - 3.78 (m, 2H), 2.33 - 2.27 (m, 2H), 1.73-1.81 (m, 2H) ppm; LCMS: 95%, [M+H]+= 370.19.

[0774] 4-(4-(((31?,41?)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-methylpyridin-2(LH)-one (Example 25-E1)

[0775]

[0776] The reaction was carried out according to general procedure A using 1-9 and 4-bromo-l-methylpyridin-2(U7)-one. The crude product was purified by reverse phase chromatography (C-18 gold column; Mobile phase A: 0.1% formic acid in water, Mobile Phase B: 40-50% acetonitrile) to afford Example 25-E1 (24 mg, 45% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 8 = 7.71 (d, J = 7.1 Hz, 1H), 7.26 - 7.23 (m, 2H), 6.93 (d, J= 9.0 Hz, 1H), 6.67 (d, J= 1.9 Hz, 1H), 6.61 - 6.53 (m, 1H), 4.84 - 4.74 (m, 3H), 3.95 - 3.88 (m, J= 4.7, 4.7, 4.7, 4.7 Hz, 1H), 3.83 (s, 3H), 3.79 - 3.72 (m, 1H), 3.43 (s, 3H), 2.02 - 1.93 (m, 2H), 1.58 - 1.48 (m, J=4.6, 4.6, 14.1 Hz, 1H) ppm; LCMS: 99%, [M+H]+= 332.1; HPLC: 97%.

[0777] 4-(4-(((35',45)-36,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-methylpyridin- 2( l / / )-one (Example 25-E2)

[0778]

[0779] Attorney Docket# COGN-01-PCT

[0780] The reaction was carried out according to general procedure A using 1-9** and 4-bromo-l-methylpyridin-2(U7)-one. The crude product was purified by preparative HPLC [Column: XB-C18; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 20 mL; loading(mg / inj ection): 79; gradient (time / %B): 0 / 10,3 / 10,10 / 30,20 / 70 to afford Example 25-E2 (10 mg, 19% yield) as white gummy solid.

[0781] 'H NMR (400 MHz, DMSO-d6) 6 = 7.71 (d, J= 7.1 Hz, 1H), 7.27 - 7.22 (m, 2H), 6.93 (d, J= 9.0 Hz, 1H), 6.67 (d, J= 1.9 Hz, 1H), 6.60 - 6.56 (m, 1H), 4.79 (t, = 4.1 Hz, 3H), 3.92 - 3.90 (m, 1H), 3.83 (s, 3H), 3.81 - 3.76 (m, 1H), 3.43 (s, 3H), 2.46 - 2.43 (m, 1H), 2.03 - 1.90 (m, 2H), 1.55 - 1.49 (m, 1H) ppm; LCMS: 99%, [M+H]+= 332.27; HPLC: 98%.

[0782] 4-(4-(((31?,41?)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-isopropylpyridin- 2(lH)-one (Example 26-E1)

[0783]

[0784] The reaction was carried out according to general procedure A using 1-8 and l-isopropyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2(U7)-one. The crude product was purified by preparative HPLC (Column: X-Select C18 (250 x 30 mm); 5p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 23 mL; loading(mg / inj ection): 20; gradient (time / %B): 0 / 10,3 / 10,10 / 30,30 / 60,40 / 75,60 / 99) to afford 4-(4-(((37?,47?)-3,4-dihydroxycy cl opentyl)oxy)-3 -methoxyphenyl)- 1-isopropylpyridin-2(U7)-one (Example 26-E1, 13 mg, 17% yield) as an off-white solid.1H NMR (400 MHz, DMSO-d6) 6 = 7.74 (d, J= 7.3 Hz, 1H), 7.26 - 7.21 (m, 2H), 6.93 (d, J = 9.1 Hz, 1H), 6.64 (d, J= 2.0 Hz, 1H), 6.62 - 6.58 (m, 1H), 5.17 - 5.01 (m, 1H), 4.79 (t, J = 4.3 Hz, 3H), 3.92 - 3.89 (m, 1H), 3.83 (s, 3H), 3.81 - 3.76 (m, 1H), 2.47 - 2.44 (m, 1H), 1.99 - 1.94 (m, 2H), 1.56 - 1.50 (m, 1H), 1.31 (d, J = 6.9 Hz, 6H) ppm; LCMS: 98%, [M+H]+= 360.2; HPLC: 98%.

[0785] Attorney Docket# COGN-01-PCT

[0786] 4-(4-(((35',45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-isopropylpyridin- 2( l / / )-one (Example 26-E2)

[0787]

[0788] The reaction was carried out according to general procedure A using 1-8** and 1-isopropyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2(U7)-one by heating at 100 °C for 5 h. The crude product was purified by preparative HPLC (Column: X-Select Cl 8 (250 x 30 mm); 5p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 20 mL; loading(mg / inj ection): 80; gradient (time / %B): 0 / 10,3 / 10,10 / 25,30 / 50,31 / 99,35 / 99) to afford 4-(4-(((35,45)-3, 4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-isopropylpyridin-2(U7)-one (Example 26-E2, 15 mg, 42% yield) as pale yellow semi-solid.1H NMR (400 MHz, DMSO-de) 8 = 7.74 (d, J= 7.2 Hz, 1H), 7.27 - 7.20 (m, 2H), 6.93 (d, J= 9.0 Hz, 1H), 6.64 (d, J= 2.0 Hz, 1H), 6.63 - 6.59 (m, 1H), 5.09 - 5.02 (m, 1H), 4.84 - 4.76 (m, 3H), 3.94 - 3.88 (m, 1H), 3.83 (s, 3H), 3.80 - 3.75 (m, 1H), 2.48 - 2.46 (m, 1H), 1.99 - 1.95 (m, 2H), 1.56 - 1.48 (m, 1H), 1.30 (d, J= 6.8 Hz, 6H) ppm; LCMS: 99%, [M+H]+= 360.28; HPLC: 99%.

[0789] 4-(4-(((31?,41?)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-(2,2,2-trifluoroethyl) pyridin-2(TH)-one (Example 27-E1)

[0790] Attorney Docket# COGN-01-PCT

[0791]

[0792] The reaction was carried out according to procedure A using 1-8 and 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l-(2,2,2-trifluoroethyl)pyridin-2(U7)-one by heating at 100 °C for 5 h. The crude product was purified by preparative HPLC (Column: X-BRIDGE Cl 8 (250 x 30 mm );5p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 20 mL; loading(mg / inj ection): 40; gradient (time / %B): 0 / 10,3 / 10,10 / 15,30 / 50,31 / 98,35 / 98,36 / 10,40 / 10) to afford 4-(4-(((37?,47?)-3,4-dihydroxycy cl opentyl)oxy)-3 -methoxyphenyl)- 1 -(2, 2, 2-trifluoroethyl)pyridin-2(lJ7)-one (Example 27-E1, 24 mg, 62% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 7.71 (d, J= 7.3 Hz, 1H), 7.32 - 7.26 (m, 2H), 6.95 (d, J= 9.0 Hz, 1H), 6.78 (d, J = 1.9 Hz, 1H), 6.74 - 6.69 (m, 1H), 4.91 - 4.77 (m, 5H), 3.93 - 3.89 (m, 1H), 3.86 - 3.73 (m, 4H), 2.48 - 2.40 (m, 1H), 2.03 - 1.92 (m, 2H), 1.55 - 1.50 (m, 1H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -69.39 ppm; LCMS: 99.06 %, [M+H]+= 400.23; HPLC: 98%.

[0793] 4-(4-(((35',45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-(2,2,2-trifluoroethyl)pyridin-2(lH)-one (Example 27-E2)

[0794]

[0795] The reaction was carried out according to general procedure A using 1-8** and 4-(4,4,5,5-Attorney Docket# COGN-01-PCT

[0796] tetramethyl-l,3,2-dioxaborolan-2-yl)-l-(2,2,2-trifluoroethyl)pyridin-2(U7)-one by heating at 100 °C for 5 h. The crude product was purified by reverse phase chromatography (column: C-18 gold; Mobile phase A: 0.1% formic acid in water, Mobile Phase B: 40-50% acetonitrile) to 4-(4-(((3 S,4S)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-(2,2,2-trifluoroethyl)pyridin-2(lH)-one (Example 27-E2, 19 mg, 21% yield) as an off-white solid.

[0797] 'H NMR (400 MHz, DMSO-d6) 6 = 7.71 (d, J= 7.3 Hz, 1H), 7.28 (s, 2H), 6.95 (d, J= 9.0 Hz, 1H), 6.78 (d, J= 1.9 Hz, 1H), 6.74 - 6.70 (m, J= 2.1, 7.3 Hz, 1H), 4.79 (br t, J= 4.1 Hz, 5H), 3.94 - 3.88 (m, 1H), 3.84 (s, 3H), 3.81 - 3.76 (m, 1H), 2.00 - 1.94 (m, 2H), 1.57 -1.49 (m, 1H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -69.39 ppm; LCMS: 96%, [M+H]+= 400.19; HPLC: 95%.

[0798] 4-(4-(((31?,41?)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l,3-dimethylpyridin-2(lH)-one (Example 28-E1)

[0799]

[0800] The reaction was carried out according to general procedure A using 1-9 and 4-bromo-l,3-dimethylpyridin-2(U7)-one. The crude product was purified by preparative HPLC (Column: X-select C18 (250 x 30mm), 5p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 22 mL; loading(mg / inj ection): 50; gradient (time / %B): 0 / 5,4 / 5,10 / 20,25 / 40,35 / 55,60 / 99) to afford 4-(4-(((37?,47?)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l,3-dimethylpyridin-2(U7)-one (Example 28-E1, 18 mg, 69% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 7.56 (d, J= 7.0 Hz, 1H), 6.94 - 6.87 (m, 2H), 6.87 - 6.82 (m, 1H), 6.14 (d, J= 6.9 Hz, 1H), 4.81 - 4.75 (m, 3H), 3.94 - 3.89 (m, 1H), 3.81 - 3.75 (m, 4H), 3.46 (s, 3H), 2.47-2.44 (m, 1H), 2.04 - 1.92 (m, 5H), 1.57- 1.51 (m, lH)ppm; LCMS: 98%, [M+H]+= 346.31; HPLC: 99%.

[0801] 4-(4-(((3N,4N)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l,3-dimethylpyridin-

[0802] Attorney Docket# COGN-01-PCT

[0803] 2(lH)-one (Example 28-E2)

[0804]

[0805] The reaction was carried out according to general procedure A using 1-9** and 4-bromo-l,3-dimethylpyridin-2(U7)-one. The crude product was purified by preparative HPLC [Column: X-select C18 (250 x 30 mm), 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 22 mL; loading(mg / inj ection): 90; gradient (time / %B): 0 / 5,3 / 5,10 / 10,35 / 30,36 / 99,40 / 99 to afford 4-(4-(((35,45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l,3-dimethylpyridin-2(U7)-one (Example 28-E2, 10 mg, 20% yield) as an off-white gummy solid.1H NMR (400 MHz, DMSO-de) 8 = 7.57 (d, J= 7.2 Hz,lH), 6.92 - 6.87 (m, 2H), 6.85 - 6.82 (m, 1H), 6.14 (d, J= 7.0 Hz, 1H),

[0806] 4.78 (t, J= 3.9 Hz, 3H), 3.95 - 3.89 (m, 1H), 3.80 - 3.73 (m, 4H), 3.46 (s, 3H), 2.47 - 2.44 (m, 1H), 1.99 - 1.94 (m, 5H), 1.58 - 1.50 (m, 1H) ppm; LCMS: 99%, [M+H]+= 346.27; HPLC: 98%.

[0807] 5-(4-(((31?,41?)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-methylpyridin- 2(lH)-one (Example 29-E1)

[0808]

[0809] The reaction was carried out according to general procedure A using 1-8 and l-methyl-5-Attorney Docket# COGN-01-PCT

[0810] (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2(U7)-one. The crude product was purified by reverse phase chromatography (column: C-18 gold; Mobile phase A: 0.1% formic acid in water, Mobile Phase B: 40-50% acetonitrile) to afford Example 29-E1 (12 mg, 36% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.05 (d, J= 2.6 Hz, 1H), 7.80 (dd, J= 2.8, 9.6 Hz, 1H), 7.11 (d, J= 2.4 Hz, 1H), 7.05 - 7.01 (m, 1H), 6.89 (d, J= 8.4 Hz, 1H), 6.45 (d, J= 9.2 Hz, 1H), 4.79 - 4.75 (m, 3H), 3.94 - 3.88 (m, 1H), 3.81 (s, 3H), 3.79 - 3.73 (m, 1H), 3.50 (s, 3H), 2.46 - 2.44 (m, 1H), 2.00 - 1.88 (m, 2H), 1.57 -1.48 (m, lH)ppm; LCMS: 99%, [M+H]+= 332.1; HPLC: 99%.

[0811] 5-(4-(((35',45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-methylpyridin- 2(lH)-one (Example 29-E2)

[0812]

[0813] The reaction was carried out according to general procedure A using 1-8** and l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2(U7)-one. The crude product was purified by preparative HPLC [column: X-Select C18 (250 x 30 mm), 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 23; loading (mg / inj ection): 70; gradient (time / %B): 0 / 5,3 / 5,10 / 10,40 / 40,60 / 98] to afford Example 29-E2 (29 mg, 67% yield) as pale yellow gummy solid.1H NMR (400 MHz, DMSO-d6) 6 = 8.05 (d, J= 2.6 Hz, 1H), 7.82 - 7.77 (m, 1H), 7.11 (d, J = 2.1 Hz, 1H), 7.06

[0814] - 7.01 (m, 1H), 6.89 (d, J= 8.5 Hz, 1H), 6.45 (d, J= 9.4 Hz, 1H), 4.80 - 4.74 (m, 3H), 3.92

[0815] - 3.89 (m, 1H), 3.82 (s, 4H), 3.50 (s, 3H), 2.48 - 2.40 (m, 1H), 2.01 - 1.88 (m, 2H), 1.55 -1.49 (m, 1H) ppm; LCMS: 99.05 %, [M+H]+= 332.22; HPLC: 99%.

[0816] 5-(4-(((31?,41?)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-isopropylpyridin- 2(lH)-one (Example 30-E1)

[0817] Attorney Docket# COGN-01-PCT

[0818]

[0819] The reaction was carried out according to general procedure A using 1-8 and l-isopropyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2(177)-one. The crude product was purified by reverse phase chromatography (column: C-18 gold; Mobile phase A: 0.1% formic acid in water, Mobile Phase B: 40-50% acetonitrile) to afford Example 30-E1 (22 mg, 65.32 % yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 7.86 (d, J =

[0820] 2.5 Hz, 1H), 7.75 - 7.72 (m, 1H), 7.10 (d, J= 2.1 Hz, 1H), 7.07 - 7.02 (m, 1H), 6.89 (d, J=

[0821] 8.5 Hz, 1H), 6.45 (d, J= 9.6 Hz, 1H), 5.14 - 5.05 (m, 1H), 4.77 (t, J= 3.9 Hz, 3H), 3.94 -3.89 (m, 1H), 3.80 (m, 3H), 3.79 - 3.73 (m, 1H), 2.46 -2.40 (m, 1H), 2.02 - 1.87 (m, 2H), 1.55 - 1.49 (m, 1H), 1.37- 1.34 (m, 6H) ppm; LCMS: 99%, [M+H]+= 360.0; HPLC: 96%.

[0822] 5-(4-(((35,45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-isopropylpyridin- 2(lH)-one (Example 30-E2)

[0823]

[0824] The reaction was carried out according to general procedure A using 1-8** and 1-isopropyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2(U7)-one. The crude product was purified by reverse phase chromatography (Column: C-18 gold; Mobile phase A: 0.1% formic acid in water, Mobile Phase B: 40-50% acetonitrile) to afford Example 30-E2 (8 mg, 23% yield) as an off-white gummy solid.1H NMR (400 MHz, DMSO-de) 8 = 7.86 (d,Attorney Docket# COGN-01-PCT

[0825] J= 2.5 Hz, 1H), 7.77 - 7.70 (m, 1H), 7.13 - 7.09 (m, 1H), 7.08 - 7.03 (m, 1H), 6.89 (d, J = 8.4 Hz, 1H), 6.45 (d, J = 9.4 Hz, 1H), 5.10 - 5.05 (m, 1H), 4.81 - 4.74 (m, 3H), 3.93 - 3.89 (m, 1H), 3.82 (s, 3H), 3.80 - 3.76 (m, 1H), 2.47 - 2.42 (m, 1H), 2.02 - 1.90 (m, 2H), 1.57 - 1.49 (m, 1H), 1.38 - 1.34 (m, 6H) ppm; LCMS: 99.38 %, [M+H]+= 360.0; HPLC:

[0826] 95%.

[0827] 5-(4-(((31?,41?)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-(2,2,2-trifluoroethyl)pyridin-2(lH)-one (Example 31-E1)

[0828]

[0829] The reaction was carried out according to general procedure A using 1-9 and 5-bromo-l-(2,2,2-trifluoroethyl)pyridin-2(U7)-one. The crude product was purified by preparative HPLC [column: X-Select C18 (250 x 30 mm), 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 40; gradient (time / %B): 0 / 10,3 / 10,10 / 25,30 / 50,31 / 99,35 / 99] to afford Example 31-E1 (15 mg, 32.40 % yield) as an off-white solid.1H NMR (400 MHz, DMSO-d6) 6 = 8.02 (s, 1H), 7.90 (br d, J= 9.5 Hz, 1H), 7.09 (d, J= 2.0 Hz, 1H), 7.03 - 7.00 (m, 1H), 6.92 (d, J= 8.5 Hz, 1H), 6.57 (d, J= 9.5 Hz, 1H), 4.92 - 4.88 (m, 2H), 4.78 - 4.73 (m, 3H), 3.91 - 3.89 (m, 1H), 3.81 (s, 3H), 3.80 - 3.74 (m, 1H), 2.46 - 2.40 (m, 1H), 2.00 - 1.91 (m, 2H), 1.56 - 1.50 (m, 1H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -69.24 ppm;

[0830] LCMS: 96%, [M+H]+= 400.0; HPLC: 99%.

[0831] 5-(4-(((35',45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-(2,2,2-trifluoroethyl)pyridin-2(lH)-one (Example 31-E2)

[0832] Attorney Docket# COGN-01-PCT

[0833]

[0834] The reaction was carried out according to general procedure A using 1-9** and 5-bromo-l-(2,2,2-trifluoroethyl)pyridin-2(U7)-one. The crude product was purified by preparative HPLC [column: X-Select C18 (250 x 30 mm), 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 40; gradient (time / %B): 0 / 10,3 / 10,10 / 25,30 / 50,31 / 99,35 / 99] to afford Example 31-E2 (12 mg, 26% yield) as an off-white gummy solid^H NMR (400 MHz, DMSO-d6) 6 = 8.04 - 8.01 (m, 1H), 7.91 - 7.88 (m, 1H), 7.09 (d, J= 2.1 Hz, 1H), 7.04 -7.01 (m, 1H), 6.92 (d, J= 8.4 Hz, 1H), 6.57 (d, J= 9.6 Hz, 1H), 4.92 - 4.84 (m, 2H), 4.79 - 4.73 (m, 3H), 3.92 - 3.90 (m, 1H), 3.81 (s, 3H), 3.80 - 3.83 (m, 1H), 2.46 -2.40 (m, 1H), 2.01 - 1.89 (m, 2H), 1.56 - 1.48 (m, 1H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -69.24 ppm; LCMS: 98.25 %, [M+H]+= 400.1; HPLC: 96%.

[0835] 5-(4-(((31?,41?)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l,3-dimethylpyridin-2(lH)-one (Example 32-E1)

[0836]

[0837] The reaction was carried out according to general procedure A using 1-8 and 1,3-dimethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2(U7)-one. The crude product was purified by preparative HPLC [column: X-Select C18 (250 x 30 mm), 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow:

[0838] Attorney Docket# COGN-01-PCT

[0839] 22; loading (mg / inj ection): 35; gradient (time / %B): 0 / 2,3 / 2,25 / 50,30 / 99] to afford Example 32-E1 (23 mg, 68% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 7.90 (s, 1H), 7.72 - 7.69 (m, 1H), 7.10 (d, J= 2.1 Hz, 1H), 7.05 - 7.02 (m, 1H), 6.88 (d, J= 8.5 Hz, 1H), 4.77 (t, J= 3.8 Hz, 3H), 3.93 - 3.89 (m, 1H), 3.82 (s, 3H), 3.79 - 3.74 (m, 1H), 3.51 (s, 3H), 2.46 (d, J= 7.3 Hz, 1H), 2.07 (s, 3H), 2.01 - 1.88 (m, 2H), 1.57 - 1.48 (m, 1H) ppm;

[0840] LCMS: 99%, [M+H]+ =346.10; HPLC: 99%.

[0841] 5-(4-(((35',45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l,3-dimethylpyridin- 2(lH)-one (Example 32-E2)

[0842]

[0843] The reaction was carried out according to general procedure A using 1-8** and 1,3-dimethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2(U7)-one. The crude product was purified by preparative HPLC [column: X-Select C18 (250 x 30 mm), 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 30; gradient (time / %B): 0 / 2,3 / 2,25 / 50,30 / 99] to afford 5-(4-(((3£,45')-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l,3-dimethylpyridin-2(U7)-one (Example 32-E2, 18 mg, 53% yield) as an off-white gummy solid. 'H NMR (400 MHz, DMSO-d6) 6 = 7.90 (d, J= 2.4 Hz, 1H), 7.71 (br d, J= 1.3 Hz, 1H), 7.10 (d, J= 2.0 Hz, 1H), 7.05 - 7.02 (m, 1H), 6.88 (d, J= 8.4 Hz, 1H), 4.77 (br s, 3H), 3.93 - 3.89 (m, 1H), 3.81 (s, 3H), 3.79 - 3.76 (m, 1H), 3.50 (s, 3H), 2.45 -2.40 (m, 1H), 2.07 (s, 3H), 2.00 -1.97 (m, 2H), 1.56 - 1.49 (m, lH).ppm; LCMS: 99.16 %, [M+H]+= 346.1;

[0844] HPLC: 99%

[0845] 4-(4-(((ls,37?,4 )-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-methylpyridin- 2(lH)-one (Example 33-D1)

[0846] Attorney Docket# COGN-01-PCT

[0847]

[0848] The reaction was carried out according to general procedure A using 1-2 (111 mg, 0.32 mmol), 4-bromo-l-methylpyridin-2(lH)-one (50 mg, 0.26 mmol), potassium phosphate tribasic (140 mg, 0.64 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (21 mg, 0.03 mmol) in DMF (2 mL) at 100 °C for 5 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (50 mm x 3.0 mm) 2.5p, particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 22 mL; loading(mg / inj ection): 65; gradient (time / %B): 0 / 10,3 / 10,10 / 15,35 / 45,60 / 98) to afford 4-(4-(((ls,3 / ?,45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-methylpyridin-2(lH)-one (Example 33-D1, 21 mg, 24% yield) as an off-white solid.1H NMR (400 MHz, DMSO-d6) 6 = 7.71 (d, J =7.2 Hz, 1 H), 7.24 (s, 2 H), 6.95 - 6.90 (m, 1 H), 6.67 (d, = 2.0 Hz, 1 H), 6.61 - 6.55 (m, 1 H), 4.89 - 4.84 (m, 1 H), 4.51 (d, J= 4.4 Hz, 2 H), 4.06 - 3.98 (m, 2 H), 3.82 (s, 3 H), 3.43 (s, 3 H), 2.11 - 2.04 (m, 2 H) 1.86 - 1.80 (m, 2 H) ppm;

[0849] LCMS: 99%, [M+H]+= 332.1; HPLC: 99%.

[0850] 4-(4-(((lr,37?,45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-methylpyridin-

[0851]

[0852] Attorney Docket# COGN-01-PCT

[0853] The reaction was carried out according to general procedure A using 1-2** (109 mg, 0.32 mmol), 4-bromo-l-methylpyridin-2(lH)-one (50 mg, 0.26 mmol), potassium phosphate tribasic (140 mg, 0.64 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (21 mg, 0.03 mmol) in DMF (2 mL) at 100 °C for 5 h. The crude product was purified by preparative HPLC (column: YMC; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 15 mL; loading(mg / inj ection): 70; gradient (time / %B): 0 / 10,3 / 10,10 / 20,35 / 35,45 / 45,60 / 99) to afford 4-(4-(((lr,37?,4S)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-methylpyridin-2(lH)-one (Example 33-D2, 8 mg, 9% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 8 = 7.71 (d, J = 7.2 Hz, 1H), 7.28 - 7.20 (m, 2H), 6.92 (d, J= 8.8 Hz, 1H), 6.67 (d, J= 2.0 Hz, 1H), 6.58 (dd, J= 2.0, 7.2 Hz, 1H), 4.71 - 4.61 (m, 1H), 4.49 (d, J= 4.6 Hz, 2H), 3.87 - 3.75 (m, 5H), 3.43 (s, 3H), 2.34 - 2.24 (m, 2H), 1.81 - 1.67 (m, 2H) ppm; LCMS: 99%, [M+H]+= 332.0;

[0854] HPLC: 99%

[0855] 4-(4-(((ls,37?,45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-isopropylpyridin-2(lH)-one (Example 34-D1)

[0856]

[0857] The reaction was carried out according to general procedure A using 1-1 (60 mg, 0.20 mmol), l-isopropyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2(U7)-one (70 mg, 0.26 mmol), potassium phosphate tribasic (110 mg, 0.50 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (25 mg, 0.03 mmol) in DMF (5 mL) at 100 °C for 5 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm *30 mm) 5p, particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 20 mL;

[0858] Attorney Docket# COGN-01-PCT

[0859] loading(mg / inj ection): 95; gradient (time / %B): 0 / 15,3 / 15,10 / 30,35 / 55) to afford 4-(4-(((15,37?,45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-isopropylpyridin-2(U7)-one (Example 34-D1, 27 mg, 38% yield) as an off-white solid.1H NMR (400 MHz, DMSO-d6) 6 = 7.74 (d, J= 7.2 Hz, 1H), 7.26 - 7.21 (m, 2H), 6.93 (d, J= 8.8 Hz, 1H), 6.64 (d, = 2.0 Hz, 1H), 6.60 (dd, J = 2.0, 7.2 Hz, 1H), 5.06 (s, 1H), 4.87 (br s, 1H), 4.51 (d, J = 4.0 Hz, 2H), 4.06 - 3.98 (m, 2H), 3.83 (s, 3H), 2.11 - 2.03 (m, 2H), 1.90 - 1.78 (m, 2H), 1.30 (d, J = 6.8 Hz, 6H) ppm; LCMS: 98%, [M+H]+= 360.24; HPLC: 96%.

[0860] 4-(4-(((lr,37?,4 )-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-isopropylpyridin-2(LH)-one (Example 34-D2)

[0861]

[0862] The reaction was carried out according to general procedure A using 1-1** (50 mg, 0.16 mmol), l-isopropyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2(U7)-one (52 mg, 0.20 mmol), potassium phosphate tribasic (87 mg, 0.40 mmol) and [1,1 -bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (13 mg, 0.01 mmol) in DMF (2 mL) at 100 °C for 5 h. The crude product was purified by preparative HPLC (column: X-Select C18 (250 mm x 30 mm) 5p, particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 20 mL; loading(mg / inj ection): 150; gradient (time / %B): 0 / 10,3 / 10,10 / 25,35 / 75,45 / 99) to afford 4-(4-(((lr,37?,45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-isopropylpyridin-2(U7)-one (Example 34-D2, 28 mg, 47% yield) as an off-white solid.1H NMR (400 MHz, DMSO-d6) 6 = 7.73 (d, J = 7.2 Hz, 1H), 7.26 - 7.20 (m, 2H), 6.93 (d, J = 8.8 Hz, 1H), 6.66 - 6.58 (m, 2H), 5.06 (s, 1H), 4.71 - 4.61 (m, 1H), 4.49 (d, J = 4.6 Hz, 2H), 3.86 - 3.77 (m, 5H), 2.33 - 2.25 (m, 2H), 1.78-1.72 (m, 2H), 1.30 (d, J = 6.8 Hz, 6H) ppm;

[0863] LCMS: 98%, [M+H]+= 360.0; HPLC: 99%.

[0864] Attorney Docket# COGN-01-PCT

[0865] 4-(4-(((ls,37?,45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-(2,2,2-trifluoroethyl)-pyridin-2( l / / )-one (Example 35-D1)

[0866]

[0867] The reaction was carried out according to general procedure A using 1-1 (60 mg, 0.20 mmol), 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l-(2,2,2-trifluoroethyl)pyridin-2(U7)-one (75 mg, 0.24 mmol), potassium phosphate tribasic (110 mg, 0.50 mmol) and [1,1 '-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with di chloromethane (25 mg, 0.03 mmol) in DMF (5 mL) at 100 °C for 5 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm x 30 mm) 5p, particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 22 mL; loading(mg / inj ection): 60; gradient (time / %B): 0 / 10,3 / 10,10 / 30,35 / 50) to afford 4-(4-(((15,3 / ?,45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-(2,2,2-trifluoroethyl)pyridin-2(U7)-one (Example 35-D1, 25 mg, 32% yield) as an off-white solid.

[0868] 'H NMR (400 MHz, DMSO-d6) 6 = 7.74 - 7.68 (m, 1H), 7.29 - 7.29 (m, 1H), 7.32 - 7.26 (m, 1H), 6.99 - 6.90 (m, 1H), 6.81 - 6.76 (m, 1H), 6.71 (dd, J= 2.0, 7.2 Hz, 1H), 4.87 (m, 3H), 4.51 (d, J= 4.0 Hz, 2H), 4.02 (br s, 2H), 3.83 (s, 3H), 2.15 - 2.02 (m, 2H), 1.88 - 1.79 (m, 2H) ppm;19F NMR (377 MHz, DMSO-d6) 8 = -69.39 ppm; LCMS: 99%, [M+H]+= 400.15; HPLC: 98%.

[0869] 4-(4-(((lr,37?,45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-(2,2,2-trifluoroethyl)-pyridin-2(lH)-one (Example 35-D2)

[0870] Attorney Docket# COGN-01-PCT

[0871]

[0872] The reaction was carried out according to general procedure A using 1-1** (50 mg, 0.16 mmol), 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l-(2,2,2-trifluoroethyl)pyridin-2(U7)-one (60 mg, 0.20 mmol), potassium phosphate tribasic (87 mg, 0.40 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (13 mg, 0.02 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select C18 (250 mm x 30 mm) 5p, particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 20 mL; loading(mg / inj ection): 100; gradient (time / %B): 0 / 10,3 / 10,10 / 25,35 / 75,45 / 99) to afford 4-(4-(((lr,37?,45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-(2,2,2-trifluoroethyl)pyridin-2(U7)-one (Example 35-D2, 13 mg, 20% yield) as an off-white solid.

[0873] 'H NMR (400 MHz, DMSO-d6) 6 = 7.71 (d, J= 7.2 Hz, 1H), 7.31 - 7.26 (m, 2H), 6.94 (d, J= 8.8 Hz, 1H), 6.78 (d, J= 2.0 Hz, 1H), 6.72 (br d, J= 7.2 Hz, 1H), 4.87 (q, J= 9.2 Hz, 2H), 4.73 - 4.63 (m, 1H), 4.50 (d, J= 4.6 Hz, 2H), 3.86 - 3.78 (m, 5H), 2.35 - 2.24 (m, 2H), 1.78-1.72 (m, 2H) ppm;19F NMR (377 MHz, DMSO-d6) 8 = -70.55 ppm; LCMS: 98%, [M+H]+= 400.0; HPLC: 99%.

[0874] 4-(4-(((ls,37?,45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l,3-dimethylpyridin-2(LH)-one (Example 36-D1)

[0875]

[0876] The reaction was carried out according to general procedure A using 1-2 (60 mg, 0.20Attorney Docket# COGN-01-PCT

[0877] mmol), 4-bromo-l,3-dimethylpyridin-2(U7)-one (60 mg, 0.30 mmol), potassium phosphate tribasic (125 mg, 0.58 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (16 mg, 0.02 mmol) in DMF (1 mL) at 100 °C for 16 h. The crude product was purified by reverse phase chromatography (using a Cl 8 gold column) and product fractions were eluted with 0.1% formic acid in water in 40-50% acetonitrile to afford 4-(4-(((ls,3R,4S)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l,3-dimethylpyridin-2(lH)-one (Example 36-D1, 10 mg, 16.9% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d66 = 7.57 (d, J= 7.2 Hz, 1H), 6.96 - 6.81 (m, 3H), 6.15 (d, J= 7.2 Hz, 1H), 4.88 - 4.81 (m, 1H), 4.53 (d, J= 4.4 Hz, 2H), 4.02 (m, 2H), 3.76 (s, 3H), 3.46 (s, 3H), 2.13 - 2.01 (m, 2H), 1.98 (s, 3H), 1.93 - 1.77 (m, 2H) ppm; LCMS: 97%, [M+H]+= 346.31; HPLC: 95%.

[0878] 4-(4-(((lr,37?,4 )-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l,3-dimethylpyridin-2(LH)-one (Example 36-D2)

[0879]

[0880] The reaction was carried out according to general procedure A using 1-2** (103 mg, 0.29 mmol), 4-bromo-l,3-dimethylpyridin-2(U7)-one (50 mg, 0.25 mmol), potassium phosphate tribasic (131 mg, 0.60 mmol) and [l,l'-bis(diphenylphosphino)ferrocene] dichloropalladium(II), complex with dichloromethane (20 mg, 0.02 mmol) in DMF (2 mL) at 100 °C for 5 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm x 30 mm) 5p, particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 22 mL; loading(mg / inj ection): 70; gradient (time / %B): 0 / 10,3 / 10,15 / 50,27 / 60,35 / 99) to afford 4-(4-(((lr,37?,4S)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l,3-dimethylpyridin-2(U7)-one (Example 36-D2, 23 mg, 26% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 8 = 7.56 (d, = 7.2 Hz, 1H), 6.93 - 6.87 (m, 2H), 6.86 - 6.81 (m, 1H), 6.14 (d, J= 7.2 Hz, 1H), 4.65-4.62 (m, 1H), 4.49 (d, J = 4.4 Hz, 2H), 3.84 - 3.74 (m, 5H), 3.46 (s, 3H), 2.32 - 2.23 (m,

[0881] Attorney Docket# COGN-01-PCT

[0882] 2H), 1.98 (s, 3H), 1.81 - 1.73 (m, 2H) ppm; LCMS: 99%, [M+H]+= 346.31; HPLC: 97%.

[0883] 5-(4-(((ls,3^45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-methylpyridin-

[0884]

[0885] The reaction was carried out according to general procedure A using 1-1 (50 mg, 0.16 mmol), l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2(U7)-one (58 mg, 0.25 mmol), potassium phosphate tribasic (104 mg, 0.48 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (13 mg, 0.02 mmol) in DMF (1 mL) at 100 °C for 16 h. The crude product was purified by reverse phase chromatography (using a Cl 8 gold column) and product fractions were eluted with 0.1% formic acid in water in 40-50% acetonitrile to afford 5-(4-(((l,37?,45)-3,4-dihydroxycy cl opentyl)oxy)-3 -methoxyphenyl)- l-methylpyridin-2(l / 7)-one (Example 37-Dl, 18 mg, 32.9% yield) as an off-white solid.[HNMR (400 MHz, DMSO-d6) 8 = 8.06 (d, J= 2.4 Hz, 1H), 7.80 (dd, J= 2.8, 9.6 Hz, 1H), 7.11 (d, J= 2.0 Hz, 1H), 7.04 (dd, J = 2.0, 8.4 Hz, 1H), 6.88 (d, J= 8.4 Hz, 1H), 6.45 (d, J = 9.2 Hz, 1H), 4.85 - 4.78 (m, 1H), 4.51 (d, J= 4.4 Hz, 2H), 4.06 - 3.97 (m, 2H), 3.81 (s, 3H), 3.50 (s, 3H), 2.11 - 2.00 (m, 2H), 1.88 - 1.78 (m, 2H) ppm; LCMS: 99%, [M+H]+= 332.29; HPLC: 99%.

[0886] 5-(4-(((lr,3^45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-methylpyridin-

[0887]

[0888] Attorney Docket# COGN-01-PCT

[0889] The reaction was carried out according to general procedure A using 1-1** (50 mg, 0.16 mmol), l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2(U7)-one (58 mg, 0.25 mmol), potassium phosphate tribasic (87 mg, 0.40 mmol) and [1,1 -bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (13 mg, 0.02 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select C18 (250 mm x 30 mm) 5p, particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 22 mL; loading(mg / inj ection): 114; gradient (time / %B):

[0890] 0 / 10,3 / 10,10 / 35,20 / 55,30 / 65,40 / 75,50 / 99) to afford 5-(4-(((lr,37?,45)-3,4-dihydroxycy cl opentyl)oxy)-3 -methoxyphenyl)- l-methylpyridin-2( IT / )-one (Example 37-D2, 28 mg, 50% yield) as green solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.04 (d, J= 2.8 Hz, 1H), 7.79 (dd, J= 2.8, 9.6 Hz, 1H), 7.11 (d, J= 2.0 Hz, 1H), 7.03 (dd, J= 2.0, 8.4 Hz, 1H), 6.88 (d, J= 8.4 Hz, 1H), 6.45 (d, J= 9.6 Hz, 1H), 4.66 - 4.57 (m, 1H), 4.48 (d, J= 4.0 Hz, 2H), 3.86 - 3.74 (m, 5H), 3.50 (s, 3H), 2.29 - 2.22 (m, 2H), 1.79 - 1.71 (m, 2H) ppm;

[0891] LCMS: 98%, [M+H]+= 332.1; HPLC: 95%.

[0892] 5-(4-(((ls,37?,4 )-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-isopropylpyridin-2(lH)-one (Example 38-D1)

[0893]

[0894] The reaction was carried out according to general procedure A using 1-1 (50 mg, 0.16 mmol), l-isopropyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2(U7)-one (52 mg, 0.19 mmol), potassium phosphate tribasic (87 mg, 0.40 mmol) and [1,1 -bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (13 mg, 0.02 mmol) in DMF (2 mL) at 100 °C for 5 h. The crude product was purified by preparative HPLC (column: X-Bridge C18 (250 mm x 30 mm) 5p, particle size; mobile phase A: l0 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 20 mL; loading(mg / inj ection): 72; gradient (time / %B): 0 / 10,3 / 10,10 / 25,35 / 55,45 / 65,60 / 99) to afford 5-(4-(((ls,3R,4S)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-Attorney Docket# COGN-01-PCT

[0895] isopropylpyridin-2(l / / )-one (Example 38-D1, 22 mg, 36% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) 6 = 7.88 - 7.85 (m, 1H), 7.77 - 7.71 (m, 1H), 7.13 - 7.04 (m, 2H), 6.89 (d, J= 8.4 Hz, 1H), 6.45 (d, J= 9.6 Hz, 1H), 5.15 - 5.05 (m, 1H), 4.86 - 4.79 (m, 1H), 4.49 (d, J= 4.0 Hz, 2H), 4.02 (br d, J= 2.8 Hz, 2H), 3.82 (s, 3H), 2.10 - 1.99 (m, 2H), 1.88 - 1.79 (m, 2H), 1.36 (d, J= 6.8 Hz, 6H) ppm; LCMS: 99%, [M+H]+= 360.0; HPLC: 98%.

[0896] 5-(4-(((lr,37?,4 )-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-isopropylpyridin-2(LH)-one (Example 38-D2)

[0897]

[0898] The reaction was carried out according to general procedure A using 1-1** (50 mg, 0.16 mmol), l-isopropyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2(U7)-one (52 mg, 0.19 mmol), potassium phosphate tribasic (87 mg, 0.40 mmol) and [1,1 -bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (13 mg, 0.02 mmol) in DMF (2 mL) at 100 °C for 16 h. The crude product was purified by preparative HPLC (column: X-Select C18 (250 mm x 30 mm) 10g, particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 22 mL; loading(mg / inj ection): 180; gradient (time / %B): 0 / 10,3 / 10,10 / 20,35 / 45,60 / 98) to afford 5-(4-(((lr,37?,45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-isopropylpyridin-2(U7)-one (Example 38-D2, 25 mg, 42% yield) as an off-white solid.1H NMR (400 MHz, DMSO-d6) 6 = 7.86 (d, J= 2.4 Hz, 1H), 7.74 (dd, J= 2.8, 9.6 Hz, 1H), 7.09 (d, J= 2.0 Hz, 1H), 7.05 (dd, J= 2.0, 8.4 Hz, 1H), 6.88 (d, J= 8.4 Hz, 1H), 6.45 (d, J = 9.6 Hz, 1H), 5.09 (m, 1H), 4.66 - 4.57 (m, 1H), 4.49 (d, J= 4.0 Hz, 2H), 3.85 - 3.76 (m, 5H), 2.30 - 2.21 (m, 2H), 1.75 (m, 2H), 1.36 (d, J= 6.8 Hz, 6H) ppm; LCMS: 98%, [M+H]+= 360.0; HPLC: 99%.

[0899] 5-(4-(((ls,31?,45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-(2,2,2-

[0900] Attorney Docket# COGN-01-PCT

[0901] trifluoroethyl)pyridin-2(lH)-one (Example 39-D1)

[0902]

[0903] The reaction was carried out according to general procedure A using 1-2 (60 mg, 0.17 mmol), 5-bromo-l-(2,2,2-trifluoroethyl)pyridin-2(177)-one (60 mg, 0.23 mmol), potassium phosphate tribasic (125 mg, 0.58 mmol) and [l,l'-bis(diphenylphosphino)ferrocene] dichloropalladium(II), complex with dichloromethane (16 mg, 0.02 mmol) in DMF (1 mL) at 100 °C for 16 h. The crude product was purified by reverse phase chromatography (using a C18 gold column) and product fractions were eluted with 0.1% formic acid in water in 40-50% acetonitrile to afford 5-(4-(((ls,37?,45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l-(2,2,2-trifluoroethyl)pyridin-2(U7)-one (Example 39-D1, 10 mg, 14.6% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 8 = 8.03 (s, 1H), 7.90 (dd, J = 2.8, 9.6 Hz, 1H), 7.09 (d, J= 2.0 Hz, 1H), 7.03 (dd, J= 2.0, 8.4 Hz, 1H), 6.92 (d, J = 8.4 Hz, 1H), 6.57 (d, J= 9.6 Hz, 1H), 4.95 - 4.80 (m, 3H), 4.52 (d, J= 4.4 Hz, 2H), 4.06 - 3.98 (m, 2H), 3.81 (s, 3H), 2.11 - 2.01 (m, 2H), 1.87 - 1.79 (m, 2H) ppm;19F NMR (377 MHz, DMSO-de) 6 = -69.24 ppm; LCMS: 97%, [M+H]+= 400.28; HPLC: 97%.

[0904] 5-(4-((( lr / ?.4. S)-3.4-diliydroxycyclopeiityl)oxy)-3-inethoxyphenyl)-l-(2.2.2-trifluoroethyl)-pyridin-2(lH)-one (Example 39-D2)

[0905]

[0906] The reaction was carried out according to general procedure A using 1-2** (82 mg, 0.23 mmol), 5-bromo-l-(2,2,2-trifluoroethyl)pyridin-2(U7)-one (50 mg, 0.19 mmol), potassiumAttorney Docket# COGN-01-PCT

[0907] phosphate tribasic (103 mg, 0.48 mmol) and [l,l'-bis(diphenylphosphino)ferrocene] dichloropalladium(II), complex with di chloromethane (16 mg, 0.02 mmol) in DMF (2 mL) at 100 °C for 5 h. The crude product was purified by preparative HPLC (column: X-Select C18 (250 mm x 30 mm) 5 p, particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 22 mL; loading(mg / inj ection): 45; gradient (time / %B): 0 / 5,3 / 5,10 / 20,39 / 99) to afford 5-(4-(((lr,3A,4S)-3,4-dihydroxycy cl opentyl)oxy)-3 -methoxyphenyl)- 1 -(2, 2, 2-trifluoroethyl)pyridin-2(U7)-one (Example 39-D2, 20 mg, 25% yield) as an off-white solid.XH NMR (400 MHz, DMSO-de) 8 = 8.05 - 8.02 (m, 1H), 7.90 (dd, J= 2.8, 9.6 Hz, 1H), 7.09 (d, J= 2.0 Hz, 1H), 7.05 - 7.00 (m, 1H), 6.94 - 6.88 (m, 1H), 6.57 (d, J= 9.6 Hz, 1H), 4.94 - 4.85 (m, 2H), 4.67 - 4.59 (m, 1H), 4.51 (d, J= 4.4 Hz, 2H), 3.84 - 3.76 (m, 5H), 2.31 - 2.22 (m, 2H), 1.79 - 1.70 (m, 2H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -69.24 ppm; LCMS: 99%, [M+H]+= 400.1;

[0908] HPLC: 98%

[0909] 5-(4-(((ls,37?,4 )-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l,3-dimethylpyridin-2( 1 / / )-one (Example 40-D1)

[0910]

[0911] The reaction was carried out according to general procedure A using 1-1 (50 mg, 0.16 mmol), l,3-dimethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2(U7)-one (49 mg, 0.19 mmol), potassium phosphate tribasic (87 mg, 0.40 mmol) and [1,1 -bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (13 mg, 0.02 mmol) in DMF (2 mL) at 100 °C for 5 h. The crude product was purified by preparative HPLC [(column: X-Select (250 mm x 30 mm), 5p particle size; mobile phase A: l0 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 22 mL; loading(mg / inj ection): 150; gradient (time / %B): 0 / 5,3 / 5,10 / 15,35 / 40,60 / 98 to afford 5-(4-(((l,3A,45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l,3-dimethylpyridin-2(U7)-one (Example 40-D1, 50 mg, 88% yield) as a white solid. 'H NMR (400 MHz,

[0912] Attorney Docket# COGN-01-PCT

[0913] DMSO-d6) 6 = 7.90 (d, J= 2.4 Hz, 1H), 7.73 - 7.68 (m, 1H), 7.10 (d, J= 2.0 Hz, 1H), 7.03 (dd, J= 2.0, 8.4 Hz, 1H), 6.88 (d, J= 8.4 Hz, 1H), 4.85 - 4.78 (m, 1H), 4.49 (d, J= 4.4 Hz, 2H), 4.05 - 3.98 (m, 2H), 3.81 (s, 3H), 3.50 (s, 3H), 2.07 (s, 3H), 2.06 - 2.00 (m, 2H), 1.87 - 1.78 (m, 2H) ppm; LCMS: 99%, [M+H]+= 346.05; HPLC: 98%.

[0914] 5-(4-(((lr,37?,45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l,3-dimethylpyridin-2(LH)-one (Example 40-D2)

[0915]

[0916] The reaction was carried out according to general procedure A using 1-1** (50 mg, 0.16 mmol), l,3-dimethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2(U7)-one (49 mg, 0.19 mmol), potassium phosphate tribasic (87 mg, 0.40 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (13 mg, 0.02 mmol) in DMF (2 mL) at 100 °C for 5 h. The crude product was purified by preparative HPLC [(column: X-Select C18 (250 mm x 30 mm) 10g, particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 22 mL; loading(mg / inj ection): 12; gradient (time / %B): 0 / 5,3 / 5,10 / 15,35 / 45,60 / 98 to afford 5-(4-(((lr,37?,45)-3,4-dihydroxycyclopentyl)oxy)-3-methoxyphenyl)-l,3-dimethylpyridin-2(177)-one (Example 40-D2, 33 mg, 58.6% yield) as an off-white solid.1H NMR (400 MHz, DMSO-d6) 6 = 7.90 (d, J= 2.4 Hz, 1H), 7.72 - 7.69 (m, 1H), 7.10 (d, J= 2.0 Hz, 1H), 7.02 (dd, J= 2.0, 8.4 Hz, 1H), 6.87 (d, J= 8.4 Hz, 1H), 4.66 - 4.57 (m, 1H), 4.47 (br d, J= 3.6 Hz, 2H), 3.84 - 3.79 (m, 5H), 3.50 (s, 3H), 2.32 - 2.19 (m, 2H), 2.07 (s, 3H), 1.79 - 1.70 (m, 2H) ppm; LCMS: 99%, [M+H]+= 346.10; HPLC: 99%.

[0917] (ll?,21?)-4-(2-methoxy-4-(pyrimidin-5-yl)phenoxy)cyclopentane-l,2-diol (Example 41- El)

[0918] Attorney Docket# COGN-01-PCT

[0919]

[0920] The reaction was carried out according to general procedure A using 1-8 and pyrimidin-5-ylboronic acid. The crude product was purified by preparative HPLC [column: X-Select C18 (250 x 30 mm), 5p particle size; mobile phase A: 0.1% formic acid in water mobile phase B: acetonitrile; flow: 23; loading (mg / inj ection): 42; gradient (time / %B): 0 / 5,4 / 5,10 / 20,25 / 40,35 / 55,60 / 99] to afford Example 41-E1 (25 mg, 50% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 8 = 9.13 (d, J = 4 Hz, 3H), 7.38 (d, J = 2.1 Hz, 1H), 7.34 - 7.30 (m, 1H), 7.00 (d, J= 8.4 Hz, 1H), 4.81 - 4.78 (m, 3H), 3.94 - 3.90 (m, 1H), 3.85 (s, 3H), 3.80 - 3.77 (m, 1H), 2.46 - 2.44 (m, 1H), 2.00 - 1.88 (m, 2H), 1.57 - 1.48 (m, lH)ppm; LCMS: 99%, [M+H]+= 303.29; HPLC: 99%.

[0921] (15',25)-4-(2-methoxy-4-(pyrimidin-5-yl)phenoxy)cyclopentane-l,2-diol (Example 41- E2)

[0922]

[0923] The reaction was carried out according to general procedure A using 1-8** and pyrimidin-5-ylboronic acid. The crude product was purified by preparative HPLC [column: X-Select C18 (250 x 30 mm), 5p particle size; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 23; loading (mg / inj ection): 70; gradient (time / %B): 0 / 5,3 / 5,10 / 10,40 / 40,60 / 98] to afford Example 41-E2 (23 mg, 46% yield) as an off-white solid.XH NMR (400 MHz, DMSO-d6) 5 = 9.13 (d, J= 4 Hz, 3H), 7.38 (d, J= 2.1Attorney Docket# COGN-01-PCT

[0924] Hz, 1H), 7.34 - 7.30 (m, 1H), 7.00 (d, J= 8.4 Hz, 1H), 4.84 - 4.78 (m, 3H), 3.94 - 3.90 (m, 1H), 3.85 (s, 3H), 3.80 - 3.77 (m, 1H), 2.48 - 2.45 (m, 1H), 2.02 - 1.95 (m, 2H), 1.55 - 1.49 (m, 1H) ppm; LCMS: 99.81 %, [M+H]+= 303.25; HPLC: 99%.

[0925] (ll?,21?)-4-(2-methoxy-4-(pyrazin-2-yl)phenoxy)cyclopentane-l,2-diol (Example 42- El)

[0926]

[0927] The reaction was carried out according to general procedure A using 1-8 and pyrazin-2-ylboronic acid. The crude product was purified by preparative HPLC [column: YMC-C8; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 16; loading (mg / inj ection): 10; gradient (time / %B): 0 / 10,3 / 10,10 / 25,25 / 45] to afford Example 42-E1 (4 mg, 7% yield) as an off-white solid.1H NMR (400 MHz, DMSO-de) 8 = 9.23 (s, 1H), 8.65 (s, 1H), 8.53 (d, J= 2.4 Hz, 1H), 7.71 - 7.69 (m, 2H), 7.00 (d, J= 8.4 Hz, 1H), 4.84 - 4.79 (m, 3H), 3.94 - 3.90 (m, 1H), 3.85 (s, 3H), 3.80 - 3.77 (m, 1H), 2.46 -2.44 (m, 1H), 2.00- 1.88 (m, 2H), 1.57 - 1.48 (m, lH)ppm; LCMS: 97%, [M+H]+= 303.0;

[0928] HPLC: 97%

[0929] (15',25)-4-(2-methoxy-4-(pyrazin-2-yl)phenoxy)cyclopentane-l,2-diol (Example 42- E2)

[0930]

[0931] Attorney Docket# COGN-01-PCT

[0932] The reaction was carried out according to general procedure A using 1-8** and pyrazin-2-ylboronic acid. The crude product was purified by preparative HPLC [column: Luna-PH; mobile phase A: 10 mM ammonium bicarbonate in water mobile phase B: acetonitrile; flow: 16; loading (mg / inj ection): 5; gradient (time / %B): 0 / 10,3 / 10,10 / 15,25 / 25,30 / 30] to afford Example 42-E2 (4 mg, 8% yield) as an off- white gummy solid. 'H NMR (400 MHz, DMSO-d6) 6 = 9.23 (d, J= 1.6, 1H), 8.66 - 8.65 (m, 1H), 8.53 (d, J= 2.4 Hz, 1H), 7.71 -7.69 (m, 2H), 7.00 (d, J = 8.4 Hz, 1H), 4.84 - 4.78 (m, 3H), 3.94 - 3.90 (m, 1H), 3.85 (s, 3H), 3.82 - 3.78 (m, 1H), 2.02 - 1.95 (m, 2H), 1.55 - 1.49 (m, 1H) ppm; LCMS: 96.64 %, [M+H]+= 303.16; HPLC: 99%.

[0933] Note: One aliphatic proton merged with the DMSO peak.

[0934] (l / ?.2 / ?)-4-(2-methoxy-4-( 1 -methyl- l / / -pyr;iz()l-3-yl)phen()xy)cyclopeiit;ine-1.2-diol

[0935] (Example 43-E1)

[0936]

[0937] The reaction was carried out according to general procedure A using 1-8 and (1-methyl-lJT-pyrazol-3-yl)boronic acid. The crude product was purified by preparative HPLC [column: X-Select C18 (250 x 30 mm), 5p particle size; mobile phase A: 0.1% formic acid in water mobile phase B: acetonitrile; flow: 23; loading (mg / inj ection): 42; gradient (time / %B): 0 / 5,4 / 5,10 / 20,25 / 40,35 / 55,60 / 99] to afford Example 43-E1 (16 mg, 33% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 7.67 (d, J= 2.4 Hz, 1H), 7.32 (d, J= 2Hz, 1H), 7.26 (dd, J= 2, 8.4 Hz, 1H), 6.86 (d, J= 8.4 Hz, 1H), 6.60 (d, J = 2 Hz, 1H), 4.78 -4.75 (m, 3H), 3.94 - 3.87 (m, 1H), 3.85 (s, 3H), 3.81 - 3.76 (m, 4H), 2.46 - 2.44 (m, 1H), 2.02 - 1.95 (m, 2H), 1.55 - 1.49 (m, 1H) ppm; LCMS: 96%, [M+H]+= 303.0; HPLC: 98%.

[0938] (LS.2. S)-4-(2-inethoxy-4-( l-inetliyl-l / / -pyraz()l-3-yl)plien()xy)cyclopentane-1.2-diol

[0939] (Example 43-E2)

[0940] Attorney Docket# COGN-01-PCT

[0941]

[0942] The reaction was carried out according to general procedure A using 1-8** and (1-methyl- IT / -pyrazol-3-yl)boronic acid. The crude product was purified by preparative HPLC [column: Luna-PH; mobile phase A: 10 mM ammonium bicarbonate in water; mobile phase B: acetonitrile; flow: 16; loading (mg / inj ection): 5; gradient (time / %B): 0 / 10,3 / 10,10 / 15,25 / 25,30 / 30] to afford Example 43-E2) (24 mg, 47% yield) as an off-white gummy solid. 'H NMR (400 MHz, DMSO-A) 6 = 7.67 (s, 1H), 7.32 (s, 1H), 7.25 (br d, J = 8.4 Hz, 1H), 6.86 (d, J= 8.4 Hz, 1H), 6.57 - 6.65 (m, 1H), 4.77 - 4.75 (m, 3H), 3.94 - 3.85 (m, 1H), 3.85 (s, 3H), 3.81 - 3.76 (m, 4H), 2.46 - 2.44 (m, 1H), 2.02 - 1.95 (m, 2H), 1.55 -1.49 (m, 1H) ppm; LCMS: 99.32 %, [M+H]+ =305.30; HPLC: 99%.

[0943] (l / ?.2 / ?)-4-(2-methoxy-4-( 1 -methyl- l / / -pyr;iz()l-5-yl)phen()xy)cyclopeiit;ine-1.2-diol

[0944] (Example 44-E1)

[0945]

[0946] The reaction was carried out according to general procedure A using 1-8 and (1-methyl-lJT-pyrazol-5-yl)boronic acid. The crude product was purified by preparative HPLC [column: X-Select C18 (250 x 30 mm), 5p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 120; gradient (time / %B): 0 / 10,3 / 10,10 / 30,35 / 55] to afford Example 44-E1 (29 mg, 63% yield) as an off-white solid.

[0947] 'H NMR (400 MHz, DMSO-de) 6 = 7.42 (d. J= 1.6 Hz. 1H). 7.04 (d. J= 2 Hz. 1H). 7.00

[0948] Attorney Docket# COGN-01-PCT

[0949] - 6.98 (m, 1H), 6.97 - 6.93 (m, 1H), 6.33 (d, J= 1.6 Hz, 1H), 4.78 - 4.75 (m, 3H), 3.94 -3.85 (m, 1H), 3.83 (s, 3H), 3.81 - 3.76 (m, 4H), 2.46 - 2.44 (m, 1H), 2.02 - 1.95 (m, 2H), 1.55 - 1.49 (m, 1H) ppm; LCMS: 98%, [M+H]+= 305.22; HPLC: 98%.

[0950] (LS.2. S)-4-(2-inethoxy-4-( l-inethyl-l / / -pyiaz()l-5-yl)phenoxy)cyclopentane-1.2-diol

[0951] (Example 44-E2)

[0952]

[0953] The reaction was carried out according to general procedure A using 1-8** and (1-methyl-lH-pyrazol-5-yl)boronic acid The crude product was purified by preparative HPLC [column: X-Select C18 (250 x 30 mm), 5p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 15; loading (mg / inj ection): 20; gradient (time / %B): 0 / 10,3 / 10,15 / 50,27 / 60,35 / 99] to afford Example 44-E2) (35 mg, 88% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-A) 6 = 7.42 (d, J = 2 Hz, 1H), 7.04 (d, J = 1.6 Hz, 1H), 7.00 - 6.93 (m, 2H), 6.33 (d, J= 1.6 Hz, 1H), 4.82 - 4.75 (m, 3H), 3.94 - 3.88 (m, 1H), 3.83 (s, 3H), 3.81 - 3.76 (m, 4H), 2.46 - 2.44 (m, 1H), 2.02 - 1.95 (m, 2H), 1.55 -1.49 (m, 1H) ppm; LCMS: 98.40 %, [M+H]+ =305.30; HPLC: 95%.

[0954] (l / ?.2 / ?)-4-(2-inethoxy-4-( 1 -methyl- l / / -pyraz()l-4-yl)plien()xy)cyclopentane-1.2-diol

[0955] (Example 45-E1)

[0956]

[0957] Attorney Docket# COGN-01-PCT

[0958] The reaction was carried out according to general procedure A using 1-8 and (1-methyl-lH-pyrazol-4-yl)boronic acid. The crude product was purified by preparative HPLC [column: X-Select C18 (250 x 30 mm), 5p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 70; gradient (time / %B): 0 / 10,3 / 10,10 / 30,35 / 55] to afford Example 45-E1 (16 mg, 41% yield) as an off-white solid.

[0959] 'H NMR (400 MHz, DMSO-d6) 6 = 8.03 (s, 1H), 7.77 (s, 1H), 7.10 (d, J= 2 Hz, 1H), 7.03 - 7.01 (m, 1H), 6.83 (d, J= 8.4 Hz, 1H), 4.76 - 4.70 (m, 3H), 3.94 - 3.85 (m, 1H), 3.83 (s, 3H), 3.81 - 3.76 (m, 4H), 2.46 - 2.44 (m, 1H), 2.02 - 1.95 (m, 2H), 1.55 - 1.49 (m, 1H) ppm;

[0960] LCMS: 99%, [M+H]+= 305.30; HPLC: 99%.

[0961] (LS.2. S)-4-(2-inethoxy-4-( l-inethyl-l / / -pyr;iz()l-4-yl)phen()xy)cyclopeiit;ine-1.2-diol

[0962]

[0963] The reaction was carried out according to general procedure A using 1-8** and (1-methyl- lH-pyrazol-4-yl)boronic acid. The crude product was purified by preparative HPLC [column: X-Select C18 (250 x 30 mm), 5p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 15; loading (mg / inj ection): 20; gradient (time / %B): 0 / 10,3 / 10,15 / 50,27 / 60,35 / 99] to afford Example 45-E2, 31 mg, 76% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-A) 6 = 8.03 (s, 1H), 7.77 (s, 1H), 7.10 (d, J= 2 Hz, 1H), 7.03 - 7.01 (m, 1H), 6.83 (d, J= 8.4 Hz, 1H), 4.76 - 4.70 (m, 3H), 3.94 -3.85 (m, 1H), 3.83 (s, 3H), 3.81 - 3.76 (m, 4H), 2.46 - 2.44 (m, 1H), 2.02 - 1.95 (m, 2H), 1.55 - 1.49 (m, 1H) ppm; LCMS: 99.45 %, [M+H]+ =305.26; HPLC: 99%.

[0964] (ll?,21?)-4-(2-methoxy-4-(oxazol-2-yl)phenoxy)cyclopentane-l,2-diol (Example 46-E1)Attorney Docket# COGN-01-PCT

[0965]

[0966] The reaction was carried out according to general procedure A using 1-8 and oxazol-2-ylboronic acid. The crude product was purified by preparative HPLC [column: X-Select C18 (250 x 30 mm), 5p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 22; loading (mg / inj ection): 70; gradient (time / %B): 0 / 5,3 / 5,10 / 25,35 / 40,60 / 98] to afford Example 46-E1 (5 mg, 18% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 5 = 8.14 (s, 1H), 7.52 - 7.47 (m, 2H), 7.31 (s, 1H), 7.01 (d, J = 8.4 Hz, 1H), 4.82 - 4.73 (m, 3H), 3.94 - 3.85 (m, 1H), 3.83 (s, 3H), 3.80 - 3.73 (m, 1H), 2.02 - 1.95 (m, 2H), 1.55 - 1.49 (m, 1H) ppm; LCMS: 98%, [M+H]+= 292.25;

[0967] HPLC: 98%

[0968] (15',25)-4-(2-methoxy-4-(oxazol-2-yl)phenoxy)cyclopentane-l,2-diol (Example 46-E2)

[0969]

[0970] The reaction was carried out according to general procedure A using 1-8** and oxazol-2-ylboronic acid. The crude product was purified by preparative HPLC [column: X-Select C18 (250 x 30 mm), 5p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 15; loading (mg / inj ection): 20; gradient (time / %B): 0 / 10,3 / 10,15 / 50,27 / 60,35 / 99] to afford Example 46-E2 (10 mg, 11% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-A) 5 = 8.14 (s, 1H), 7.52 - 7.47 (m, 2H), 7.31 (s, 1H), 7.01 (d, J = 8.4 Hz, 1H), 4.82 - 4.73 (m, 3H), 3.94 - 3.85 (m, 1H), 3.83 (s, 3H), 3.80 - 3.73 (m, 1H), 2.02 - 1.95 (m, 2H), 1.55 - 1.49 (m, 1H) ppm; LCMS: 98.07 %, [M+H]+ =292.25;

[0971] Attorney Docket# COGN-01-PCT

[0972] HPLC: 98%

[0973] (ll?,21?)-4-(2-methoxy-4-(oxazol-5-yl)phenoxy)cyclopentane-l,2-diol (Example 47-E1)

[0974]

[0975] The reaction was carried out according to general procedure A using 1-8 and oxazol-5-ylboronic acid. The crude product was purified by reverse phase column chromatography (column: C-18 gold; Mobile phase A: 0.1% formic acid in water, Mobile Phase B: 40-50% acetonitrile) to afford Example 47-E1 (20 mg, 70% yield) as white solid.1H NMR (400 MHz, DMSO-d6) 6 = 8.36 (s, 1H) 7.57 (s, 1H) 7.27 - 7.22 (m, 2H) 6.96 (d, J= 8.4 Hz, 1H) 4.79 (t, J= 3.67 Hz, 3H) 3.92 - 3.90 (m, 1H) 3.78 - 3.84 (m, 4H) 2.46 - 2.47 (m, 1H) 1.98 -1.95 (m, 2H), 1.48 - 1.56 (m, 1H) ppm; LCMS: 99%, [M+H]+= 292.0; HPLC: 99.56.

[0976] (15',25)-4-(2-methoxy-4-(oxazol-5-yl)phenoxy)cyclopentane-l,2-diol (Example 47-E2)

[0977]

[0978] The reaction was carried out according to general procedure A using 1-8** and oxazol-2-ylboronic acid. The crude product was purified by reverse phase column chromatography (column: C-18 gold; Mobile phase A: 0.1% formic acid in water, Mobile Phase B: 40-50% acetonitrile) to afford Example 47-E2) (36 mg, 69% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.36 (s, 1H) 7.57 (s, 1H) 7.27 - 7.22 (m, 2H) 6.96 (d, J= 8.4 Hz, 1H) 4.79 (t, J = 3.67 Hz, 3H) 3.92 - 3.90 (m, 1H) 3.81 - 3.84 (m, 4H) 2.46 - 2.47 (m, 1H)Attorney Docket# COGN-01-PCT

[0979] 1.98 - 1.95 (m, 2H), 1.48 - 1.56 (m, 1H) ppm; LCMS: 98.31 %, [M+H] 292.1; HPLC:

[0980] 99%.

[0981] (ll?,25',4s)-4-(2-methoxy-4-(pyrimidin-5-yl)phenoxy)cyclopentane-l,2-diol (Example

[0982]

[0983] The reaction was carried out according to general procedure A using 1-1 (50 mg, 0.16 mmol), pyrimidin-5-ylboronic acid (25 mg, 0.19 mmol), potassium phosphate tribasic (75 mg, 0.34 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (15 mg, 0.02 mmol) in DMF (5 mL) at 100 °C for 12 h. The crude product was purified by preparative HPLC (column: X-Select CSH Cl 8 (250 mm x 30 mm) 5p, particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 22 mL; loading(mg / inj ection): 50; gradient (time / %B): 0 / 5,3 / 5,10 / 25,35 / 45,60 / 68) to afford (17?, 25, 4 )-4-(2 -methoxy -4-(pyrimidin-5-yl)phenoxy)cyclopentane-l,2-diol (Example 48-D1, 22 mg, 44% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 8 = 9.12 (s, 3H), 7.37 (d, J= 2.4 Hz, 1H), 7.32 (dd, J =2.4, 8.4 Hz, 1H), 7.00 (d, J= 8.4 Hz, 1H), 4.67-4.62 (m, 1H), 4.50 (d, J= 4.4 Hz, 2H), 3.85 (s, 3H), 3.82-3.79 (m, 2H), 2.32-2.25 (m, 2H), 1.79 - 1.73 (m, 2H) ppm; LCMS: 99%, [M+H]+= 303.0; HPLC: 99%.

[0984] (ll?,2»S,4r)-4-(2-methoxy-4-(pyrimidin-5-yl)phenoxy)cyclopentane-l,2-diol (Example 48-D2)

[0985] Attorney Docket# COGN-01-PCT

[0986]

[0987] The reaction was carried out according to general procedure A using 1-1** (50 mg, 0.16 mmol), pyrimidin-5-ylboronic acid (25 mg, 0.19 mmol), potassium phosphate tribasic (75 mg, 0.34 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (15 mg, 0.02 mmol) in DMF (5 mL) at 100 °C for 12 h. The crude product was purified by preparative HPLC (column: X-Select CSH Cl 8 (250 mm x 30 mm) 5p, particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 22 mL; loading(mg / inj ection): 100; gradient (time / %B): 0 / 5,3 / 5,10 / 15,35 / 45,60 / 98) to afford (U?,25',4r)-4-(2-methoxy-4-(pyrimidin-5-yl)phenoxy)cyclopentane-l,2-diol (Example 48-D2, 18 mg, 20% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 5 = 9.13 (s, 2H), 9.12 (s, 1H), 7.37 (d, J= 2.4 Hz, 1H), 7.32 (dd, J =2.0, 8.4 Hz, 1H), 7.00 (d, J= 8.4 Hz, 1H) 4.90-4.85 (m, 1H), 4.51 (d, J = 4.4 Hz, 2H), 4.05-4.01 (m, 2H), 3.85 (s, 3H), 2.11 - 2.05 (m, 2H), 1.87 - 1.81 (m, 2H) ppm;

[0988] LCMS: 99%, [M+H]+= 303.0; HPLC: 99%.

[0989] (ll?,25',4s)-4-(2-methoxy-4-(pyrimidin-2-yl)phenoxy)cyclopentane-l,2-diol (Example

[0990]

[0991] The reaction was carried out according to general procedure A using 1-1 (50 mg, 0.16 mmol), pyrimidin-2-ylboronic acid (31 mg, 0.25 mmol), potassium phosphate tribasic (88 mg, 0.40 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II),

[0992] Attorney Docket# COGN-01-PCT

[0993] complex (3 mg, 0.003 mmol) in DMF (4 mL) at 100 °C for 8 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm x 30 mm) 5p, particle size; mobile phase A: 0.1% TFA in water B: acetonitrile; flow: 22 mL; loading(mg / inj ection): 4; gradient (time / %B): 0 / 10,3 / 10,15 / 50,27 / 60,35 / 99) to afford (1R, 2S, 4s)-4-(2 -methoxy -4-(pyrimidin-2-yl)phenoxy)cyclopentane-l,2-diol (Example 49-Dl, 6 mg, 13% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.84 (d, J = 6 Hz, 2H), 7.99-7.94 (m, 2H), 7.35 (m, 1H), 7.00 (m, 1H), 4.92-4.88 (m, 1H), 4.50 (d, J = 5 Hz, 2H), 4.02 (br s, 2H), 3.83 (s, 3H), 2.14-2.07 (m, 2H), 1.87 - 1.84 (m, 2H) ppm;

[0994] LCMS: 97%, [M+H]+= 303.0; HPLC: 95.01 %.

[0995] (ll?,2»S,4r)-4-(2-methoxy-4-(pyrimidin-2-yl)phenoxy)cyclopentane-l,2-diol (Example

[0996]

[0997] The reaction was carried out according to general procedure A using 1-1** (50 mg, 0.16 mmol), pyrimidin-5-ylboronic acid (25 mg, 0.19 mmol), potassium phosphate tribasic (75 mg, 0.34 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (15 mg, 0.02 mmol) in DMF (5 mL) at 100 °C for 12 h. The crude product was purified by preparative HPLC (column: X-Select CSH Cl 8 (250 mm x 30 mm) 5p, particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 22 mL; loading(mg / inj ection): 100; gradient (time / %B): 0 / 5,3 / 5,10 / 15,35 / 45,60 / 98) to afford (U?,25',4r)-4-(2-methoxy-4-(pyrimidin-5-yl)phenoxy)cyclopentane-l,2-diol (Example 49-D2, 18 mg, 20% yield) as an off-white solid.1H NMR (400 MHz, DMSO-d6) 6 = 8.84 (d, J= 4.8 Hz, 2H), 7.98-7.93 (m, 2H), 7.35 (t, J= 4.8, Hz, 1H), 7.00 (d, J= 8.4 Hz, 1H), 4.73-4.69 (m, 1H), 4.50 (d, J= 4.4 Hz, 2H), 3.83-3.80 (m, 5H), 2.32 - 2.29 (m, 2H), 1.79 - 1.76 (m, 2H) ppm; LCMS: 99%, [M+H]+= 303.2; HPLC: 99%.

[0998] (ll?,2»S,4s)-4-(2-methoxy-4-(pyrimidin-4-yl)phenoxy)cyclopentane-l,2-diol (ExampleAttorney Docket# COGN-01-PCT

[0999]

[1000] To a degassed solution of (lA,25,45)-4-(4-bromo-2-methoxyphenoxy)cyclopentane-l,2-diol (1-1) (40 mg, 0.129 mmol) in 1, 4 dioxane (2 mL) were added 4-(tributylstannyl)pyrimidine (58 mg; 0.157 mmol), and Tetrakis(triphenylphosphine)palladium(0) (15 mg, 0.012mmol), and the reaction mixture was stirred at 100 °C for 16 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was filtered over a celite bed and washed with EtOAc. The combined filtrate was washed with water, dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure to obtain the crude. The crude product was purified through preparative HPLC (column: XTIMATE C18 (250 x 30 mm), 5p, particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 16 mL; loading(mg / inj ection): 15; gradient (time / %B): 0 / 15,3 / 15,25 / 65) to afford (1A, 2S, 4.s)-4-(2 -methoxy -4-(pyrimidin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 50-Dl, 4 mg, 9% yield) as sticky white solid.1H NMR (400 MHz, DMSO-de) 8 = 9.17 (d, J = 1.2 Hz, 1H), 8.78 (d, J= 5.2 Hz, 1H), 8.08 - 8.02 (m, 1H), 7.82 - 7.76 (m, 2H), 7.01 (d, J = 9.2 Hz, 1H), 4.95 - 4.89 (m, 1H), 4.53 (d, J= 4.0 Hz, 2H), 4.06 - 4.00 (m, 2H), 3.85 (s, 3H), 2.14 - 2.07 (m, 2H), 1.89 - 1.82 (m, 2H) ppm; LCMS: 99%, [M+H]+= 303.16; HPLC: 98%.

[1001] (ll?,2»S,4r)-4-(2-methoxy-4-(pyrimidin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 50-D2)

[1002] Attorney Docket# COGN-01-PCT

[1003]

[1004] To a degassed solution of (lA,25,4r)-4-(4-bromo-2-methoxyphenoxy)cyclopentane-l,2-diol (1-1**) (30 mg, 0.09 mmol) in 1, 4 dioxane (3 mL) were added 4-(tributylstannyl)pyrimidine (44 mg; 0.12 mmol), and Tetrakis(triphenylphosphine)palladium(0) (12 mg, O. Olmmol), and the reaction mixture was stirred at 100 °C for 16 h. Reaction progress was monitored by TLC. After completion of the reaction, the reaction mixture was filtered over a celite bed and washed with EtOAc. The combined filtrate was washed with water, dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified through preparative HPLC (column: YMC Cl 8 (250 x 20 mm) 5p, particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 16 mL; loading(mg / inj ection): 8; gradient (time / %B): 0 / 5,5 / 5,10 / 15,30 / 30,40 / 40,60 / 99) to afford (lA,25,45)-4-(2-methoxy-4-(pyrimidin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 50-D2, 8 mg, 27% yield) as sticky off-white solid.1H NMR (400 MHz, DMSO-d6) 8 = 9.17 (d, J= 1.2 Hz, 1H), 8.77 (d, J= 5.6 Hz, 1H), 8.07 - 8.04 (m, 1H), 7.81 - 7.76 (m, 2H), 7.01 (d, J= 8.8 Hz, 1H), 4.78 - 4.64 (m, 1H), 4.53 (d, J= 4.8 Hz, 2H), 3.85 (s, 3H), 3.83 - 3.79 (m, 2H), 2.34 - 2.29 (m, 2H), 1.80 - 1.73 (m, 2H) ppm; LCMS: 99%, [M+H]+= 303.26; HPLC: 99%.

[1005] (ll?,2»S,4s)-4-(2-methoxy-4-(pyrazin-2-yl)phenoxy)cyclopentane-l,2-diol (Example 51-

[1006]

[1007] Attorney Docket# COGN-01-PCT

[1008] The reaction was carried out according to general procedure A using 1-1 (50 mg, 0.16 mmol), pyrazin-2-ylboronic acid (25 mg, 0.19 mmol), potassium phosphate tribasic (100 mg, 0.44 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (20 mg, 0.024 mmol) in DMF (5 mL) at 100 °C for 12 h. The crude product was purified by preparative HPLC (column: X-Select CSH Cl 8 (250 mm x 30 mm) 5p, particle size; mobile phase A: 0.1% formic acid in water B: acetonitrile; flow: 22 mL; loading(mg / inj ection): 40; gradient (time / %B): 0 / 10,3 / 10,15 / 50,27 / 60,35 / 99) to afford (1R, 2S, 4s)-4-(2-m ethoxy -4-(pyrazin-2-yl)phenoxy)cy cl opentane-l,2-diol (Example 51-D1, 16 mg, 32% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 8 = 9.21 (s, 1H), 8.63 (s, 1H), 8.51 (d, J= 2.4 Hz, 1H), 7.68-7.67 (m, 2H), 6.98 (d, J= 8.8 Hz, 1H), 4.90-4.86 (m, 1H), 4.50 (d, J= 4 Hz, 2H), 4.01 (br s, 2H), 3.82 (s, 3H), 2.11-2.05 (m, 2H), 1.85-1.82 (m, 2H) ppm; LCMS: 99%, [M+H]+= 303.0; HPLC: 95%.

[1009] (ll?,2»S,4r)-4-(2-methoxy-4-(pyrazin-2-yl)phenoxy)cyclopentane-l,2-diol (Example 51-

[1010]

[1011] The reaction was carried out according to general procedure A using 1-1** (50 mg, 0.16 mmol), pyrazin-2-ylboronic acid (30 mg, 0.24 mmol), potassium phosphate tribasic (87 mg, 0.39 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex (12 mg, 0.02 mmol) in DMF (5 mL) at 100 °C for 12 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm x 30 mm) 5p, particle size; mobile phase A: 0.1% formic acid in water B: acetonitrile; flow: 22 mL; loading(mg / inj ection): 40; gradient (time / %B): 0 / 10,3 / 10,15 / 50,27 / 60,35 / 99) to afford (17?,2£,4r)-4-(2-methoxy-4-(pyrazin-2-yl)phenoxy)cyclopentane-l,2-diol (Example 51-D2, 8 mg, 16% yield) as brown sticky solid. 'H NMR (400 MHz, DMSO-d6) 6 = 9.23 (d, J= 1.2 Hz, 1H), 8.68 - 8.63 (m, 1H), 8.53 (d, J= 2.4 Hz, 1H), 7.73 - 7.67 (m, 2H), 7.00 (d, J= 8.8 Hz, 1H), 4.73 - 4.64 (m,Attorney Docket# COGN-01-PCT

[1012] 1H), 4.51 (d, J= 4.4 Hz, 2H), 3.86 - 3.79 (m, 5H), 2.34 - 2.26 (m, 2H), 1.8 - 1.74 (m, 2H) ppm; LCMS: 97%, [M+H]+= 303.0; HPLC: 96%.

[1013] ( 1 / ?.2. S.4x)-4-(2-methoxy-4-( 1 -methyl- 1 / / -pyr:izol-3-yl)phenoxy)cyclopentane-l.2-diol

[1014]

[1015] The reaction was carried out according to general procedure A using 1-1 (50 mg, 0.16 mmol), (1 -methyl- IT -pyrazol-3-yl)boronic acid (25 mg, 0.19 mmol), potassium phosphate tribasic (70 mg, 0.31 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (15 mg, 0.02 mmol) in DMF (5 mL) at 100 °C for 12 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm x 30 mm) 5p, particle size; mobile phase A: 0.1% formic acid in water B: acetonitrile; flow: 20 mL; loading(mg / inj ection): 98; gradient (time / %B): 0 / 10,3 / 10,10 / 25,35 / 75,45 / 99) to afford (l / ?,2£,4 )-4-(2-methoxy-4-(l-m ethyl- U / -pyrazol-3-yl)phenoxy)cy cl opentane-l,2-diol (Example 52-D1, 28 mg, 58% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-cL) 6 = 7.67 (d, J= 2.0 Hz, 1H), 7.32 (d, J= 2.0 Hz, 1H), 7.25 (dd, J= 2.0, 8.4 Hz, 1H), 6.85 (d, J= 8.4 Hz, 1H), 6.60 (d, J = 2.4 Hz, 1H), 4.84 - 4.79 (m, 1H), 4.50 (d, J= 4.0 Hz, 2H), 4.02 (br s, 2H), 3.85 (s, 3H), 3.78 (s, 3H), 2.08 - 2.01 (m, 2H), 1.87 - 1.80 (m, 2H) ppm; LCMS: 99%, [M+H]+= 305.26;

[1016] HPLC: 99%

[1017] ( 1 / ?.2. S.4r)-4-(2-methoxy-4-( 1 -methyl- 1 / / -pyr:izol-3-yl)phenoxy)cyclopent:ine-l.2-diol

[1018] (Example 52-D2)

[1019] Attorney Docket# COGN-01-PCT

[1020]

[1021] The reaction was carried out according to general procedure A using 1-1** (50 mg, 0.16 mmol), (1 -methyl- IT / -pyrazol-3-yl)boronic acid (25 mg, 0.19 mmol), potassium phosphate tribasic (89 mg, 0.39 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (13 mg, 0.02 mmol) in DMF (5 mL) at 100 °C for 12 h. The crude product was purified by preparative HPLC (column: X-Select CSH C18 (250 mm x 30 mm) 5p, particle size; mobile phase A: 0.1% formic acid in water B: acetonitrile; flow: 22 mL; loading(mg / inj ection): 96; gradient (time / %B): 0 / 5,3 / 5,10 / 25,35 / 45,60 / 98) to afford (U?,25,4r)-4-(2-methoxy-4-(l-methyl-lH-pyrazol-3-yl)phenoxy)cyclopentane-l,2-diol (Example 52-D2, 27 mg, 54% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-cL) 6 = 7.67 (d, J= 2.0 Hz, 1H), 7.32 (d, J= 2.0 Hz, 1H), 7.24 (dd, J= 2.0, 8.4 Hz, 1H), 6.85 (d, J= 8.4 Hz, 1H), 6.60 (d, J = 2.4 Hz, 1H), 4.65 - 4.56 (m, 1H), 4.47 (d, J= 4.8 Hz, 2H), 3.85 (s, 3H), 3.82 - 3.76 (m, 5H), 2.29 - 2.21 (m, 2H), 1.78 - 1.72 (m, 2H) ppm; LCMS: 98%, [M+H]+= 305.0; HPLC:

[1022] 99%.

[1023] ( 1 / ?.2. S.4v)-4-(2-methoxy-4-( 1 -methyl- 1 / / -pyr;izol-5-yl)plienoxy)cyclopeiit;iiie-l.2-diol

[1024]

[1025] The reaction was carried out according to general procedure A using 1-1 (50 mg, 0.16 mmol), (l-methyl-U / -pyrazol-5-yl)boronic acid (25 mg, 0.19 mmol), potassium phosphateAttorney Docket# COGN-01-PCT

[1026] tribasic (70 mg, 0.31 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (15 mg, 0.02 mmol) in DMF (5 mL) at 100 °C for 12 h. The crude product was purified by preparative HPLC [column: X-SELECT C18 (250 x 30mm), 5p, particle size; mobile phase A: 0.1% formic acid in water B: acetonitrile; flow: 25 mL; loading(mg / inj ection): 50; gradient (time / %B): 0 / 10,3 / 10,10 / 25,35 / 45,45 / 75,60 / 99 to afford ( l / ?,2A',4.s)-4-(2-methoxy-4-(l-methyl-U / -pyrazol-5-yl)phenoxy)cyclopentane-l,2-diol (Example 53-D1, 28 mg, 58% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 7.42 (d, J= 2.0 Hz, 1H), 7.04 (d, J= 2.0 Hz, 1H), 7.02 - 6.99 (m, 1H), 6.97 - 6.92 (m, 1H), 6.34 (d, J= 2.0 Hz, 1H), 4.89 - 4.82 (m, 1H), 4.51 (d, J= 4.0 Hz, 2H), 4.07 - 4.01 (m, 2H), 3.83 (s, 3H), 3.79 (s, 3H), 2.12 - 2.04 (m, 2H), 1.89 - 1.82 (m, 2H) ppm; LCMS: 98%, [M+H]+= 305.65;

[1027] HPLC: 98%

[1028] ( 1 / ?.2. S.4r)-4-(2-methoxy-4-( 1 -methyl- 1 / / -pyr;izol-5-yl)plienoxy)cyclopeiit;iiie-l.2-diol

[1029]

[1030] The reaction was carried out according to general procedure A using 1-1** (50 mg, 0.16 mmol), (l-methyl-U / -pyrazol-5-yl)boronic acid (25 mg, 0.19 mmol), potassium phosphate tribasic (75 mg, 0.34 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (15 mg, 0.02 mmol) in DMF (5 mL) at 100 °C for 12 h. The crude product was purified by preparative HPLC (column: X-Select C18250 x 30 mm 10g, particle size; mobile phase A: 0.1% formic acid in water B: acetonitrile; flow: 22 mL; loading(mg / inj ection): 85; gradient (time / %B): 0 / 10,3 / 10,10 / 25,35 / 45,45 / 75,60 / 99) to afford (17?,25,4r)-4-(2-methoxy-4-(l-methyl-lH-pyrazol-5-yl)phenoxy)cyclopentane-l,2-diol (Example 53-D2, 14 mg, 12% yield) as brown sticky liquid. 'H NMR (400 MHz, DMSO-d6) 6 = 7.42 (d, J= 2.0 Hz, 1H), 7.04 (d, J= 2.0 Hz, 1H), 7.02 - 6.97 (m, 1H), 6.97 - 6.92 (m, 1H), 6.34 (d, J= 2.0 Hz, 1H),Attorney Docket# COGN-01-PCT

[1031] 4.69 - 4.61 (m, 1H), 4.49 (d, J= 4.8 Hz, 2H), 3.85 - 3.78 (m, 8H), 2.34 - 2.24 (m, 2H), 1.80 - 1.73 (m, 2H) ppm; LCMS: 99%, [M+H]+= 305.22; HPLC: 98%.

[1032] ( 1 / ?.2. S.4x)-4-(2-methoxy-4-( 1 -methyl- 1 / / -pyr:iz()l-4-yl)phenoxy)cyclopent:ine-l,2-diol

[1033]

[1034]

[1035] The reaction was carried out according to general procedure A using 1-1 (50 mg, 0.16 mmol), (1 -methyl- IT / -pyrazol-4-yl)boronic acid (25 mg, 0.19 mmol), potassium phosphate tribasic (87 mg, 0.40 mmol) and [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (14 mg, 0.02 mmol) in DMF (3 mL) at 100 °C for 8 h. The crude product was purified by reverse phase column chromatography (using gold C18 column, eluent: 40-50% acetonitrile in 0.1% formic acid in water) to afford ( l / ,2b',4.s)-4-(2-methoxy-4-( l-methyl- IT / -pyrazol- 4-yl)phenoxy)cyclopentane-l,2-diol (Example 54-D1, 32 mg, 61% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-cL) 6 = 8.03 (s, 1H), 7.77 (s, 1H), 7.10 (d, J = 2.0 Hz, 1H), 7.03 (dd, J= 2.0, 8.4 Hz, 1H), 6.82 (d, J= 8.4 Hz, 1H), 4.82 - 4.75 (m, 1H), 4.48 (br s, 2H), 4.02 (br t, J= 4.4 Hz, 2H), 3.84 (s, 3H), 3.78 (s, 3H), 2.09 - 1.96 (m, 2H), 1.89 - 1.77 (m, 2H) ppm; LCMS: 97%, [M+H]+= 305.1; HPLC: 98%.

[1036] ( 1 / ?.2. S.4r)-4-(2-methoxy-4-( 1 -methyl- 1 / / -pyr:iz()l-4-yl)phenoxy)cyclopent:ine-l,2-diol

[1037] (Example 54-D2)

[1038] Attorney Docket# COGN-01-PCT

[1039]

[1040] The reaction was carried out according to general procedure A using 1-1** (50 mg, 0.16 mmol), (1 -methyl- IT / -pyrazol-4-yl)boronic acid (25 mg, 0.19 mmol), potassium phosphate tribasic (87 mg, 0.40 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (14 mg, 0.02 mmol) in DMF (2 mL) at 100 °C for 5h. The crude product was purified by reverse phase column chromatography (gold C18 column; eluent: 40-50% acetonitrile in 0.1% formic acid in water) to afford ( l / ,2A',4.s)-4-(2-methoxy-4-( l-methyl- l7 / -pyrazol-4-yl)phenoxy)cyclopentane-l,2-diol (Example 54-D2, 24 mg, 48% yield) as dark brown solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.03 (s, 1H), 7.78 (s, 1H), 7.10 (d, J = 2.0 Hz, 1H), 7.02 (dd, J= 2.0, 8.4 Hz, 1H), 6.82 (d, J= 8.4 Hz, 1H), 4.66 - 4.34 (m, 3H), 3.84 (s, 3H), 3.81 - 3.77 (m, 5H), 2.28 - 2.19 (m, 2H), 1.78 - 1.70 (m, 2H) ppm; LCMS: 99%, [M+H]+= 305.05; HPLC: 98%.

[1041] (ll?,2»S,4s)-4-(2-methoxy-4-(oxazol-2-yl)phenoxy)cyclopentane-l,2-diol (Example 55-

[1042]

[1043] The reaction was carried out according to general procedure A using 1-2 (177 mg, 0.35 mmol), 2-bromooxazole (50 mg, 0.33 mmol), potassium phosphate tribasic (179 mg, 0.83 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with di chloromethane (27 mg, 0.03 mmol) in DMF (4 mL) at 100 °C for 8 h. The crude productAttorney Docket# COGN-01-PCT

[1044] was purified by reverse phase column chromatography (gold Cl 8 column, eluent: 40-50% acetonitrile in 0.1% formic acid in water) to afford (U?,25,45)-4-(2-methoxy-4-(oxazol-2-yl)phenoxy)cyclopentane-l,2-diol (Example 55-D1, 30 mg, 29% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 5 = 8.15 (d, J = 0.8 Hz, 1H), 7.52 (dd, J = 2.0, 8.4 Hz, 1H), 7.47 (d, J = 2.0 Hz, 1H), 7.31 (d, J = 0.8 Hz, 1H), 7.00 (d, J = 8.4 Hz, 1H), 4.89 (s, 1H), 4.54 (br s, 2H), 4.02 (t, J = 4.4 Hz, 2H), 3.82 (s, 3H), 2.14 - 2.08 (m, 2H), 1.91 -1.79 (m, 2H) ppm; LCMS: 95%, [M+H]+= 292.1; HPLC: 98%.

[1045] (ll?,2»S,4r)-4-(2-methoxy-4-(oxazol-2-yl)phenoxy)cyclopentane-l,2-diol (Example 55-

[1046]

[1047] The reaction was carried out according to general procedure A using 1-2** (177 mg, 0.35 mmol), 2-bromooxazole (50 mg, 0.33 mmol), potassium phosphate tribasic (179 mg, 0.83 mmol) and [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with di chloromethane (27 mg, 0.03 mmol) in DMF (2 mL) at 100 °C for 5 h. The crude product was purified by preparative HPLC [(column: YMC ACTUS C8 (250 x 20 mm) 5p particle size, mobile phase A: 0.1% formic acid in water B: acetonitrile; flow: 14 mL; loading(mg / injection):25; gradient (time / %B): 0 / 5,3 / 5,10 / 15,35 / 40,60 / 99] to afford (U?,25,4r)-4-(2-methoxy-4-(oxazol-2-yl)phenoxy)cyclopentane-l,2-diol (Example 55-D2, 16 mg, 16% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 5 = 8.14 (s, 1H), 7.51 (dd, J = 2.0, 8.4 Hz, 1H), 7.47 (d, = 2.0 Hz, 1H), 7.33 - 7.29 (m, 1H), 6.99 (d, = 8.4 Hz, 1H), 4.68 (m, 1H), 4.50 (d, J = 4.5 Hz, 2H), 3.85 - 3.78 (m, 5H), 2.34 - 2.26 (m, 2H), 1.76 (m, 2H) ppm; LCMS: 99%, [M+H]+= 292.21; HPLC: 99%.

[1048] (ll?,2N,4s)-4-(2-methoxy-4-(oxazol-5-yl)phenoxy)cyclopentane-l,2-diol (Example 56-Dl)

[1049] Attorney Docket# COGN-01-PCT

[1050]

[1051] The reaction was carried out according to general procedure A using 1-1 (50 mg, 0.16 mmol), 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)oxazole (38 mg, 0.19 mmol), potassium phosphate tribasic (87 mg, 0.40 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (14 mg, 0.02 mmol) in DMF (3 mL) at 100 °C for 8 h. The crude product was purified by reverse phase column chromatography using gold Cl 8 column and eluted with 40-50% acetonitrile in 0.1% formic acid in water to afford (U?,25,45)-4-(2-methoxy-4-(oxazol-5-yl)phenoxy)cyclopentane-l,2-diol (Example 56-D1, 30 mg, 59% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.38 - 8.35 (m, 1H), 7.57 (s, 1H), 7.28 - 7.22 (m, 2H), 6.95 (d, J= 8.4 Hz, 1H), 4.88 - 4.82 (m, 1H), 4.51 (d, J= 4.4 Hz, 2H), 4.05 - 3.98 (m, 2H), 3.81 (s, 3H), 2.12 - 2.03 (m, 2H), 1.87 - 1.80 (m, 2H) ppm; LCMS: 95%, [M+H]+= 292.25; HPLC: 95%.

[1052] (ll?,2»S,4r)-4-(2-methoxy-4-(oxazol-5-yl)phenoxy)cyclopentane-l,2-diol (Example 56-

[1053]

[1054] The reaction was carried out according to general procedure A using 1-1** (50 mg, 0.16 mmol), 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)oxazole (38 mg, 0.19 mmol), potassium phosphate tribasic (87 mg, 0.40 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethaneAttorney Docket# COGN-01-PCT

[1055] (14 mg, 0.02 mmol) in DMF (3 mL) at 100 °C for 8 h. The crude product was purified by reverse phase column chromatography (gold Cl 8 column, eluent: 40-50% acetonitrile in 0.1% formic acid in water) to afford (U?, 25, 4r)-4-(2 -methoxy -4-(oxazol-5-yl)phenoxy)cyclopentane-l,2-diol (Example 56-D2, 26 mg, 53% yield) as pale pink solid.

[1056] 'H NMR (400 MHz, DMSO-d6) 6 = 8.35 (s, 1H), 7.56 (s, 1H), 7.25 - 7.21 (m, 2H), 6.95 (d, J= 8.4 Hz, 1H), 4.66 - 4.62 (m, 1H), 4.48 (d, J= 4.8 Hz, 2H), 3.81 - 3.83 (m, 5H), 2.28 - 2.25 (m, 2H), 1.78 - 1.73 (m, 2H) ppm; LCMS: 96%, [M+H]+= 292.25; HPLC: 99%.

[1057] (ll?,21?)-4-(4-(5-chloropyridin-3-yl)-2-methoxyphenoxy)-l,2-dimethylcyclopentane-

[1058]

[1059]

[1060] The reaction was carried out according to general procedure A using 1-7 and (5-chl oropyri din-3 -yl)boronic acid. The crude product was purified by preparative HPLC [column: Xtimate C18 (250 x 30 mm), 5p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 20 mL; loading(mg / inj ection): 15; gradient (time / %B): 0 / 15,3 / 15,25 / 65] to afford (U?,27?)-4-(4-(5-chloropyridin-3-yl)-2-m ethoxyphenoxy)- 1,2-dimethylcy cl opentane-l,2-diol (Example 57-E1 (18 mg, 40% yield) as a white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.86 (d, J= 1.9 Hz, 1H), 8.55 (d, J = 2.0 Hz, 1H), 8.23 (t, J= 2.0 Hz, 1H), 7.35 - 7.27 (m, 2H), 6.92 (d, J= 8.4 Hz, 1H), 4.87 -4.75 (m, 1H), 4.43 - 4.27 (m, 2H), 3.85 (s, 3H), 2.42 - 2.36 (m, 1H), 2.22 - 2.15 (m, 1H), 2.14 - 2.07 (m, 1H), 1.76 - 1.72 (m, 1H), 1.15 (d, J = 14.0 Hz, 6H) ppm; LCMS: 99%, [M+H]+= 364.17; HPLC: 99%.

[1061] (15',25)-4-(4-(5-chloropyridin-3-yl)-2-methoxyphenoxy)-l,2-dimethylcyclopentane- 1,2-diol (Example 57-E2)

[1062] Attorney Docket# COGN-01-PCT

[1063]

[1064] The reaction was carried out according to general procedure A using 1-7** and (5-chl oropyri din-3 -yl)boronic acid. The crude product was purified by reverse phase column chromatography (Column: C18 gold; mobile phase A: 0.1% formic acid in water, mobile phase B: 20-30% acetonitrile) to afford (15,25)-4-(4-(5-chloropyridin-3-yl)-2-m ethoxyphenoxy)- 1,2-dimethylcy cl opentane-l,2-diol (Example 57-E2) (14 mg, 26% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.86 (d, J= 2.0 Hz, 1H), 8.55 (d, J= 2.0 Hz, 1H), 8.24 (t, J= 2.4 Hz, 1H), 7.32 - 7.28 (m, 2H), 6.92 (d, J= 8.3 Hz, 1H), 4.81 - 4.73 (m, 1H), 4.40 (s, 1H), 4.33 (s, 1H), 3.84 (s, 3H), 2.40 - 2.33 (m, 1H), 2.21 - 2.07 (m, 2H), 1.78 - 1.71 (m, 1H), 1.14 (d, J= 14.0 Hz, 6H) ppm; LCMS: 99%, [M+H]+= 364.20; HPLC: 99%.

[1065] (ll?,25',4s)-4-(4-(5-chloropyridin-3-yl)-2-methoxyphenoxy)-l,2-dimethylcyclopentane-

[1066]

[1067] The reaction was carried out according to general procedure A using 1-6 and (5-chl oropyri din-3 -yl)boronic acid. The crude product was purified by preparative HPLC (column: YMC (250 x 19 mm) 5p, mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 22 mL; loading(mg / inj ection): 15; gradient (time / %B): 0 / 10,3 / 10,10 / 35,35 / 45,60 / 99) to afford (17?,2£,4s)-4-(4-(5-chloropyridin-3-yl)-2-m ethoxyphenoxy)- 1,2-dimethylcy cl opentane-l,2-diol (Example 58-D1, 11 mg, 20.3% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.86 (d, J= 2.0 Hz, 1H),Attorney Docket# COGN-01-PCT

[1068] 8.55 (d, J= 2 Hz, 1H), 8.23 (t, J= 2.2, 1H), 7.33 (d, J= 2 Hz, 1H), 7.30 - 7.27 (m, 1H), 6.94 (d, J= 8.4 Hz, 1H), 4.84 - 4.80 (m 1H), 4.26 (s, 2H), 3.84 (s, 3H), 2.39 - 2.33 (m, 2H), 1.75 - 1.71 (m, 2H), 1.15 (s, 6H) ppm; LCMS: 99%, [M+H]+= 364.19; HPLC: 98%.

[1069] (ll?,2»S,4r)-4-(4-(5-chloropyridin-3-yl)-2-methoxyphenoxy)-l,2-dimethylcyclopentane-

[1070]

[1071]

[1072] The reaction was carried out according to general procedure A using 1-6** and (5-chl oropyri din-3 -yl)boronic acid. The crude product was purified by preparative HPLC (column: YMC (250 x 19 mm) 5p; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 14 mL; loading(mg / inj ection): 10; gradient (time / %B): 0 / 10,3 / 10,10 / 35,35 / 75,60 / 99) to afford (U?,25,4r)-4-(4-(5-chloropyridin-3-yl)-2-m ethoxyphenoxy)- 1,2-dimethylcy cl opentane-l,2-diol (Example 58-D2, 13 mg, 24% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.84 (d, J= 2.0 Hz, 1H), 8.53 (d, = 2.4 Hz, 1H), 8.22 (t, J= 2.2, 1H), 7.31 (d, = 2.4 Hz, 1H), 7.27 - 7.25 (m, 1H), 6.94 (d, J= 8.4 Hz, 1H), 4.67 - 4.63 (m 1H), 4.22 (s, 2H), 3.82 (s, 3H), 2.20 - 2.14 (m, 2H), 2.02 - 1.97 (m, 2H), 1.05 (s, 6H) ppm; LCMS: 99%, [M+H]+= 364.17; HPLC: 97%.

[1073] (ll?,25',4s)-4-(4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-l,2-diol

[1074]

[1075] Attorney Docket# COGN-01-PCT

[1076] The reaction was carried out according to general procedure A using 1-3 and (2-(trifluoromethyl)pyridin-4-yl)boronic acid. The crude product was purified by reverse phase chromatography (using C18 gold column) and product fractions were eluted with 0.1% formic acid in water in 40-50% acetonitrile to afford (\,2S,4.s)-4-(4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 59-D1, 36 mg, 61.8% yield) as brown gummy solid. 'H NMR (400 MHz, DMSO-de) 8 = 8.75 (d, J= 5.2 Hz, 1H), 8.12 (s, 1H), 8.00 (br d, J= 5.2 Hz, 1H), 7.88 (d, J= 8.8 Hz, 2H), 7.02 (d, J= 8.8 Hz, 2H), 4.98 - 4.91 (m, 1H), 4.56 (br s, 2H), 4.06 - 3.99 (m, 2H), 2.19 - 2.07 (m, 2H), 1.86 - 1.80 (m, 2H) ppm;19F NMR (377 MHz, DMSO-cL) 6 = -66.39 ppm; LCMS: 99%, [M+H]+= 335.19; HPLC: 99%.

[1077] (ll?,2N,4r)-4-(4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-l,2-diol

[1078]

[1079] The reaction was carried out according to general procedure A using 1-3** and (2-(trifluoromethyl)pyridin-4-yl)boronic acid. The crude product was purified by preparative HPLC (column: YMC C18 (250 x 20 mm)) 5p, particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 20 mL; loading(mg / inj ection): 30; gradient (time / %B): 0 / 10,3 / 10,10 / 35,20 / 55,30 / 65,40 / 75,50 / 99) to afford (17?,25,4r)-4-(4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 59-D2, 18 mg, 28% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.75 (d, J= 5.2 Hz, 1H), 8.15 - 8.10 (m, 1H), 8.04 - 7.96 (m, 1H), 7.88 (d, J= 8.8 Hz, 2H), 7.02 (d, J= 8.8 Hz, 2H), 4.79 - 4.71 (m, 1H), 4.53 (d, J= 4.4 Hz, 2H), 3.86 - 3.79 (m, 2H), 2.37 - 2.27 (m, 2H), 1.82 - 1.73 (m, 2H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -66.39 ppm; LCMS: 99%, [M+H]+= 335.17; HPLC: 97%.

[1080] (ll?,2N,4s)-4-(2-chloro-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 60-D1)

[1081] Attorney Docket# COGN-01-PCT

[1082]

[1083] The reaction was carried out according to general procedure A using 1-4 and (2-(trifluoromethyl)pyridin-4-yl)boronic acid. The crude product was purified by reverse phase chromatography (using a C18 gold column) and product fractions were eluted with 0.1% formic acid in water in 40-50% acetonitrile to afford (U?,25,45)-4-(2-chloro-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 60-D1, 32 mg, 53% yield) as an off white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.77 (d, J= 5.2 Hz, 1H), 8.20 (s, 1H), 8.10 - 8.03 (m, 2H), 7.88 (dd, J= 2.4, 8.8 Hz, 1H), 7.22 (d, J= 8.8 Hz, 1H), 5.10 - 4.99 (m, 1H), 4.57 (d, J= 4.4 Hz, 2H), 4.07 - 4.04 (m, 2H), 2.21 - 2.07 (m, 2H), 1.90 - 1.85 (m, 2H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -66.33 ppm; LCMS: 99%, [M+H]+= 374.0; HPLC: 99%.

[1084] (ll?,2N,4r)-4-(2-chloro-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-l,2-

[1085]

[1086] The reaction was carried out according to general procedure A using 1-4** and 2-trifluoromethylpyridin-4-yl)boronic acid. The crude product was purified by reverse phase chromatography (using a C18 gold column) and product fractions were eluted with 0.1% formic acid in water in 40-50% acetonitrile to afford (U?,25,4r)-4-(2-chloro-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 60-D2, 15 mg, 24% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.77 (d, J= 5.2 Hz, 1H), 8.21 (s, 1H), 8.10 - 8.04 (m, 2H), 7.93 - 7.79 (m, 1H), 7.20 (d, J= 8.8 Hz, 1H), 4.85 -Attorney Docket# COGN-01-PCT

[1087] 4.78 (m, 1H), 4.59 (d, J= 4.4 Hz, 2H), 3.83 (br d, 5.2 Hz, 2H), 2.40 - 2.31 (m, 2H), 1.83 - 1.76 (m, 2H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -66.33 ppm; LCMS: 99%, [M+H]+= 374.07; HPLC: 99%.

[1088] (ll?,2N,4s)-4-(2-methyl-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-l,2-

[1089]

[1090]

[1091] The reaction was carried out according to general procedure A using 1-5 and 2- (trifluoromethyl)pyridin-4-yl-boronic acid. The crude product was purified by reverse phase chromatography (using C 18 gold column) and product fraction was eluted with 0.1% formic acid in water in 40-50% acetonitrile to afford (l / <2A',4.s)-4-(2-methyl-4-(2- (trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 61-D1, 48 mg, 76% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 8 = 8.74 (d, J= 5.2 Hz, 1H), 8.14 - 8.10 (m, 1H), 8.02 - 7.96 (m, 1H), 7.80 - 7.71 (m, 2H), 6.99 (d, J= 8.8 Hz, 1H), 4.99 - 4.89 (m, 1H), 4.54 (d, J= 4.4 Hz, 2H), 4.06 - 4.03 (m, 2H), 2.20 (s, 3H), 2.16 - 2.07 (m, 2H), 1.88 - 1.83 (m, 2H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -66.36 ppm;

[1092] LCMS: 96%, [M+H]+= 354.0; HPLC: 96%.

[1093] (ll?,2N,4r)-4-(2-methyl-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-l,2-

[1094]

[1095]

[1096] The reaction was carried out according to general procedure A using 1-5** and (2-

[1097] Attorney Docket# COGN-01-PCT

[1098] (trifluoromethyl)pyridin-4-yl)boronic acid. The crude product was purified by reverse phase chromatography (using a C18 gold column) and product fraction was eluted with 0.1% formic acid in water in 40-50% acetonitrile to afford (U?,25,4r)-4-(2-methyl-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 61-D2, 31 mg, 52% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.73 (d, J= 5.2 Hz, 1H), 8.12 (s, 1H), 7.99 (br d, J= 4.8 Hz, 1H), 7.80 - 7.69 (m, 2H), 6.98 (d, J= 8.4 Hz, 1H), 4.76 - 4.72 (m, 1H), 4.52 (d, J= 4.4 Hz, 2H), 3.85 - 3.82 (m, 2H), 2.39 - 2.30 (m, 2H), 2.22 (s, 3H), 1.83 - 1.71 (m, 2H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -66.36 ppm; LCMS:

[1099] 97%, [M+H]+= 354.71; HPLC: 97%.

[1100] (ll?,21?)-4-(2-methoxy-4-(pyridin-3-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol

[1101]

[1102] The reaction was carried out according to general procedure A using 1-7 and pyridin-3-ylboronic acid. The crude product was purified by reverse phase column chromatography (column: C18 gold; mobile phase A: 0.1% formic acid in water, mobile phase B: 30-40% acetonitrile) to afford (U?,27?)-4-(2-methoxy-4-(pyri din-3 -yl)phenoxy)- 1,2-dimethylcyclopentane-l,2-diol (Example 62-E1 (16 mg, 40% yield) as an off-white solid.

[1103] 'H NMR (400 MHz, DMSO-d6) 6 = 8.88 (d, J= 2.0 Hz, 1H), 8.52 - 8.49 (m, 1H), 8.07 -8.02 (m, 1H), 7.45 - 7.42 (m, 1H), 7.26 (d, J= 2.1 Hz, 1H), 7.24 - 7.20 (m, 1H), 6.92 (d, J = 8.4 Hz, 1H), 4.81 - 4.76 (m, 1H), 4.42 - 4.28 (m, 2H), 3.84 (s, 3H), 2.42 - 2.34 (m, 1H), 2.23 - 2.15 (m, 1H), 2.14 - 2.07 (m, 1H), 1.78 - 1.71 (m, 1H), 1.15 (s, 3H), 1.11 (s, 3H)ppm;

[1104] LCMS: 98%, [M+H]+= 330.23; HPLC: 97%.

[1105] (lN,25)-4-(2-methoxy-4-(pyridin-3-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol

[1106] (Example 62-E2)

[1107] Attorney Docket# COGN-01-PCT

[1108]

[1109] The reaction was carried out according to general procedure A using 1-7** and pyridin-3-ylboronic acid. The crude product was purified by reverse phase column chromatography [column: C18 gold; mobile phase A: water, mobile phase B: 30 - 40% acetonitrile; flow: 15 ml / min) to afford (15,25)-4-(2-methoxy-4-(pyridin-3-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol (Example 62-E2) (15 mg, 38% yield) as an off-white solid.

[1110] 'H NMR (400 MHz, DMSO-d6) 6 = 8.88 (d, J= 1.6 Hz, 1H), 8.52 - 8.49 (m,lH), 8.07 -8.02 (m, 1H), 7.46 - 7.42 (m, 1H), 7.26 (d, J= 2.0 Hz, 1H), 7.24 - 7.20 (m, 1H), 6.92 (d, J = 8.4 Hz, 1H), 4.82 - 4.75 (m, 1H), 4.44 - 4.29 (m, 2H), 3.84 (s, 3H), 2.41 - 2.34 (m, 1H), 2.17 - 2.11 (m, 2H), 1.80 - 1.70 (m, 1H), 1.15 (s, 3H), 1.11 (s, 3H) ppm; LCMS: 99%, [M+H]+= 330.23; HPLC: 98%.

[1111] (ll?,21?)-4-(2-methoxy-4-(5-(trifluoromethyl)pyridin-3-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol (Example 63-E1)

[1112]

[1113] The reaction was carried out according to general procedure A using 1-7 and (5-(trifluorom ethyl)pyri din-3 -yl)boronic acid. The crude product was purified by reverse phase column chromatography (column: C18 gold; mobile phase A: 0.1% formic acid in water, mobile phase B: 40-50% acetonitrile) to afford (U?,27?)-4-(2-methoxy-4-(5-(trifluoromethyl)pyri din-3 -yl)phenoxy)-l,2-dimethylcy cl opentane-l,2-diol (Example 63-E1 (28 mg, 58% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 9.20 (d, J= 1.9 Hz, 1H), 8.91 - 8.87 (m, 1H), 8.43 (s, 1H), 7.42 - 7.32 (m, 2H), 6.94 (d, J= 8.4 Hz,Attorney Docket# COGN-01-PCT

[1114] 1H), 4.83 - 4.78 (m, 1H), 4.44 - 4.28 (m, 2H), 3.86 (s, 3H), 2.43 - 2.35 (m, J= 8.6, 14.2 Hz, 1H), 2.21 - 2.08 (m, 2H), 1.79 - 1.72 (m, J= 2.4, 14.3 Hz, 1H), 1.15 (d, J= 14.0 Hz, 6H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -61.82 ppm; LCMS: 97%, [M+H]+= 398.22;

[1115] HPLC: 99%

[1116] (lN,25)-4-(2-methoxy-4-(5-(trifluoromethyl)pyridin-3-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol (Example 63-E2)

[1117]

[1118] The reaction was carried out according to general procedure A using 1-7** and (5-(trifluorom ethyl)pyri din-3 -yl)boronic acid. The crude product was purified by reverse phase column chromatography (column: C18 gold; mobile phase A: 0.1% formic acid in water, mobile phase B: 30-40% acetonitrile; Flow: 15 ml / min) to afford (15,2, )-4-(2-methoxy-4-(5-(trifluoromethyl)pyridin-3-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol (Example 63-E2) (14 mg, 21% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 9.20 (d, J= 1.2 Hz 1H), 8.89 (s, 1H), 8.44 (s, 1H), 7.42 - 7.32 (m, 2H), 6.98 (d, J= 8.4 Hz 1H), 4.74 - 4.63 (m, 1H), 4.39 (s, 1H), 4.32 (s, 1H), 3.86 (s, 3H), 2.41 - 2.31 (m, 1H), 2.21 - 2.08 (m, 2H), 1.77 - 1.73 (m, 1H), 1.07 (s, 6H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -61.83 ppm; LCMS: 96%, [M+H]+= 398.22; HPLC: 95%.

[1119] (ll?,21?)-4-(2-methoxy-4-(pyridin-4-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol

[1120] (Example 64-E1)

[1121] Attorney Docket# COGN-01-PCT

[1122]

[1123] The reaction was carried out according to general procedure A using 1-7 and pyridin-4-ylboronic acid. The crude product was purified by reverse phase column chromatography (column: C18 gold; mobile phase A: 0.1% formic acid in water, mobile phase B: 40-50% acetonitrile) to afford ((U?,27?)-4-(2-methoxy-4-(pyridin-4-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol (Example 64-E1 (16 mg, 40% yield) as an off-white solid.

[1124] 'H NMR (400 MHz, DMSO-d6) 6 = 8.57 (d, J= 6.0 Hz, 2H), 7.69 (d, J= 6.1 Hz, 2H), 7.38 - 7.30 (m, 2H), 6.93 (br d, J= 8.8 Hz, 1H), 4.81 - 4.77 (m, 1H), 4.46 - 4.31 (m, 2H), 3.84 (s, 3H), 2.39 - 2.32 (m, 1H), 2.22 - 2.16 (m, 1H), 2.15 - 2.08 (m, 1H), 1.75 (m, 1H), 1.13 (d, J= 14.4 Hz, 6H) ppm; LCMS: 96%, [M+H]+= 330.0; HPLC: 97%.

[1125] (15',25)-4-(2-methoxy-4-(pyridin-4-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol

[1126]

[1127] The reaction was carried out according to general procedure A using 1-7** and pyridin-4-ylboronic acid. The crude product was purified by reverse phase column chromatography (column: C18 gold; mobile phase A: 0.1% formic acid in water, mobile phase B: 40-50% acetonitrile) to afford (15,25)-4-(2-methoxy-4-(pyridin-4-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol (Example 64-E2) (13 mg, 33% yield) as an off-white solid.

[1128] 'H NMR (400 MHz, DMSO-d6) 6 = 8.57 (d, J= 6.0 Hz, 2H), 7.69 (d, J= 6.1 Hz, 2H), 7.38 - 7.30 (m, 2H), 6.94 (d, J= 8.9 Hz, 1H), 4.81- 4.77 (m, 1H), 4.44 - 4.28 (m, 2H), 3.85 (s,Attorney Docket# COGN-01-PCT

[1129] 3H), 2.41 - 2.34 (m, 1H), 2.27 - 2.03 (m, 2H), 1.76 - 1.67 (m, 1H), 1.15 (d, J= 14.1 Hz, 6H) ppm; LCMS: 99%, [M+H]+= 330.23; HPLC: 99%.

[1130] (ll?,21?)-4-(2-methoxy-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol (Example 65-E1)

[1131]

[1132] The reaction was carried out according to general procedure A using 1-7 and (2-(trifluoromethyl)pyridin-4-yl)boronic acid. The crude product was purified by reverse phase column chromatography (column: C18 gold; mobile phase A: 0.1% formic acid in water, mobile phase B: 40-50% acetonitrile) to afford (U?,27?)-4-(2-methoxy-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol (Example 65-E1 (27 mg, 56% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.75 (d, J= 4.8 Hz, 1H), 8.16 (s, 1H), 8.03 - 8.01 (m,lH), 7.49 - 7.42 (m, 2H), 6.96 (d,lH), 4.83 -4.79 (m,lH), 4.49 - 4.33 (m, 2H), 3.87 (s, 3H), 2.40 - 2.36 (m, 1H), 2.23 - 2.11 (m, 2H), 1.75 - 1.71 (m, 1H), 1.15 (d, 6H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -66.26 ppm;

[1133] LCMS: 99%, [M+H]+= 398.22; HPLC: 95%.

[1134] (15',25)-4-(2-methoxy-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol (Example 65-E2)

[1135]

[1136] The reaction was carried out according to general procedure A using 1-7** and (2-(trifluoromethyl)pyridin-4-yl)boronic acid. The crude product was purified by reverse phaseAttorney Docket# COGN-01-PCT

[1137] column chromatography (column: C18 gold; mobile phase A: 0.1% formic acid in water, mobile phase B: 40-50% acetonitrile) to afford (15,25)-4-(2-methoxy-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol (Example 65-E2) (12 mg, 25% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.75 (d, J= 5.3 Hz, 1H), 8.16 (s, 1H), 8.03 (d, J= 5.0 Hz, 1H), 7.50 - 7.42 (m, 2H), 6.96 (d, J= 8.1 Hz, 1H), 4.85 - 4.80 (m, 1H), 4.41 (s, 1H), 4.34 (s, 1H), 3.87 (s, 3H), 2.42 - 2.32 (m, 1H), 2.23 - 2.17 (m, 1H), 2.15 - 2.10 (m, 1H), 1.81 - 1.68 (m, J = 2.2, 14.2 Hz, 1H), 1.15 (d, J = 13.8 Hz, 6H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -66.26 ppm; LCMS: 97%, [M+H]+= 398.10; HPLC: 97%.

[1138] (ll?,2N,4s)-4-(2-methoxy-4-(pyridin-3-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol

[1139]

[1140] The reaction was carried out according to general procedure A using 1-6 and pyridin-3-ylboronic acid. The crude product was purified by reverse phase column chromatography (column: C18 gold; mobile phase A: 0.1% formic acid in water, mobile phase B: 40-50% acetonitrile) to afford (U?,25,45)-4-(2-methoxy-4-(pyridin-3-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol (Example 66-D1, 37 mg, 74% yield) as an off-white solid.

[1141] 'H NMR (400 MHz, DMSO-d6) 6 = 8.88 (d, J = 2.0 Hz, 1H), 8.51 (dd, J = 1.2, 4.7 Hz, 1H), 8.07 - 8.01 (m, 1H), 7.44 (m, 1H), 7.33 - 7.19 (m, 2H), 6.93 (d, J= 8.4 Hz, 1H), 4.84 -4.79 (m, 1H), 4.26 (s, 2H), 3.84 (s, 3H), 2.39 - 2.33 (m, 2H), 1.74 - 1.71 (m, 2H), 1.16 (s, 6H) ppm; LCMS: 97%, [M+H]+= 330.27; HPLC: 95%.

[1142] (ll?,2N,4r)-4-(2-methoxy-4-(pyridin-3-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol

[1143] (Example 66-D2)

[1144] Attorney Docket# COGN-01-PCT

[1145]

[1146] The reaction was carried out according to general procedure A using 1-6** and pyridin-3-ylboronic acid. The crude product was purified by reverse phase column chromatography (column: C18 gold; mobile phase A: water, mobile phase B: acetonitrile, flow:15 ml / min) to afford (U?,25',4r)-4-(2-methoxy-4-(pyridin-3-yl)phenoxy)-l,2-dimethylcyclopentane- 1,2-diol (Example 66-D2, 23 mg, 55.5% yield) as an off-white solid.1H NMR (400 MHz, DMSO-d6) 6 = 8.88 (d, J= 1.9 Hz, 1H), 8.51 (dd, J= 1.4, 4.7 Hz, 1H), 8.04 - 8.03 (m, 1H), 7.44 - 7.42 (m, 1H), 7.28 - 7.19 (m, 2H), 6.95 (d, J= 8.4 Hz, 1H), 4.66 - 4.63 (m, 1H), 4.25 (s, 2H), 3.84 (s, 3H), 2.19 - 2.16 (m, 2H), 2.12 - 1.92 (m, 2H), 1.07 (s, 6H) ppm; LCMS:

[1147] 96%, [M+H]+= 330.20; HPLC: 97%.

[1148] (ll?,2»S,4s)-4-(2-methoxy-4-(5-(trifluoromethyl)pyridin-3-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol (Example 67-D1)

[1149]

[1150] The reaction was carried out according to general procedure A using 1-6 and (5-(trifluorom ethyl)pyri din-3 -yl)boronic acid. The crude product was purified by reverse phase column chromatography (column: C18 gold; mobile phase A: 0.1% formic acid in water, mobile phase B: 40-50% acetonitrile) to afford (17?,2£,4 )-4-(2-methoxy-4-(5-(trifluoromethyl)pyri din-3 -yl)phenoxy)-l,2-dimethylcy cl opentane-l,2-diol (Example 67-Dl, 16 mg, 26% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 8 = 9.19 (d, J= 1.6 Hz, 1H), 8.89 (s, 1H), 8.44 (s, 1H), 7.40 (d, J= 2.0 Hz, 1H), 7.35 (dd, J= 2.0, 8.3 Hz, 1H), 6.96 (d, = 8.4Hz, 1H), 4.84 - 4.81 (m, 1H), 4.27 (s, 2H), 3.86 (s, 3H), 2.37 - 2.32Attorney Docket# COGN-01-PCT

[1151] (m, 2H), 1.81 - 1.68 (m, 2H), 1.16 (s, 6H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -60.68 ppm; LCMS: 98%, [M+H]+= 398.22; HPLC: 98%.

[1152] (ll?,2N,4r)-4-(2-methoxy-4-(5-(trifluoromethyl)pyridin-3-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol (Example 67-D2)

[1153]

[1154] The reaction was carried out according to general procedure A using 1-6** and (5-(trifluorom ethyl)pyri din-3 -yl)boronic acid. The crude product was purified by reverse phase column chromatography (column: C18 gold; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; Flow: 15 ml / min) to afford (U?,25',4r)-4-(2-methoxy-4-(5-(trifluoromethyl)pyri din-3 -yl)phenoxy)-l,2-dimethylcy cl opentane-l,2-diol (Example 67-D2, 14 mg, 28% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 9.20 (d, J= 1.2Hz 1H), 8.89 (s, 1H), 8.44 (s, 1H), 7.42 - 7.32 (m, 2H), 6.98 (d, J= 8.4 Hz 1H), 4.74 - 4.63 (m, 1H), 4.25 (s, 2H), 3.86 (s, 3H), 2.24 - 2.17 (m, 2H), 2.04 -1.99 (m, 2H), 1.07 (s, 6H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -61.81 ppm; LCMS: 95%, [M+H]+= 398.22; HPLC: 95%.

[1155] (ll?,2N,4s)-4-(2-methoxy-4-(pyridin-4-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol

[1156]

[1157] The reaction was carried out according to general procedure A using 1-6 and pyridin-4-ylboronic acid. The crude product was purified by reverse phase column chromatographyAttorney Docket# COGN-01-PCT

[1158] (column: C18 gold; mobile phase A: 0.1% formic acid in water, mobile phase B: 40-50% acetonitrile) to afford (U?,25,45)-4-(2-methoxy-4-(pyridin-4-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol (Example 68-D1, 46 mg, 90% yield) as an off-white solid.

[1159] 'H NMR (400 MHz, DMSO-d6) 6 = 8.58 (d, J= 6 Hz, 2H), 7.69 - 7.68 (m, 2H), 7.35 -7.32 (m, 2H), 6.96 (d, J= 8.8 Hz, 1H), 4.84 - 4.81 (m, 1H), 4.27 (s, 2H), 3.85 (s, 3H), 2.40 - 2.32 (m, 2H), 1.75 - 1.71 (m, 2H), 1.15 (s, 6H) ppm; LCMS: 96%, [M+H]+= 330.23;

[1160] HPLC: 98%

[1161] (ll?,2»S,4r)-4-(2-methoxy-4-(pyridin-4-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol

[1162]

[1163]

[1164] The reaction was carried out according to general procedure A using 1-6** and pyridin-4-ylboronic acid. The crude product was purified by reverse phase column chromatography (column: C18 gold; mobile phase A: 0.1% formic acid in water, mobile phase B: 40-50% acetonitrile) to afford (U?,25,4r)-4-(2-methoxy-4-(pyridin-4-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol (Example 68-D2, 20 mg, 51% yield) as yellow sticky solid.

[1165] 'H NMR (400 MHz, DMSO-d6) 6 = 8.57 (d, J= 6.1 Hz, 2H), 7.69 (d, J= 6.0 Hz, 2H), 7.36

[1166] - 7.29 (m, 2H), 6.96 (d, J= 8.4 Hz, 1H), 4.72 - 4.64 (m, 1H), 4.25 (s, 2H), 3.85 (s, 3H), 2.27

[1167] - 2.13 (m, 2H), 2.13 - 1.91 (m, 2H), 1.07 (s, 6H) ppm; LCMS: 98%, [M+H]+= 330.23;

[1168] HPLC: 99%

[1169] (ll?,2»S,4s)-4-(2-methoxy-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol (Example 69-D1)

[1170] Attorney Docket# COGN-01-PCT

[1171]

[1172] The reaction was carried out according to general procedure A using 1-6 and (2-(trifluoromethyl)pyridin-4-yl)boronic acid. The crude product was purified by reverse phase column chromatography (column: C18 gold; mobile phase A: 0.1% formic acid in water, mobile phase B: 40-50% acetonitrile) to afford (17?,2£,4 )-4-(2-methoxy-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol (Example 69-Dl, 25 mg, 41% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.75 (d, J= 5.1 Hz, 1H), 8.16 (s, 1H), 8.05 - 8.01 (m, 1H), 7.50 - 7.42 (m, 2H), 6.97 - 6.92 (m, 1H), 4.90 - 4.82 (m, 1H), 4.28 (s, 2H), 3.87 (s, 3H), 2.43 - 2.35 (m, 2H), 1.78 - 1.70 (m, 2H), 1.16 (s, 6H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -66.27 ppm; LCMS: 98%, [M+H]+= 398.22; HPLC: 99%.

[1173] (ll?,2»S,4r)-4-(2-methoxy-4-(2-(trifluoromethyl)pyridin-4-yl)phenoxy)-l,2-dimethylcyclopentane-l,2-diol (Example 69-D2)

[1174]

[1175] The reaction was carried out according to general procedure A using 1-6** and (2-(trifluoromethyl)pyridin-4-yl)boronic acid. The crude product was purified by reverse phase column chromatography (column: C18 gold; mobile phase A: 0.1% formic acid in water, mobile phase B: 40-50% acetonitrile) to afford (U?,25',4r)-4-(2-methoxy-4-(2-(trifluoromethvl)Dvridin-4-vl)nhenoxv)-l,2-dimethvlcvcloDentane-l,2-diol (Example 69-Attorney Docket# COGN-01-PCT

[1176] D2, 16 mg, 32% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6) 6 = 8.75 (d, J= 5.1 Hz, 1H), 8.16 (s, 1H), 8.03 (br d, J= 4.5 Hz, 1H), 7.50 - 7.39 (m, 2H), 7.05 - 6.92 (m, 1H), 4.68 - 4.68 (m, 1H), 4.26 (s, 2H), 3.87 (s, 3H), 2.28 - 2.13 (m, 2H), 2.11 - 1.93 (m, 2H), 1.07 (s, 6H) ppm;19F NMR (377 MHz, DMSO-d6) 6 = -66.25 ppm; LCMS: 96%, [M+H]+= 398.22; HPLC: 95%.

[1177] Synthesis of (17?,2N,4s)-4-(2-methoxy-4-(l-(trifluoromethyl)-lH-pyrazol-4-yl)phenoxy)cyclopentane-l,2-diol (Example 70-D1).

[1178]

[1179] The reaction was carried out according to general procedure A using 1-1 and 4-(4, 4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l-(trifluoromethyl)-U / -pyrazole. The crude product was purified through preparative HPLC (Column: Xtimate Cl 8 (19 * 250 mm), 5 p particle size; mobile phase A: 0.1% formic acid in water; mobile phase B: acetonitrile; flow: 18 mL; loading (mg / inj ection): 20; gradient (time / %B): 0 / 10, 3 / 10, 10 / 30, 20 / 40, 30 / 80, 31 / 98) to afford (l / ?,2k,4.s)-4-(2-methoxy-4-(l-(trifluorornethyl)-l7 / -pyrazol-4-yl)phenoxy)cyclopentane-l,2-diol (Example 70-D1, 26 mg, 29% yield) as an off-white sticky solid.

[1180] 1H NMR (400 MHz, DMSO-d6): 6 = 8.89 (s, 1H), 8.41 (s, 1H), 7.31 (d, J= 2 Hz, 1H), 7.24 (dd, J= 2.0, 8.4 Hz, 1H), 6.89 (d, J= 8.4 Hz, 1H), 4.85-4.81 (m, 1H), 4.49 (d, J= 4.40 Hz, 2H), 4.03-3.99 (m, 2H), 3.80 (s, 3H), 2.09-2.02 (m, 2H), 1.86-1.80 (m, 2H).19F NMR (377 MHz, DMSO-d6): 3 = -5924

[1181] LC-MS: 99.72%; [M+H]+= 359.17. HPLC: 99.25%.

[1182] Synthesis of (17?,2N,4r)-4-(2-methoxy-4-(l-(trifluoromethyl)-lZ / -pyrazol-4-yl)phenoxy)cyclopentane-l,2-diol (Example 70-D2).

[1183] Attorney Docket# COGN-01-PCT

[1184]

[1185] The reaction was carried out according to general procedure A using 1-1** and 4-(4,4,5,5-tetramethyl-1, 3, 2-dioxaborolan-2-yl)-l -(trifluoromethyl)- l / / -pyrazole. The crude compound was purified by reversed phase column chromatography (using a Cl 8 gold column) and desired fractions were eluted with 40-50% acetonitrile in 0.1% formic acid in water to afford (U?,25',4r)-4-(2-methoxy-4-(l-(trifluoromethyl)-l / / -pyrazol-4-yl)phenoxy)cyclopentane-l,2-diol (Example 70-D2, 17 mg, 28.9% yield) as an off-white sticky solid.

[1186] 'H NMR (400 MHz, DMSO-d6): 6 = 8.89 (s, 1H), 8.42 (s, 1H), 7.31 (d, J= 2.0 Hz, 1H), 7.24 (dd, J= 2.0, 8.4 Hz, 1H), 6.89 (d, J= 8.4 Hz, 1H), 4.64 - 4.60 (m, 1H), 4.48 (d, J= 4.4 Hz, 2H), 3.81 (s, 3H), 3.80-3.78 (m, 2H), 2.28-2.23 (m, 2H), 1.76-1.73 (m, 2H).19F NMR (377 MHz, DMSO-d6): δ = -59.23. LC-MS: 98.71%; [M+H]+= 359.19. HPLC: 99.30%.

[1187] Synthesis of (ll?,25',4s)-4-(4-(pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 71-D1)

[1188]

[1189] The reaction was carried out according to general procedure A using 1-3 and pyridin-4-ylboronic acid. The crude product was purified by reverse phase chromatography (using C18 gold column) and product fractions were eluted with 40-50% acetonitrile in 0.1% formic acid in water to afford (U?,25,45)-4-(4-(pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 71-D1, 14.74 mg, 29.6% yield) as an off white solid.

[1190] Attorney Docket# COGN-01-PCT

[1191] 'H NMR (400 MHz, DMSO-d6): 3 = 8.59-8.55 (m, 2H), 7.75 (d, J= 8.8 Hz, 2H), 7.67-7.63 (m, 2H), 6.99 (d, J= 8.8 Hz, 2H), 4.96-4.89 (m, 1H), 4.56 (br s, 2H), 4.02 (br t, J= 4.4 Hz, 2H), 2.18-2.05 (m, 2H), 1.90-1.78 (m, 2H). LCMS: 98.14%, [M+H]+=272.17. HPLC:

[1192] 99.56%.

[1193] Synthesis of (17?,2N,4r)-4-(4-(pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 71-D2)

[1194]

[1195] The reaction was carried out according to general procedure A using 1-3** and pyridin-4-ylboronic acid. The crude product was purified by reverse phase chromatography (using C18 gold column) and product fractions were eluted with 40-50% acetonitrile in 0.1% formic acid in water to afford (U?,25,4r)-4-(4-(pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 71-D2, 29.68 mg, 59.7% yield) as an off-white solid.

[1196] 'H NMR (400 MHz, DMSO-d6): 6 = 8.57 (d, J= 6.4 Hz, 2H), 7.75 (d, J= 8.8 Hz, 2H), 7.66 (d, J= 6.4 Hz, 2H), 6.99 (d, J= 8.8 Hz, 2H), 4.76-4.68 (m, 1H), 4.56 (d, J= 4.4 Hz, 2H), 3.81 (br d, J= 4.2 Hz, 2H), 2.35-2.27 (m, 2H), 1.77-1.71 (m, 2H). LCMS: 95.43%, [M+H]+=272.2; HPLC: 97.91%.

[1197] Synthesis of (17?,2N,4s)-4-(2-chloro-4-(pyridin-4-yl)phenoxy)cyclopentane-l,2-diol

[1198] (Example 72-D1)

[1199]

[1200] Attorney Docket# COGN-01-PCT

[1201] The reaction was carried out according to general procedure A using 1-4 and pyridin-4-ylboronic acid. The crude product was purified by reverse phase chromatography (using a C18 gold column) and product fraction was eluted with 40-50% acetonitrile in 0.1% formic acid in water to afford (U?,25,45)-4-(2-chloro-4-(pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 72-D1, 20 mg, 40% yield) as an off-white solid.

[1202] 'H NMR (400 MHz, DMSO-d6): 3 = 8.60-8.58 (m, 2H), 7.9 (d, J= 2.4 Hz, 1H), 7.77-7.74 (m, 1H), 7.71-7.69 (m, 2H), 7.21-7.19 (d, J = 8.8 Hz, 1H) 5.02-4.90 (m, 1H), 4.58 (br s, 2H), 4.05 (br s, 2H), 2.17-2.10 (m, 2H), 1.90-1.84 (m, 2H). LCMS: 95.19%, [M+H]+= 306.0. HPLC: 97.71%.

[1203] Synthesis of (ll?,25',4r)-4-(2-chloro-4-(pyridin-4-yl)phenoxy)cyclopentane-l,2-diol

[1204] (Example 72-D2)

[1205]

[1206] The reaction was carried out according to general procedure A using 1-4** and pyridin-4-ylboronic acid. The crude product was purified by preparative HPLC (Column: X-Select C18 (250 x 30 mm); 5 p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow (mL / min): 20; loading (mg / inj ection): 30; gradient (time / %B): 0 / 10, 3 / 10, 10 / 30, 30 / 50, 40 / 80) to afford (l / ?,2A',4 / j-4-(2-chloro-4-(pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 72-D2, 20.27 mg, 42% yield) as an off-white solid.

[1207] 'H NMR (400 MHz, DMSO-d6): 3 = 8.59-8.58 (m, 2H), 7.92-7.9 (m, 1H), 7.76-7.69 (m, 3H), 7.18 (d, J= 8.8 Hz, 1H), 4.8-4.76 (m, 1H), 4.56 (d, J= 2 Hz, 2H), 3.85-3.79 (m, 2H), 2.37-2.34 (m, 2H), 1.82-1.76 (m, 2H). LCMS: 98.72%, [M+H]+= 306.17. HPLC: 98.05%.

[1208] Synthesis of (ll?,25',4s)-4-(2-methyl-4-(pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 73-D1).

[1209] Attorney Docket# COGN-01-PCT

[1210]

[1211] The reaction was carried out according to general procedure A using 1-5 and pyridin-4-ylboronic acid. The crude product was purified by reverse phase chromatography by preparative HPLC [Column: XT mate C18 (250 x 21.1mm), 5 p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow (mL / min): 16; loading (mg / inj ection): 18; gradient (time / %B): 0 / 5, 3 / 5, 10 / 20, 35 / 70, 60 / 98] to afford (l / f 2A’,4.s)-4-(2-methyl-4-(pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 73-D1, 16.44 mg, 34% yield) as white solid.

[1212] 'H NMR (400 MHz, DMSO-d6): 3 = 8.58-8.54 (m, 2H), 7.66-7.59 (m, 4H), 6.96 (d, J = 8.4 Hz, 1H), 4.95-4.87 (m, 1H), 4.53 (br s, 2H), 4.08-4.01 (m, 2H), 2.18 (s, 3H), 2.16-2.08 (m, 2H), 1.90-1.82 (m, 2H). LCMS: 99.47%, [M+H]+= 286.1. HPLC: 99.07%.

[1213] Synthesis of (ll?,25',4r)-4-(2-methyl-4-(pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 73-D2).

[1214]

[1215] The reaction was carried out according to general procedure A using 1-5** and pyridin-4-ylboronic acid. The crude product was purified by preparative HPLC [(Column: YMC C8 (250 x 20 mm ) 5 p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow (mL / min): 16; loading (mg / inj ection): 17; gradient (time / %B) 0 / 5, 3 / 5, 10 / 20, 35 / 70, 60 / 98 to afford (U?,25,4r)-4-(2-methyl-4-(pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 73-D2, 10 mg, 21% yield) as an off-white solid.

[1216] Attorney Docket# COGN-01-PCT

[1217] 'H NMR (400 MHz, DMSO-d6): 3 = 8.56 (d, J= 6.0 Hz, 2H), 7.70-7.57 (m, 4H), 6.96 (d, J= 8.4 Hz, 1H), 4.77-4.66 (m, 1H), 4.54 (br d, J= 4.0 Hz, 2H), 3.88-3.77 (m, 2H), 2.38-2.24 (m, 2H), 2.2 (s, 3H), 1.85-1.69 (m, 2H) LCMS: 98.78%, [M+H]+= 286.3. HPLC:

[1218] 98.6%.

[1219] Synthesis of (17?,2N,4s)-4-(4-(5-chloropyridin-3-yl)phenoxy)cyclopentane-l,2-diol

[1220] (Example 74-D1)

[1221]

[1222] The reaction was carried out according to general procedure A using 1-3 and (5-chl oropyri din-3 -yl)boronic acid. The crude product was purified by reverse phase chromatography (using Cl 8 gold column) and product fractions were eluted with 40-50% acetonitrile in 0.1% formic acid in water to afford (l / ,2A',4.s)-4-(4-(5-chloropyridin-3-yl)phenoxy)cyclopentane-l,2-diol (Example 74-D1, 32.93 mg, 57% yield) as an off white solid.

[1223] 'H NMR (400 MHz, DMSO-d6): = 8.82 (d, J= 2.0 Hz, 1H), 8.55 (d, J= 2.4 Hz, 1H), 8.18 (t, J= 2.0 Hz, 1H), 7.71 (d, J= 8.8 Hz, 2H), 6.98 (d, J= 8.8 Hz, 2H), 4.94-4.88 (m, 1H), 4.54 (br s, 2H), 4.03 (br s, 2H), 2.22-2.04 (m, 2H), 1.89-1.79 (m, 2H). LCMS: 97.60%, [M+H]+=306.15. HPLC: 96.64%.

[1224] Synthesis of (17?,2N,4r)-4-(4-(5-chloropyridin-3-yl)phenoxy)cyclopentane-l,2-diol

[1225] (Example 74-D2)

[1226] Attorney Docket# COGN-01-PCT

[1227]

[1228] The reaction was carried out according to general procedure A using 1-3** and (5-chl oropyri din-3 -yl)boronic acid. The crude product was purified by preparative HPLC [column: XTIMATE; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow (mL / min): 20; loading (mg / inj ection): 15; gradient (time / %B): 0 / 10, 3 / 10, 10 / 35, 35 / 75, 60 / 99] to afford (U?,25,4r)-4-(4-(5-chloropyridin-3-yl)phenoxy)cyclopentane-l,2-diol (Example 74-D2, 5.87 mg, 10% yield) as an off-white solid.

[1229] 'H NMR (400 MHz, DMSO-ck): = 8.82 (d, J = 2.0 Hz, 1H), 8.55 (d, J = 2.4 Hz, 1H), 8.18 (t, J= 2.0 Hz, 1H), 7.74-7.68 (m, 2H), 6.98 (d, J= 8.8 Hz, 2H), 4.71 (s, 1H), 4.52 (d, J= 4.8 Hz, 2H), 3.82 (br d, J= 4.4 Hz, 2H), 2.35-2.29 (m, 2H), 1.79-1.70 (m, 2H). LCMS:

[1230] 99.77%, [M+H]+= 306.13. HPLC: 98.33%.

[1231] Synthesis of (ll?,25',4s)-4-(2-chloro-4-(5-chloropyridin-3-yl)phenoxy)cyclopentane-1,2-diol (Example 75-D1)

[1232]

[1233] The reaction was carried out according to general procedure A using 1-4 and (5-chl oropyri din-3 -yl)boronic acid. The crude product was purified by preparative HPLC [column: YMC C8 (250 x 20 mm), 5 p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow (mL / min): 16; loading (mg / inj ection): 34; gradient (time / %B): 0 / 10, 3 / 10, 10 / 35, 20 / 55, 30 / 65, 40 / 75, 50 / 99] to afford (17?,2S,4s)-4-(2-chloro-Attorney Docket# COGN-01-PCT

[1234] 4-(5-chloropyridin-3-yl)phenoxy)cyclopentane-l,2-diol (Example 75-D1, 30 mg, 54% yield) as an off-white solid.

[1235] 'H NMR (400 MHz, DMSO-d6): 3 = 8.86 (d, J= 2.0 Hz, 1H), 8.58 (d, J= 2.4 Hz, 1H), 8.26 (t, J= 2.4 Hz, 1H), 7.91 (d, J= 2.4 Hz, 1H), 7.73 (dd, J= 2.4, 8.4 Hz, 1H), 7.19 (d, J = 8.8 Hz, 1H), 5.02-4.98 (m, 1H), 4.57 (d, J= 4.4 Hz, 2H), 4.05 (br s, 2H), 2.16-2.07 (m, 2H), 1.90-1.85 (m, 2H). LCMS: 99.79%, [M+H]+= 340.15. HPLC: 99.47%.

[1236] Synthesis of (ll?,25',4r)-4-(2-chloro-4-(5-chloropyridin-3-yl)phenoxy)cyclopentane-1,2-diol (Example 75-D2)

[1237]

[1238] The reaction was carried out according to general procedure A using 1-4** and (5-chl oropyri din-3 -yl)boronic acid. The crude product was purified by preparative HPLC [column: X-select C18 (250 x 30 mm), 5 p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow (mL / min): 20; loading (mg / inj ection): 25; gradient (time / %B): 0 / 20, 3 / 20, 20 / 60, 30 / 95) to afford (U?,25,4r)-4-(2-chloro-4-(5-chl oropyri din-3 -yl)phenoxy)cy cl opentane-l,2-diol (Example 75-D2, 22.71 mg, 42% yield) as an off-white solid. 'H NMR (400 MHz, DMSO-d6): 3 = 8.86 (d, J= 2.0 Hz, 1H), 8.58 (d, J= 2.4 Hz, 1H), 8.26 (t, J= 2.4 Hz, 1H), 7.91 (d, J= 2.4 Hz, 1H), 7.72 (dd, J= 2.4, 8.8 Hz, 1H), 7.16 (d, J= 8.8 Hz, 1H), 4.80-4.76 (m, 1H), 4.56 (d, J= 4.8 Hz, 2H), 3.83 (br s,2H), 2.38-2.32 (m, 2H), 1.82-1.76 (m, 2H).

[1239] LCMS: 96.61%, [M+H]+= 340.11.

[1240] HPLC: 97.21%

[1241] Synthesis of (ll?,25',4s)-4-(4-(5-chloropyridin-3-yl)-2-methylphenoxy)cyclopentane-1,2-diol (Example 76-D1).

[1242] Attorney Docket# COGN-01-PCT

[1243]

[1244] The reaction was carried out according to general procedure A using 1-5 and (5-chl oropyri din-3 -yl)boronic acid. The crude product was purified by preparative HPLC [column: X-Select CSH C18 (4.6 * 150 mm), 5 p particle size; particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow (mL / min): 20; loading (mg / inj ection): 10; gradient (time / %B): 0.0 / 05, 1.0 / 05, 8.0 / 100, 12.0 / 100, 14.0 / 05, 18.0 / 5] to afford (U?,25,45)-4-(4-(5-chloropyridin-3-yl)-2-methylphenoxy)cyclopentane-l,2-diol (Example 76-D1, 8 mg, 15% yield) as an off-white solid.

[1245] 'H NMR (400 MHz, DMSO-d6): 6 = 8.82 (d, J= 2.0 Hz, 1H), 8.53 (d, J= 2.4 Hz, 1H), 8.16 (t, J= 2.0 Hz, 1H), 7.62-7.55 (m, 2H), 6.95 (d, J= 8.8 Hz, 1H), 4.94-4.88 (m, 1H), 4.53 (d, J= 4.0 Hz, 2H), 4.07-4.01 (m, 2H), 2.18 (s, 3H), 2.16-2.05 (m, 2H), 1.91-1.80 (m, 2H).

[1246] LCMS: 99.89%, [M+H]+= 320.15.

[1247] HPLC: 98.11%.

[1248] Synthesis of (ll?,25',4r)-4-(4-(5-chloropyridin-3-yl)-2-methylphenoxy)cyclopentane-1,2-diol (Example 76-D2).

[1249]

[1250] The reaction was carried out according to general procedure A using 1-5** and (5-chl oropyri din-3 -yl)boronic acid. The crude product was purified by preparative HPLC [column: YMC TRIATE C18 (250 x 19 mm), 5 p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow (mL / min): 18; loading(mg / inj ection): 15;

[1251] Attorney Docket# COGN-01-PCT

[1252] gradient (time / %B): 0 / 20, 3 / 20, 10 / 40, 30 / 70, 31 / 98, 35 / 98] to afford (17?,25,4r)-4-(4-(5-chloropyri din-3 -yl)-2-methylphenoxy)cy cl opentane-l,2-diol (Example 76-D2, 15.77 mg, 29% yield) as an off-white solid.

[1253] 'H NMR (400 MHz, DMSO-d6): 3 = 8.82 (d, J= 2.0 Hz, 1H), 8.53 (d, J= 2.4 Hz, 1H), 8.17 (t, J= 2.4 Hz, 1H), 7.61-7.54 (m, 2H), 6.95 (d, J= 8.8 Hz, 1H), 4.75-4.67 (m, 1H), 4.51 (d, J= 4.8 Hz, 2H), 3.86-3.78 (m, 2H), 2.35-2.28 (m, 2H), 2.20 (s, 3H), 1.80-1.73 (m, 2H). LCMS: 99.42%, [M+H]+= 320.23. HPLC: 99.36%.

[1254] Synthesis

[1255]

[1256] (ll?,2»S,4s)-4-(2-methoxy-4-(2-methoxypyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 77-D1).

[1257]

[1258] The reaction was carried out according to general procedure A using 1-1 and (2-methoxypyridin-4-yl)boronic acid. The crude product was purified by reverse-phase column chromatography (using a C18 gold column) by eluting with 40-50% acetonitrile in water using acidic buffer (0.1% formic acid in water) to afford (U?,25,45)-4-(2-methoxy-4-(2-methoxypyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 77-D1, 33 mg, 59% yield) as a pale brown solid.

[1259] 'H NMR (400 MHz, DMSO-d6): 3 = 8.17 (d, J= 5.60 Hz, 1H), 7.32-7.28 (m, 3H), 7.09 (s, 1H), 6.96 (d, J= 8.80 Hz, 1H), 4.90-4.87 (m, 1H), 4.52 (br s, 2H), 4.06-3.99 (m, 2H), 3.88 (s, 3H), 3.83 (s, 3H), 2.11-2.04 (m, 2H), 1.86-1.83 (m, 2H). LC-MS: 96.88%; [M+H]+332.24. HPLC: 97.88%.

[1260] Synthesis of (17?,2N,4r)-4-(2-methoxy-4-(2-methoxypyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 77-D2).

[1261] Attorney Docket# COGN-01-PCT

[1262]

[1263] The reaction was carried out according to general procedure A using 1-1** and (2-methoxypyridin-4-yl)boronic acid. The crude product was purified by reverse phase column chromatography (using a Cl 8 gold column) and pure fractions were eluted with 0.1% formic acid in water (25-30% acetonitrile in water) to afford (U?,25,4r)-4-(2-methoxy-4-(2-methoxypyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 77-D2, 30 mg, 60% yield) as an off white solid.

[1264] 'H NMR (400 MHz, DMSO-d6): <5 = 8.17 (d, J= 5.20 Hz, 1H), 7.31-7.29 (m, 3H), 7.09 (s, 1H), 6.96 (d, J= 8.80 Hz, 1H), 4.69-4.64 (m, 1H), 4.53 (br s, 2H), 3.88 (s, 3H), 3.85 (s, 3H), 3.81-3.79 (m, 2H), 2.32-2.25 (m, 2H), 1.79-1.73 (m, 2H). LC-MS: 99.21%; [M+H]+= 332.24. HPLC: 99.40%.

[1265] Synthesis of (ll?,25',4s)-4-(2-methoxy-4-(2-(trifluoromethoxy)pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 78-D1).

[1266]

[1267] Step 1: The reaction was carried out according to general procedure B using 1-2 and 2-chloro-4-iodo-6-(trifluoromethoxy)pyridine (21). The crude product was purified by reverse phase column chromatography (using a Cl 8 gold column) and pure fractions were eluted with 0.1% formic acid in water / acetonitrile (50-100%) to afford (1R, 2A’,4.s)-4-(4-(2-chloro-6-(trifluoromethoxy)pyridin-4-yl)-2-methoxyphenoxy)cyclopentane-l,2-diol (22, 60 mg, 40% yield) as a sticky yellow solid.

[1268] Attorney Docket# COGN-01-PCT

[1269] 'H NMR (400 MHz, DMSO-d6): 3 = 7.96 (s, 1H), 7.70 (s, 1H), 7.49-4.46 (m, 2H), 6.99 (d, J= 8.40 Hz, 1H), 4.92-4.87 (m, 1H), 4.53-4.51 (m, 2H), 4.04-4.01 (m, 2H), 3.86 (s, 3H), 2.15-2.06 (m, 2H), 1.78-1.89 (m, 2H). LC-MS: 86.46%; [M+H]+= 420.24.

[1270] Step-2: To a stirred solution of (lA,25,45)-4-(4-(2-chloro-6-(trifluoromethoxy)pyridin-4-yl)-2-methoxyphenoxy)cyclopentane-l,2-diol (32, 40 mg, 0.08 mmol) in methanol (5.0 mL) was added ammonium formate (119 mg, 1.79 mmol) and 10% palladium on activated carbon (50% wet) (40 mg) allowed the reaction mixture to sir at 65 °C for 16 h. Progress of the reaction was monitored by LCMS. After completion of the reaction, reaction mixture was filtered through celite, washed with methanol and concentrated to obtain the crude product which was purified by preparative HPLC (Column: XSelect CSH C18 (250 x 19 mm), 5 p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 21 mL; loading (mg / inj ection): 20; gradient (time / %B): 0 / 5, 3 / 5, 15 / 10, 25 / 20, 45 / 35, 60 / 98) to afford (lA,2£,4s)-4-(2-methoxy-4-(2-(trifluoromethoxy)pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 78-D1, 14.4 mg, 43% yield) as a sticky yellow solid.

[1271] 'H NMR (400 MHz, DMSO-d6): 3 = 8.36 (d, J = 5.20 Hz, 1H), 7.78 (dd, J= 5.60, 1.60 Hz, 1H), 7.62 (d, J= 1.20 Hz, 1H), 7.44-7.41 (m, 2H), 6.99 (d, J= 8.80 Hz, 1H), 4.92-4.87 (m, 1H), 4.02 (t, J = 4.40 Hz, 2H), 3.86 (s, 3H), 2.11-2.06 (m, 2H), 1.87-1.83 (m, 2H) (Exchangeable OH proton signals were not seen in 'H-NMR).19F NMR (377 MHz, DMSO-d6): 3 = -54.74. LC-MS: 95.85%; [M+H]+= 386.3. HPLC: 97.40%.

[1272] Synthesis of (ll?,2N,4r)-4-(2-methoxy-4-(2-(trifluoromethoxy)pyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 78-D2).

[1273]

[1274] The reaction was carried out according to general procedure B using 1-2** and 2-chloro-4-iodo-6-(trifluoromethoxy)pyridine (21). The crude compound was purified by reverse phase column chromatography (using a Cl 8 gold column) and pure products were eluted withAttorney Docket# COGN-01-PCT

[1275] 0.1% formic acid in water / acetonitrile (60-80%) to afford (lA,25,4r)-4-(4-(2-chloro-6-(trifluorom ethoxy )pyridin-4-yl)-2-methoxyphenoxy)cy cl opent-ane-l,2-diol (23, 120 mg, 60% yield) as a sticky brown solid.

[1276] LC-MS: 97.01%; [M+H]+= 420.22.

[1277] Step-2: To a stirred solution of (lA,25',4r)-4-(4-(2-chloro-6-(trifluoromethoxy)pyridin-4-yl)-2-methoxyphenoxy)cyclopentane-l,2-diol (33, 120 mg, 0.277 mmol) in methanol (4.0 mL) was added ammonium formate (360 mg, 5.537 mmol) and 10% palladium on activated carbon (50% wet) (120 mg) allowed the reaction mixture to stirred at 65 °C for 16 h. Progress of the reaction was monitored by LCMS. After completion of the reaction, the reaction mixture was filtered through celite, washed with methanol and concentrated to get crude product. The crude compound was purified by preparative HPLC (Column: X-Bridge C18 (150 x 19 mm); 5 p particle size; mobile phase A: 0.1% formic acid in water, mobile phase B: acetonitrile; flow: 18 mL; loading (mg / inj ection): 22; gradient (time / %B): 0 / 10, 3 / 10, 30 / 80, 31 / 98, 35 / 98) to afford (lA,25,4r)-4-(2-methoxy-4-(2- (trifluorom ethoxy )pyridin-4-yl)phenoxy)cy cl opentane-l,2-diol (Example 78-D2, 33 mg, 30 % yield) as an off white sticky solid.

[1278] 'H NMR (400 MHz, DMSO-d6): 3 = 8.36 (d, J= 5.20 Hz, 1H), 7.78 (dd, J= 5.60, 1.60 Hz, 1H), 7.62 (d, J = 1.20 Hz, 1H), 7.43-7.40 (m, 2H), 6.99 (d, J= 9.20 Hz, 1H), 4.75-4.66 (m, 1H), 4.51 (d, = 4.80 Hz, 2H), 3.86 (s, 3H), 3.82-3.79 (m, 2H), 2.29-2.27 (m, 2H), 1.79-1.73 (m, 2H);19F NMR (377 MHz, DMSO-d6): 3 = -54.73. LC-MS: 99.43%; [M+H]+386.3. HPLC: 99.46%.

[1279] Synthesis of (17?,2N,4s)-4-(2-methoxy-4-(2-methylpyridin-4-yl)phenoxy)cyclopentane-1,2-diol (Example 79-D1).

[1280]

[1281] Attorney Docket# COGN-01-PCT

[1282] The reaction was carried out according to general procedure B using 1-1 and (2-methylpyridin-4-yl)boronic acid. The crude product was purified by preparative HPLC (Column: XSelect C18 (250 x 30 mm), 5 p particle size; mobile phase A: 10 mM ammonium bicarbonate in water, mobile phase B: acetonitrile; flow: 25 mL; loading(mg / inj ection): 22; gradient (time / %B): 0 / 10, 3 / 10, 35 / 99) to afford (1R, 25',4 )-4-(2-methoxy-4-(2-methylpyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 79-D1, 9.0 mg, 17% yield) as an off-white solid.

[1283] 'H NMR (400 MHz, DMSO-d6): 3 = 8.44 (d, J= 5.60 Hz, 1H), 7.56 (s, 1H), 7.48 (dd, J = 5.60, 1.60 Hz, 1H), 7.32-7.30 (m, 2H), 6.97 (d, J= 8.80 Hz, 1H), 4.90-4.85 (m, 1H), 4.51 (d, = 4.40 Hz, 2H), 4.05-4.01 (m, 2H), 3.84 (s, 3H), 2.10-2.06 (m, 2H), 1.87-1.81 (m, 2H).

[1284] LC-MS: 99.61%; [M+H]+= 316.1. HPLC: 99.24%.

[1285] Synthesis of (17?,2N,4r)-4-(2-methoxy-4-(2-methylpyridin-4-yl)phenoxy)cyclopentane-1,2-diol (Example 79-D2)

[1286]

[1287] The reaction was carried out according to general procedure B using 1-1** and (2-methoxypyridin-4-yl)boronic acid. The crude product was purified by preparative HPLC (Column: Gemini C18 (250 x 10 mm)5 p particle size; mobile phase A: 0.1% formic acid in water; mobile phase B: acetonitrile; flow: 18 mL; loading (mg / inj ection): 15; gradient (time / %B): 0 / 2, 3 / 2, 10 / 15, 40 / 30, 60 / 98) to afford (lA,25,4r)-4-(2-methoxy-4-(2-methylpyridin-4-yl)phenoxy)cyclopentane-l,2-diol (Example 79-D2, 12.0 mg, 25% yield) as an off-white solid.

[1288] 'H NMR (400 MHz, DMSO-d6): 6 = 8.44 (d, J= 5.20 Hz, 1H), 7.56 (s, 1H), 7.48 (dd, J = 5.20, 1.60 Hz, 1H), 7.32-7.30 (m, 2H), 6.97 (d, J= 8.40 Hz, 1H), 4.70-4.63 (m, 1H), 4.50 (d, J= 4.40 Hz, 2H), 3.85 (s, 3H), 3.82...

Claims

1. Attorney Docket# COGN-01-PCTWHAT IS CLAIMED IS:

1. A compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof:wherein:Ri is substituted or unsubstituted phenyl, heterocyclic, or pyridones;R2 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl; and R3 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkylcarbonyl, arylcarbonyl, aryloxy, heteroaryloxy, carbocyclyl, halo, haloalkyl, or hydroxy alkyl;2. A compound having the structure of Formula (I), or pharmaceutically acceptable salt or solvate thereof:Attorney Docket# COGN-01-PCTR2 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl;R3 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkylcarbonyl, arylcarbonyl, aryloxy, heteroaryloxy, carbocyclyl, halo, haloalkyl, or hydroxy alkyl;R4 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl;Attorney Docket# COGN-01-PCTRs is alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, acyl, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, carbocyclyl, or haloalkyl;Re is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxy alkyl;R7 is alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, acyl, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, carbocyclyl, or haloalkyl;Rs is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxy alkyl; and A-E are independently selected from CH, O, N, or NR$>, wherein:R9 is alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkylene, acyl, aminoalkyl, carbonyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, carbocyclyl, haloalkyl, or hydroxy alkyl.

3. The compound of claim 1 or claim 2, with the structure of Formula (la), or pharmaceutical acceptable salt or solvate thereof:Attorney Docket# COGN-01-PCTwherein:R2 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl;R3 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkylcarbonyl, arylcarbonyl, aryloxy, heteroaryloxy, carbocyclyl, halo, haloalkyl, orhydroxy alkyl;R4 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl; and A-E are independently selected from CH or N.

4. The structure of Formula (la) of claim 3, wherein R2is H, OCH3, Cl, or CH3; R3 is H or CH3; and R4is H, CH3, CF3, Cl, SO2CH3, CN, OCH3 or OCF3.Attorney Docket# COGN-01-PCT5. The compound of claim 1 or claim 2, with the structure of Formula (lb), or pharmaceutical acceptable salt or solvate thereof:wherein:R2 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl;R3 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkylcarbonyl, arylcarbonyl, aryloxy, heteroaryloxy, carbocyclyl, halo, haloalkyl, orhydroxy alkyl;Rs is alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, acyl, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, carbocyclyl, or haloalkyl; andRe is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene,Attorney Docket# COGN-01-PCTaralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl.

6. The structure of Formula (lb) of claim 5, wherein, R5 is CH3, CH(CHs)2, or CH2CF3; and R6is H or CH3.

7. The compound of claim 1 or claim 2, with the structure of Formula (Ic), or pharmaceutical accepted salt or solvate thereof:wherein:R2 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl;R3 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkylcarbonyl, arylcarbonyl, aryloxy, heteroaryloxy, carbocyclyl, halo, haloalkyl, or hydroxyalkyl; R7 is alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, acyl, aminoalkyl, carbonyl, aryl, arylene, heteroaryl, heteroarylene,Attorney Docket# COGN-01-PCTaralkyl, heteroaralkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, carbocyclyl, or haloalkyl; andRs is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxy alkyl.

8. The structure of Formula (Ic) of claim 7, wherein R?is CH3, CH(CHs)2, or CH2CF3; and Rs is H or CH3.

9. The compound of claim 1 or claim 2, with the structure of Formula (Id), or pharmaceutical acceptable salt or solvate thereof:wherein:R2 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, amino, amido, acyl, aminoalkyl, carbonyl, alkylthio, carboxy, aryl, arylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkenoxy, alkenoxyl, aryloxy, heteroaryloxy, carbocyclyl, cyano, halo, haloalkyl, hydroxy, or hydroxyalkyl;R3 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkenyl, alkynyl, alkylene, aminoalkyl, carbonyl, aryl,Attorney Docket# COGN-01-PCTarylene, heteroaryl, heteroarylene, aralkyl, heteroaralkyl, alkylcarbonyl, arylcarbonyl, aryloxy, heteroaryloxy, carbocyclyl, halo, haloalkyl, orhydroxy alkyl; andA-D are independently selected from CH, O, N, or NR$>, wherein:R9 is alkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, alkylene, acyl, aminoalkyl, carbonyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, carbocyclyl, haloalkyl, or hydroxy alkyl.

10. The structure of Formula 1(d) of claim 9, wherein R$>is CH3.

11. The compound of any one of claims 1-10, having the structure of Table 1.

12. The compound of claim 2, having the structure of:

13. The compound of claim 2, having the structure of:

14. The compound of any one of claims 1-13, wherein the compound exists as a single enantiomer or a single diastereomer.

15. The compounds of any one of claims 1-13, wherein the compound is optionally substituted with deuterium at one or more positions.

16. A pharmaceutical composition comprising a compound of any one of claims 1-13 and a pharmaceutically acceptable excipient.Attorney Docket# COGN-01-PCT17. The pharmaceutical composition of claim 16, wherein the pharmaceutically acceptable excipient is selected from the group consisting of carriers, diluents, binders, disintegrants, lubricants, glidants, fillers, coating agents, solubilizers, stabilizers, preservatives, flavoring agents, and coloring agents.

18. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition is formulated as a dosage form for oral, parenteral or nasal delivery.

19. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition is formulated as an oral dosage form selected from the group consisting of tablets, capsules, powders, granules, solutions, suspensions, emulsions, and syrups.

20. A method of treating, delaying progression of, or preventing degenerative cognitive disorders, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claims 1-13.

21. The method of claim 20, wherein the degenerative cognitive disorder is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, and Lewy Body Dementia.

22. The method of claim 21, wherein the degenerative cognitive disorder is Alzheimer's Disease.

23. A method of treating, delaying progression of, or preventing degenerative cognitive disorders, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claims 1-13, wherein the degenerative cognitive disorders is selected from the group consisting of Alzheimer’s Disease (AD), Parkinson’s Disease, and Lewy Body Dementia.

24. A method of treating, delaying progression of, or preventing Alzheimer’sDisease (AD), comprising administering to a subject in need thereof aAttorney Docket# COGN-01-PCTtherapeutically effective amount of a compound of claims 1-13.

25. A method of inhibiting Ap production comprising: contacting a cell comprising Ap with an effective amount of compound of one of claims 1-13 thereby inhibiting said Ap production.

26. The method of claim 25, wherein the cell is a neuronal cell or a glial cell.

27. The method of claim 25, wherein inhibiting Ap production comprises reducing C- terminal fragments of amyloid precursor protein.

28. The method of claim 23, wherein administering the therapeutically effective amount of the compound results in at least one of:reduction of C-terminal fragments of amyloid precursor protein;reduction of Api-42 levels;increased phosphorylation of GSK3P at Ser9;increased levels of synapsin;increased levels of synaptophysin;increased levels of PSD95; andincreased levels of Homer.

29. The method of claim 23, wherein administering the therapeutically effective amount of the compound results in at least one of:reduction of IB Al; andattenuation of microgliosis / microglial activation.

30. The method of claim 23, wherein administering the therapeutically effective amount of the compound results in at least one of:reduced amyloid plaque density;reduced neuroinflammation; andincreased synaptic markers.

31. The pharmaceutical composition of claim 16, further comprising combining one or more additional pharmaceutically active agents.Attorney Docket# COGN-01-PCT32. The pharmaceutical composition of claim 16, further comprising a second therapeutically active agent.

33. The pharmaceutical composition of claim 32, wherein the second therapeutically active agent is selected from the group consisting of cholinesterase inhibitor, anNMDA receptor antagonist, and an anti-inflammatory agent.

34. The pharmaceutical composition of claim 33, wherein the cholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine, and galantamine.